View Filing Data

Change in foreign currency translation gains (losses)

$ 2,737.6

$ 2,408.4

$ 2,390.5

Other comprehensive income (loss):

(436.4)

(859.8)

(961.4)

Change in net unrealized gains and losses on securities

303.0

(138.1)

(162.2)

Change in defined benefit pension and retiree health benefit plans

(512.8)

572.9

(1,327.6)

Change in effective portion of cash flow hedges

11.7

(42.0)

(14.5)

Other comprehensive income (loss) before income taxes

(634.5)

(467.0)

(2,465.7)

Provision for income taxes related to other comprehensive income (loss) items

(10.6)

(121.9)

476.6

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

(645.1)

^[1]

(588.9)

(1,989.1)

Comprehensive income

2,092.5

$ 1,819.5

$ 401.4

(693.3)

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest

$ 48.2

[1]	Other comprehensive loss in 2016 consists of $693.3 million of other comprehensive loss attributable to controlling interest and $48.2 million of other comprehensive income attributable to non-controlling interest.

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 4,582.1	$ 3,666.4
Short-term investments	1,456.5	785.4
Accounts receivable, net of allowances of $40.3 (2016) and $44.3 (2015)	4,029.4	3,513.0
Other receivables	736.9	558.6
Inventories	3,561.9	3,445.8
Prepaid expenses and other	734.6	604.4
Total current assets	15,101.4	12,573.6
Other Assets
Investments	5,207.5	3,646.6
Goodwill	3,972.7	4,039.9
Other intangibles, net	4,357.9	5,034.8
Sundry	1,913.8	2,220.5
Total other assets	15,451.9	14,941.8
Property and equipment, net	8,252.6	8,053.5
Total assets	38,805.9	35,568.9
Current Liabilities
Short-term borrowings and current maturities of long-term debt	1,937.4	6.1
Accounts payable	1,349.3	1,338.2
Employee compensation	896.9	967.0
Sales rebates and discounts	3,914.9	2,560.1
Dividends payable	548.1	539.0
Income taxes payable	119.1	358.9
Other current liabilities	2,220.9	2,460.3
Total current liabilities	10,986.6	8,229.6
Other Liabilities
Long-term debt	8,367.8	7,972.4
Accrued retirement benefits	2,453.9	2,160.3
Long-term income taxes payable	688.9	868.9
Other noncurrent liabilities	2,228.2	1,747.4
Total other liabilities	13,738.8	12,749.0
Eli Lilly and Company Shareholders' Equity
Common stock-no par value Authorized shares: 3,200,000 Issued shares: 1,101,586 (2016) and 1,106,063 (2015)	688.5	691.3
Additional paid-in capital	5,640.6	5,552.1
Retained earnings	16,046.3	16,011.8
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss	(5,274.0)	(4,580.7)
Cost of common stock in treasury	(80.5)	(90.0)
Total Eli Lilly and Company shareholders' equity	14,007.7	14,571.3
Noncontrolling interests	72.8	19.0
Total equity	14,080.5	14,590.3
Total liabilities and equity	$ 38,805.9	$ 35,568.9

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Accounts receivable, allowances	$ 40.3	$ 44.3
Issued shares, shares in thousands	1,101,586	1,106,063

Consolidated Statements of Shareholders' Equity Statement - USD ($)
shares in Thousands, $ in Millions

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Accumulated Other Comprehensive Income (Loss) [Member]

Treasury Stock [Member]

Trust for Benefit of Employees [Member]

Shares, Beginning Balance at Dec. 31, 2013

1,117,628

833

Shareholders' equity, Beginning Balance at Dec. 31, 2013

$ 17,631.4

$ 698.5

$ 5,050.0

$ 16,992.4

$ (2,002.7)

$ (93.6)

$ (3,013.2)

Increase (Decrease) in Shareholders' Equity [Roll Forward]

2,390.5

Retirement of treasury shares, shares

(1,989.1)

Cash dividends

2,108.1

(12,579)

Retirement of treasury shares, value

0.0

$ 7.9

792.1

$ 800.0

Purchase of treasury shares, shares

12,579

Purchase of treasury shares, value

(800.0)

$ (800.0)

Issuance of stock under employee stock plans, net, shares

(6,388)

(23)

Issuance of stock under employee stock plans, net, value

92.5

$ 4.0

86.3

$ 2.2

Stock-based compensation

156.0

Shareholders' equity, Ending Balance at Dec. 31, 2014

15,373.2

$ 694.6

5,292.3

16,482.7

(3,991.8)

$ (91.4)

(3,013.2)

Shares, Ending Balance at Dec. 31, 2014

1,111,437

810

Increase (Decrease) in Shareholders' Equity [Roll Forward]

2,408.4

Retirement of treasury shares, shares

(588.9)

Cash dividends

2,136.0

(9,877)

Retirement of treasury shares, value

0.0

$ 6.2

743.3

$ 749.5

Purchase of treasury shares, shares

9,877

Purchase of treasury shares, value

(749.5)

$ (749.5)

Issuance of stock under employee stock plans, net, shares

(4,503)

(14)

Issuance of stock under employee stock plans, net, value

46.3

$ 2.9

42.0

$ 1.4

Stock-based compensation

217.8

Shareholders' equity, Ending Balance at Dec. 31, 2015

14,571.3

$ 691.3

5,552.1

16,011.8

(4,580.7)

$ (90.0)

(3,013.2)

Shares, Ending Balance at Dec. 31, 2015

1,106,063

796

Increase (Decrease) in Shareholders' Equity [Roll Forward]

2,737.6

Retirement of treasury shares, shares

(645.1)

^[1]

(693.3)

Cash dividends

2,167.6

(7,306)

Retirement of treasury shares, value

0.0

$ 4.6

535.5

$ 540.1

Purchase of treasury shares, shares

7,306

Purchase of treasury shares, value

(600.1)

(60.0)

$ (540.1)

Issuance of stock under employee stock plans, net, shares

(2,829)

(85)

Issuance of stock under employee stock plans, net, value

95.5

$ 1.8

106.8

$ 9.5

Stock-based compensation

255.3

Shareholders' equity, Ending Balance at Dec. 31, 2016

$ 14,007.7

$ 688.5

$ 5,640.6

$ 16,046.3

$ (5,274.0)

$ (80.5)

$ (3,013.2)

Shares, Ending Balance at Dec. 31, 2016

1,101,586

711

[1]	Other comprehensive loss in 2016 consists of $693.3 million of other comprehensive loss attributable to controlling interest and $48.2 million of other comprehensive income attributable to non-controlling interest.

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash Flows from Operating Activities
Net income	$ 2,737.6	$ 2,408.4	$ 2,390.5
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,496.6	1,427.7	1,379.0
Change in deferred income taxes	439.5	(748.4)	36.8
Stock-based compensation expense	255.3	217.8	156.0
Acquired in-process research and development	30.0	535.0	200.2
Net proceeds from (payments for) terminations of interest rate swaps	(3.4)	(186.1)	340.7
Other non-cash operating activities, net	379.5	449.4	280.7
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables - (increase) decrease	(709.4)	(304.5)	117.4
Inventories - (increase) decrease	(328.2)	(736.3)	(307.1)
Other assets - (increase) decrease	(265.5)	(288.5)	673.2
Accounts payable and other liabilties-increase (decrease)	819.0	190.1	(809.0)
Net Cash Provided by Operating Activities	4,851.0	2,964.6	4,458.4
Cash Flows from Investing Activities
Purchases of property and equipment	(1,037.0)	(1,066.2)	(1,162.6)
Disposals of property and equipment	73.4	92.6	15.3
Cash released (restricted) for pending acquisition	0.0	5,405.6	(5,405.6)
Proceeds from sales and maturities of short-term investments	1,642.0	2,161.8	4,054.1
Purchases of short-term investments	(1,327.4)	(842.2)	(1,637.8)
Proceeds from sales of noncurrent investments	2,086.0	3,068.4	11,009.4
Purchases of noncurrent investments	(4,346.0)	(3,226.5)	(9,802.7)
Proceeds from sale of product rights	0.0	410.0	0.0
Purchase of product rights	0.0	0.0	(308.3)
Purchases of in-process research and development	(55.0)	(560.0)	(95.0)
Cash paid for acquisitions, net of cash acquired	(45.0)	(5,283.1)	(551.4)
Other investing activities, net	(130.1)	(133.6)	(24.5)
Net Cash Provided by (Used for) Investing Activities	(3,139.1)	26.8	(3,909.1)
Cash Flows from Financing Activities
Dividends paid	(2,158.5)	(2,127.3)	(2,101.2)
Net change in short-term borrowings	1,293.2	(2,680.6)	2,680.6
Proceeds from issuance of long-term debt	1,206.6	4,454.7	992.9
Repayments of long-term debt	(0.2)	(1,955.7)	(1,034.8)
Purchases of common stock	(600.1)	(749.5)	(800.0)
Other financing activities, net	(300.8)	(52.6)	96.1
Net Cash Used for Financing Activities	(559.8)	(3,111.0)	(166.4)
Effect of exchange rate changes on cash and cash equivalents	(236.4)	(85.6)	(341.5)
Net increase (decrease) in cash and cash equivalents	915.7	(205.2)	41.4
Cash and cash equivalents at beginning of year	3,666.4	3,871.6	3,830.2
Cash and Cash Equivalents at End of Year	$ 4,582.1	$ 3,666.4	$ 3,871.6

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Basis of Presentation [Text Block]

Note 1: Summary of Significant Accounting Policies

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders’ interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing.

Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.

All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs.

Revenue recognition

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, discounts, and rebates are established in the same period the related sales are recognized.

In arrangements involving the delivery of more than one element (e.g., research and development, marketing and selling, manufacturing, and distribution), each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. Our determination is based on whether the deliverable has "standalone value" to the customer. If a deliverable does not qualify as a separate unit of accounting, it is combined with the other applicable undelivered item(s) within the arrangement and these combined deliverables are treated as a single unit of accounting. The arrangement's consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable.

Initial fees we receive in collaborative and other similar arrangements from the partnering of our compounds under development are generally deferred and amortized into income through the expected product approval date. Initial fees may also be received for out-licensing agreements that include both an out-license of our marketing rights to commercialized products and a related commitment to supply the products. When we have determined that the marketing rights do not have standalone value, the initial fees received are generally deferred and amortized to income as net product sales over the term of the supply agreement.

Royalty revenue from licensees, which is based on third-party sales of licensed products and technology, is recorded as earned in accordance with the contract terms when third-party sales can be reasonably measured and collection of the funds is reasonably assured. This royalty revenue is included in collaboration and other revenue.

Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.

Developmental milestone payments earned by us are generally recorded in other–net, (income) expense. We immediately recognize the full amount of developmental milestone payments due to us upon the achievement of the milestone event if the event is objectively determinable and the milestone is substantive in its entirety. A milestone is considered substantive if the consideration earned 1) relates solely to past performance, 2) is commensurate with the enhancement in the pharmaceutical or animal health product's value associated with the achievement of the important event in its development life cycle, and 3) is reasonable relative to all of the deliverables and payment terms within the arrangement. If a milestone payment to us is part of a multiple-element commercialization arrangement and is triggered by the initiation of the commercialization period (e.g., regulatory approval for marketing or launch of the product) or the achievement of a sales-based threshold, we amortize the payment to income as we perform under the terms of the arrangement. See Note 4 for specific agreement details.

Research and development expenses and acquired in-process research and development

Research and development expenses include the following:


•	Research and development costs, which are expensed as incurred.


•	Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.

Acquired in-process research and development (IPR&D) expense includes the initial costs of IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.

Earnings per share

We calculate basic earnings per share (EPS) based on the weighted-average number of common shares outstanding and incremental shares from potential participating securities. We calculate diluted EPS based on the weighted-average number of common shares outstanding, including incremental shares from our stock-based compensation programs.

Foreign Currency Translation

Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash. The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted average currency rate for the period. Assets and liabilities are translated using the period end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).

Other significant accounting policies

Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.

Implementation of New Financial Accounting Pronouncements

12 Months Ended

Dec. 31, 2016

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

Note 2: Implementation of New Financial Accounting Pronouncements

During 2016, we elected to early adopt Accounting Standards Update 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting which changes the accounting and reporting for certain aspects of share-based payments to employees. This standard requires us to reflect any adjustments relating to share-based payments to employees as of January 1, 2016, the beginning of the annual period that includes the interim period of adoption. The following table provides a brief description of the changes to the presentation of the financial statements and the impact of adoption:



Description of changes	Method of adoption	Effect on the financial statements or other significant matters
All excess tax benefits and tax deficiencies are recognized in the statement of operations as a discrete item in the reporting period in which they occur.	Prospective	We recognized $39.5 million of excess tax benefits in income taxes in 2016. We cannot predict the impact on our consolidated financial statements in future reporting periods following adoption as this will be dependent upon various factors including the number of shares issued and changes in the price of our stock between the grant date and settlement date.
Excess tax benefits and deficiencies on the statement of cash flows are classified as an operating activity.	Retrospective	We reclassified $72.5 million of excess tax benefits in 2015 and $2.1 million of excess tax deficiencies in 2014 from cash flows from financing activities to cash flows from operating activities on the consolidated statements of cash flows.
Employee taxes paid when an employer withholds shares for tax-withholding purposes on the statement of cash flows are classified as a financing activity.	Retrospective	We reclassified $119.3 million and $93.4 million in 2015 and 2014, respectively, of employee taxes paid from cash flows from operating activities to cash flows from financing activities on the consolidated statements of cash flows.

As of December 31, 2016, we adopted Accounting Standards Update 2015-07, Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share (or Its Equivalent). This standard removed the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value (NAV) per share as a practical expedient. This standard was adopted retrospectively and only impacted the disclosure of our benefit plan investments in Note 14.

As of October 1, 2016, we adopted Accounting Standards Update 2017-01, Clarifying the Definition of a Business. This definition is used in determining whether acquisitions are accounted for as business combinations or as the acquisition of assets. This standard modifies the definition of a business, including providing a screen to determine when an acquired set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. The standard also makes other modifications to clarify what must be included in an acquired set for it to be a business and how to evaluate the set to determine whether it is a business. Our acquisitions subsequent to October 1, 2016, are subject to the application of the modified definition. The new definition would also be used to evaluate whether any disposals represent the disposal of a business.

The following table provides a brief description of accounting standards that have not yet been adopted and could have a material effect on our financial statements:



Standard	Description	Effective Date	Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09, Revenue from Contracts with Customers	This standard will replace existing revenue recognition standards and will require entities to recognize revenues to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We currently plan to use the latter approach.	This standard is effective January 1, 2018, but we are permitted to adopt this standard one year earlier if we choose. We intend to adopt this standard on January 1, 2018.	We are in the process of evaluating the impact of the adoption of the standard. We have identified two revenue streams from our contracts with customers: 1) product sales and 2) licensing arrangements. While our evaluation of our contracts for product sales is not yet complete, based upon the results of our work to date we currently do not expect the application of the new standard to these contracts to have a material impact to our consolidated financial statements either at initial implementation or on an ongoing basis. We are in the process of reviewing arrangements in which we have licensed or sold intellectual property and are not yet able to estimate the anticipated impact to our consolidated financial statements from the application of the new standard to our arrangements as we continue to interpret and apply the principles in the new standard to our arrangements.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities	This standard will require entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.	This standard is effective January 1, 2018. Early adoption of the majority of the amendments in this standard is not permitted, however, early application of certain amendments is permitted. We intend to fully adopt this standard on January 1, 2018.	We are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption.



Standard	Description	Effective Date	Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases	This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. This standard requires a modified retrospective approach to adoption.	This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on January 1, 2019.	We are in the process of determining the potential impact on our consolidated financial statements.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory	This standard will require entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.	This standard is effective January 1, 2018, with early adoption permitted. We intend to adopt this standard on January 1, 2018.	We are continuing to assess the potential impact of this standard on our consolidated financial statements and currently estimate that the cumulative effect of initially applying the standard would result in an increase to the opening balance of retained earnings of approximately $2 billion on January 1, 2018. This estimate is subject to change based upon 2017 intra-entity transfers of assets other than inventory and ongoing assessments of the future deductibility and realizability of the deferred tax assets that would result from implementation.

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

Acquisitions [Text Block]

Acquisitions

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Note 3: Acquisitions

During 2015 and 2014, we completed the acquisitions of Novartis Animal Health (Novartis AH) and Lohmann SE (Lohmann AH), respectively. Additionally, on October 1, 2015, Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS) transferred to us their commercialization rights with respect to Erbitux^® in the U.S. and Canada (collectively, North America) through a modification of our existing arrangement. We also had an immaterial acquisition of a business in April 2016. These transactions were accounted for as business combinations under the acquisition method of accounting. See Note 4 for additional information related to the Erbitux arrangement. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated financial statements from the dates of acquisition.

During 2016, we announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine, and rabies vaccine portfolio which was subsequently completed in January 2017. Details of this transaction are discussed below in Acquisitions of Businesses.

In addition to the acquisitions of businesses, we also acquired assets in development in 2016, 2015, and 2014 which are further discussed in this note below in Asset Acquisitions. Upon acquisition, the acquired IPR&D related to these products was immediately written off as an expense because the products had no alternative future use. For the years ended December 31, 2016, 2015, and 2014, we recorded acquired IPR&D charges of $30.0 million, $535.0 million, and $200.2 million, respectively. The 2016 charge was associated with the transaction discussed in this note below in Asset Acquisitions. The 2015 charges were associated with the transactions discussed in this note below in Asset Acquisitions and the upfront fee of $200.0 million related to tanezumab. The 2014 charges were associated with the transactions discussed below in Asset Acquisitions and a $55.2 million charge related to the transfer to us of Boehringer Ingelheim's rights to co-promote our new insulin glargine product in countries where it was not yet approved. See Note 4 for additional information related to the tanezumab and Boehringer Ingelheim arrangements.

In January 2017, we announced an agreement to acquire CoLucid Pharmaceuticals, Inc. (CoLucid), including its Phase III molecule, lasmiditan, an oral therapy for the acute treatment of migraine. Substantially all of the value of CoLucid is related to lasmiditan, its only significant asset, and we expect to account for the transaction as the acquisition of an asset. Under the terms of the agreement, we will acquire all of shares of CoLucid for a purchase price of $46.50 per share or approximately $960 million. The transaction is expected to close in the first quarter of 2017, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. In addition, a shareholder lawsuit has been filed seeking to enjoin the closing of the transaction. We expect an acquired IPR&D charge of approximately $850 million (no tax benefit) in the first quarter of 2017. The amount will not be finalized until after the completion of the acquisition.

Acquisitions of Businesses

Subsequent Event - Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition

Overview of Transaction

On January 3, 2017, we acquired Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine, and rabies vaccine portfolio in an all-cash transaction for approximately $885 million, subject to final inventory quantities purchased and other adjustments. Under the terms of the agreement, we acquired a manufacturing and research and development site, a U.S. vaccine portfolio including vaccines used for the treatment of bordetella, Lyme disease, rabies, and parvovirus, among others, as well as several pipeline assets. The accounting impact of this acquisition and the results of the operations will be included in our financial statements beginning on January 3, 2017.

Assets Acquired and Liabilities Assumed

The initial accounting for this acquisition is incomplete. Significant, relevant information needed to complete the initial accounting is not available because the valuation of assets acquired and liabilities assumed is not complete. As a result, determining these values is not practicable and we are unable to disclose these values or provide other related disclosures at this time.

Novartis AH Acquisition

Overview of Transaction

On January 1, 2015, we acquired from Novartis AG all of the shares of certain Novartis subsidiaries and the assets and liabilities of other Novartis subsidiaries that were exclusively related to the Novartis AH business in an all-cash transaction for a total purchase price of $5.28 billion, $5.41 billion of which was funded by cash held in escrow at December 31, 2014.

As a condition to the clearance of the transaction under the Hart-Scott-Rodino Antitrust Improvements Act, following the closing of the acquisition of Novartis AH, we divested certain animal health assets in the U.S. related to the Sentinel^® canine parasiticide franchise to Virbac Corporation for approximately $410 million.

The acquired Novartis AH business consisted of the research and development, manufacture, marketing, sale and distribution of veterinary products to prevent and treat diseases in pets, farm animals, and farmed fish. Under the terms of the agreement, we acquired manufacturing sites, research and development facilities, a global commercial infrastructure and portfolio of products, a pipeline of projects in development, and employees.

Assets Acquired and Liabilities Assumed

The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at January 1, 2015
Inventories	$	380.2
Acquired in-process research and development	298.0
Marketed products⁽¹⁾	1,953.0
Property and equipment	199.9
Assets held for sale (primarily the U.S. Sentinel rights)	422.7
Accrued retirement benefits	(108.7		)
Deferred income taxes	(60.1		)
Other assets and liabilities - net	(73.0		)
Total identifiable net assets	3,012.0
Goodwill⁽²⁾	2,271.1
Total consideration transferred - net of cash acquired	$	5,283.1

⁽¹⁾These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 19 years.

⁽²⁾The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Novartis AH with our legacy animal health business, future unidentified projects and products, and the assembled workforce of Novartis AH. Approximately $1.0 billion of the goodwill associated with this acquisition is deductible for tax purposes.

Actual and Supplemental Pro Forma Information

Our consolidated statement of operations for the year ended December 31, 2015 includes Novartis AH revenue of $1.02 billion. For 2015, Novartis AH was partially integrated into our animal health segment and as a result of these integration efforts, certain parts of the animal health business were operating on a combined basis, and we could not distinguish the operations between Novartis AH and our legacy animal health business.

The following unaudited pro forma financial information presents the combined consolidated results of our operations with Novartis AH as if the portion of Novartis AH that we retained after the sale to Virbac had been acquired as of January 1, 2014. We have adjusted the historical consolidated financial information to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma financial information is not necessarily indicative of what our consolidated results of operations would have been had we completed the acquisition at the beginning of 2014. In addition, the unaudited pro forma financial information does not attempt to project the future results of operations of our combined company.



	Unaudited Pro Forma Consolidated Results
	2015		2014
Revenue	$	19,958.7	$	20,696.7
Net income	2,518.1		2,127.9
Diluted earnings per share	2.36		1.98

The unaudited pro forma financial information above reflects primarily the following pro forma pretax adjustments:


•	Additional amortization expense of approximately $104 million for the year ended December 31, 2014, related to the fair value of identifiable intangible assets acquired.


•	Additional cost of sales in 2014, and a corresponding reduction in cost of sales in 2015, of approximately $153 million related to the fair value adjustments to acquisition date inventory that was sold in the year ended December 31, 2015.


•	A decrease to pro forma net income of approximately $112 million in the year ended December 31, 2014, associated with an increase to interest expense related to the incremental debt that we issued to partially finance the acquisition and a reduction of interest income associated with investments which would have been used to partially fund the acquisition.

In addition, all of the above adjustments were adjusted for the applicable tax impact. The taxes associated with the adjustments above reflect the statutory tax rates in the various jurisdictions where the fair value adjustments occurred.

Lohmann AH Acquisition

On April 30, 2014, we acquired Lohmann AH, a privately-held company headquartered in Cuxhaven, Germany, through a stock purchase for a total purchase price of $591.2 million, comprised of $551.4 million of net cash plus $39.8 million of assumed debt. Lohmann AH was a global leader in poultry vaccines. As part of this transaction, we acquired the rights to a range of vaccines, commercial capabilities, and manufacturing sites in Germany and the U.S. The acquisition was not material to our consolidated financial statements.

The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at April 30, 2014
Marketed products	$	275.4
Other intangible assets	23.9
Property and equipment	81.9
Deferred income taxes	(92.7		)
Other assets and liabilities - net	51.1
Total identifiable net assets	339.6
Goodwill⁽¹⁾	251.6
Total consideration transferred - net of cash acquired	$	591.2

⁽¹⁾Goodwill associated with this acquisition is not deductible for tax purposes.

Asset Acquisitions

The following table summarizes our asset acquisitions during 2016, 2015, and 2014, which are discussed in detail below.



Counterparty	Compound(s) or Therapy	Acquisition Month	Phase of Development⁽¹⁾	Acquired IPR&D Expense
AstraZeneca	Antibody selective for amyloid-beta 42 (Aβ42) - MEDI1814	December 2016	Phase I	$	30.0

Innovent Biologics, Inc. (Innovent)	Monoclonal antibody targeting protein CD-20 Immuno-oncology molecule cMet monoclonal antibody	March 2015	Pre-clinical⁽²⁾	56.0
Hanmi Pharmaceutical Co., Ltd. (Hanmi)	BTK Inhibitor - HM71224	April 2015	Phase I	50.0
BioNTech AG (BioNTech)	Cancer immunotherapies	May 2015	Pre-clinical	30.0
Locemia Solutions	Intranasal glucagon	October 2015	Phase III	149.0
Undisclosed	Technology collaboration	December 2015	N/A	25.0
Halozyme Therapeutics, Inc. (Halozyme)	Recombinant human hyaluronidase enzyme - rHuPH20	December 2015	N/A	25.0

Immunocore Limited (Immunocore)	T cell-based cancer therapies	July 2014	Pre-clinical	45.0
AstraZeneca⁽³⁾	Oral beta-secretase cleaving enzyme inhibitor - AZD3293	September 2014	Phase I	50.0
Adocia	BioChaperone Lispro	December 2014	Phase I	50.0

⁽¹⁾ The phase of development presented is as of the date of the arrangement.

⁽²⁾ Prior to acquisition, Innovent's monoclonal antibody targeting protein CD-20 had received investigational new drug approval in China to begin Phase I development.

⁽³⁾ See Note 4 for additional information on our collaboration with AstraZeneca related to this oral beta-secretase cleaving enzyme (BACE) inhibitor.

In connection with the arrangements described herein, our partners may be entitled to future royalties and/or commercial milestones based on sales should these products be approved for commercialization and/or milestones based on the successful progress of the compounds through the development process.

Our global collaboration agreement with AstraZeneca is to co-develop AstraZeneca's MEDI1814 compound being investigated for the treatment of Alzheimer's disease.

Our collaboration agreement with Innovent is to develop and commercialize a portfolio of cancer treatments. In China, we will be responsible for the commercialization efforts, while Innovent will lead the development and manufacturing efforts. Innovent also has co-promotion rights in China. We will be responsible for development, manufacturing, and commercialization efforts of Innovent's pre-clinical immuno-oncology molecules outside of China. Separate from the collaboration, we will continue the development of our cMet monoclonal antibody gene outside of China.

Our collaboration agreement with Hanmi is to develop and commercialize Hanmi's compound being investigated for the treatment of autoimmune and other diseases. We have rights to the molecule for all indications on a worldwide basis excluding Korea. We will be responsible for leading development, regulatory, manufacturing, and commercial efforts in our territories.

Our research collaboration with BioNTech is to discover novel cancer immunotherapies.

Our global collaboration and license agreement with Halozyme is to develop and commercialize products combining our proprietary compounds with Halozyme's ENHANZE^™ platform to aid in the dispersion and absorption of other injected therapeutic drugs.

Our co-discovery and co-development collaboration with Immunocore is to research and potentially develop pre-clinical novel T cell-based cancer therapies.

Our collaboration agreement with Adocia was for the worldwide development and commercialization of Adocia's ultra-rapid insulin, a molecule being developed for the treatment of patients with type 1 and type 2 diabetes. In 2017, this collaboration was terminated, and as a result, all rights we received under the agreement have reverted back to Adocia.

Collaborations

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborations [Text Block]

Note 4: Collaborations and Other Arrangements

We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. Elements within a collaboration are separated into individual units of accounting if they have standalone value from other elements within the arrangement. In these situations, the arrangement consideration is allocated to the elements on a relative selling price basis. Revenues related to products we sell pursuant to these arrangements are included in net product revenues, while other sources of revenue (e.g., royalties and profit sharing due from our partner) are included in collaboration and other revenue.

The following table summarizes our collaboration and other revenue, which is included in revenue in the consolidated statements of operations:



	2016		2015		2014
Collaboration and other revenue	$	833.7	$	808.1	$	788.4

Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.

Boehringer Ingelheim Diabetes Collaboration

We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Trajenta^®, Jentadueto^®, Jardiance^®, Glyxambi^®, and Synjardy^®, as well as our basal insulin: Basaglar^®.

The table below summarizes significant regulatory and commercialization events and milestones (received) paid for the compounds included in this collaboration:



Product Family	Product Status			Milestones (Deferred) Capitalized⁽¹⁾
Product Family	U.S.	Europe	Japan	Year	Amount
Trajenta⁽²⁾	Launched 2011	Launched 2011	Launched 2011	2016	$	—
				2015	—
				2014	—
				Cumulative⁽⁴⁾	446.4
Jardiance⁽³⁾	Launched 2014	Launched 2014	Launched 2015	2016	—
				2015	—
				2014	299.5
				Cumulative⁽⁴⁾	299.5
Basaglar	Launched 2016	Launched 2015	Launched 2015	2016	(187.5		)
				2015	—
				2014	(62.5		)
				Cumulative⁽⁴⁾	(250.0		)

⁽¹⁾ In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales.

⁽²⁾ Jentadueto is included in the Trajenta family of product results.

⁽³⁾ Glyxambi and Synjardyare included in the Jardiance family of product results.

⁽⁴⁾ The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.

In October 2014, we and Boehringer Ingelheim agreed upon certain changes to the operational and financial structure of our diabetes collaboration. Under the revised agreement the companies have continued their co-promotion work in 17 countries, representing over 90 percent of the collaboration’s anticipated market opportunity. In the other countries, the companies exclusively commercialize the respective molecules they brought to the collaboration. The modifications became effective at the end of 2014 and changed the financial terms related to the modified countries; however, the financial impact resulting from the revised terms of the agreement in these countries has not been and is not anticipated to be material. As a result of these changes, we recorded a gain of $92.0 million in 2014 related to the transfer to Boehringer Ingelheim of our license rights to co-promote linagliptin (Trajenta) and empagliflozin (Jardiance) in these countries, which was recorded as income in other–net, (income) expense. We also incurred a charge of $55.2 million related to the transfer to us of Boehringer Ingelheim's rights to co-promote Basaglar in countries where it was not yet approved, which was recorded as acquired IPR&D expense.

With the exception of the countries affected by the amendment to the collaboration agreement, the companies share equally the ongoing development costs, commercialization costs and gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's compounds as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenue with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. Each company is entitled to potential performance payments depending on the sales of the molecules it contributes to the collaboration. These performance payments result in the owner of the molecule retaining a greater share of the agreed upon gross margin of that product.

The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and revenue recognized with respect to Basaglar:



	2016		2015		2014
Trajenta	$	436.6	$	356.8	$	328.8
Jardiance	201.9		60.2		—
Basaglar	86.1		11.1		—

Erbitux

We have several collaborations with respect to Erbitux. The most significant collaborations are or, where applicable, were in Japan, and prior to the transfer of commercialization rights in the fourth quarter of 2015, the U.S. and Canada (Bristol-Myers Squibb Company); and worldwide except North America (Merck KGaA). Certain rights to Erbitux outside North America will remain with Merck KGaA (Merck) upon expiration of that agreement.

The following table summarizes our revenue recognized with respect to Erbitux:



	2016		2015		2014
Net product revenues - BMS	$	—	$	23.3	$	46.1
Net product revenues - third party	587.0		152.3		—
Collaboration and other revenue	100.0		309.4		327.2
Revenue	$	687.0	$	485.0	$	373.3

Bristol-Myers Squibb Company

Pursuant to commercial agreements with BMS, we had been co-developing Erbitux in North America with BMS exclusively. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement, and we began selling Erbitux at that time. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we provide consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average 38 percent through September 2018. The transfer of the commercialization rights was accounted for as an acquisition of a business.

The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at October 1, 2015
Marketed products⁽¹⁾	$	602.1
Deferred tax asset	232.2
Deferred tax liability	(228.2		)
Other assets and liabilities - net	57.2
Total identifiable net assets	$	663.3
Total consideration - contingent consideration liability⁽²⁾	$	(663.3	)

⁽¹⁾These intangible assets are being amortized to cost of sales using the straight-line method through the co-development period in North America as set forth in the original agreement, which was scheduled to expire in September 2018.

⁽²⁾See Note 7 for discussion on the estimation of the contingent consideration liability.

Including the Erbitux business as if we had acquired it on January 1, 2015, our combined consolidated unaudited pro forma revenue and total Erbitux revenue would have been approximately $20.2 billion and $735 million, respectively, for the year ended December 31, 2015. This unaudited pro forma financial information adjusts the historical consolidated revenue to give effect to pro forma events that are directly attributable to the acquisition. There would have been no material change to our historical consolidated net income. The unaudited pro forma financial information is not necessarily indicative of what our consolidated revenues would have been had we completed the acquisition on January 1, 2015. In addition, the unaudited pro forma financial information does not attempt to project the future results of operations of our combined company.

Until the effective date of the transfer of the business, the arrangements between us and BMS were as set forth in this paragraph. Erbitux research and development and other costs were shared by both companies according to a predetermined ratio. Responsibilities associated with clinical and other ongoing studies were apportioned between the parties under the agreements. Collaborative reimbursements due to us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses were recorded as a reduction to the respective expense line items on the consolidated statement of operations. We received a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in North America, which was recorded in collaboration and other revenue. Royalties due to third parties were recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties. We were responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in North America, and BMS purchased all of its requirements of API from us, subject to certain stipulations per the agreement. Sales of Erbitux API to BMS were reported in net product revenues.

Merck KGaA

A development and license agreement grants Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any changes to our rights.

Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as earned. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties.

Effient^®

We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. Marketing rights for major territories are shown below. We and Daiichi Sankyo each have exclusive marketing rights in certain other territories.



Territory	Marketing Rights	Selling Party
U.S.	Co-promotion	Lilly
Major European markets	Co-promotion	Pre-January 1, 2016, Lilly Post-January 1, 2016, Daiichi Sankyo
Japan	Exclusive	Daiichi Sankyo

Beginning January 1, 2016, while major European markets continue to be a co-promotion territory under the terms of our arrangement, Daiichi Sankyo exclusively promotes Effient in these markets. The economic results for the major European markets continue to be shared in the same proportion as they were previously.

The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we continue to produce the finished product for our exclusive and co-promotion territories, including the major European markets.

We record net product revenue in our exclusive and co-promotion territories where we are the selling party. Profit-share payments due to Daiichi Sankyo for co-promotion countries where we are the selling party are recorded as marketing, selling, and administrative expenses. Beginning January 1, 2016, any profit-share payments due to us from Daiichi Sankyo for the major European markets are recorded as collaboration and other revenue. We also record our share of the expenses in these co-promotion territories as marketing, selling, and administrative expenses. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales.

The following table summarizes our revenue recognized with respect to Effient:



	2016		2015		2014
Revenue	$	535.2	$	523.0	$	522.2

Olumiant^®

We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as baricitinib (trade name Olumiant), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. Incyte exercised its option to co-develop Oluminant in rheumatoid arthritis and psoriatic arthritis in 2010 and 2017, respectively. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2016, we incurred milestone-related expenses of $55.0 million in connection with regulatory submissions in the U.S. and Europe which were recorded as research and development expenses. In 2017, we capitalized as an intangible asset a $65.0 million milestone in connection with the regulatory approval in Europe, which will be amortized to cost of sales beginning upon product launch. After receipt of this milestone payment, Incyte will be eligible to receive up to $295.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones, of which $115.0 million relates to regulatory decisions for a first indication. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.

Tanezumab

We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. Following the U.S. Food and Drug Administration's (FDA's) decision in March 2015 to lift the partial clinical hold on tanezumab, certain Phase III trials resumed in July 2015. Upon the FDA's lifting of the partial clinical hold and the decision to continue the collaboration with Pfizer, we paid an upfront fee of $200.0 million which was expensed as acquired IPR&D. As of December 31, 2016, Pfizer is eligible to receive up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab.

BACE Inhibitor

In September 2014, we entered into a collaboration agreement with AstraZeneca for the worldwide co-development and co-commercialization of AstraZeneca’s AZD3293, a BACE inhibitor being investigated for the potential treatment of Alzheimer’s disease. We are responsible for leading development efforts, while AstraZeneca will be responsible for manufacturing efforts. If successful, both parties will take joint responsibility for commercialization. Under the agreement, both parties share equally in the ongoing development costs and, if successful, in gross margins and certain other costs associated with commercialization of the molecule. We expensed $50.0 million as acquired IPR&D at the inception of this arrangement. As a result of the molecule moving into Phase III testing, we incurred a $100.0 million developmental milestone, which was recorded as research and development expense in 2016. As of December 31, 2016, AstraZeneca is eligible to receive up to $350.0 million of additional payments from us contingent upon the achievement of certain development and success-based regulatory milestones.

Summary of Commission and Profit-Share Payments

The following table summarizes our aggregate amount of marketing, selling, and administrative expense associated with our commission and profit-sharing obligations for the collaborations and other arrangements described above:



	2016		2015		2014
Marketing, selling, and administrative	$	194.9	$	213.2	$	211.2

Asset Impairments, Restructuring, and Other Special Charges

12 Months Ended

Dec. 31, 2016

Unusual or Infrequent Items, or Both [Abstract]

Asset Impairments, Restructuring, And Other Special Charges [Text Block]

Note 5: Asset Impairment, Restructuring, and Other Special Charges

The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below.



	2016			2015		2014
Severance:
Human pharmaceutical products	$	85.9		$	81.5	$	225.5
Animal health	40.8			59.5		—
Total severance	126.7			141.0		225.5
Asset impairment (gains from facility sales) and other special charges:
Human pharmaceutical products	(13.0		)	24.6		204.4
Animal health	268.8			202.1		38.8
Total asset impairment and other special charges	255.8			226.7		243.2
Asset impairment, restructuring, and other special charges	$	382.5		$	367.7	$	468.7

Severance costs recognized during the years ended December 31, 2016, 2015 and 2014 resulted primarily from actions taken to reduce our cost structure, as well as the integration of Novartis AH in 2016 and 2015. Substantially all of the severance costs incurred during the year ended December 31, 2016 are expected to be paid by the end of 2017, and substantially all of the severance costs incurred during the years ended December 31, 2015 and 2014 have been paid.

Asset impairment and other special charges recognized during years ended December 31, 2016 and 2015 resulted primarily from integration costs and asset impairments due to product rationalization and site closures resulting from our acquisition and integration of Novartis AH, including the closure of a manufacturing facility in Ireland in 2016.

Asset impairment and other special charges recognized during the year ended December 31, 2014 resulted primarily from a $180.8 million asset impairment charge related to our decision to close and sell a manufacturing plant located in Puerto Rico. The manufacturing plant was written down to its estimated fair value, which was based primarily on recent sales of similar assets.

Inventories (Notes)

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

Note 6: Inventories

We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.

Inventories at December 31 consisted of the following:



	2016		2015
Finished products	$	987.3	$	1,053.4
Work in process	2,117.2		2,058.1
Raw materials and supplies	435.3		403.0
Total (approximates replacement cost)	3,539.8		3,514.5
Increase (reduction) to LIFO cost	22.1		(68.7		)
Inventories	$	3,561.9	$	3,445.8

Inventories valued under the LIFO method comprised $1.43 billion and $1.30 billion of total inventories at December 31, 2016 and 2015, respectively.

Financial Instruments

12 Months Ended

Dec. 31, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments [Text Block]

Note 7: Financial Instruments

Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.

Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded, net of tax, in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis.

Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other–net, (income) expense. We own no investments that are considered to be trading securities.

Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.

For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.

We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Japanese yen, and the Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At December 31, 2016, we had outstanding foreign currency forward commitments to purchase 1.24 billion U.S. dollars and sell 1.17 billion euro; commitments to purchase 2.13 billion euro and sell 2.24 billion U.S. dollars; commitments to purchase 246.0 million British pounds and sell 292.8 million euro; commitments to purchase 219.2 million U.S. dollars and sell 172.8 million British pounds, commitments to purchase 609.8 million U.S. dollars and sell 70.44 billion Japanese yen, and commitments to purchase 185.9 million Swiss francs and sell 183.3 million U.S. dollars, which will all settle within 30 days.

Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes issued in May 2016 and June 2015 and discussed in Note 10, which had carrying amounts of $3.34 billion and $2.27 billion as of December 31, 2016 and 2015, respectively, have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated and Swiss franc-denominated foreign operations. Our cross-currency interest rate swaps that convert a portion of our U.S. dollar-denominated floating rate debt to euro-denominated floating rate debt have also been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations.

In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.

Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statement of cash flows. At December 31, 2016, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 35 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.

We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.

We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt.

The Effect of Risk Management Instruments on the Consolidated Statement of Operations

The following effects of risk-management instruments were recognized in other–net, (income) expense:



	2016			2015			2014
Fair value hedges:
Effect from hedged fixed-rate debt	$	(30.8	)	$	(11.9	)	$	156.9
Effect from interest rate contracts	30.8			11.9			(156.9		)
Cash flow hedges:
Effective portion of losses on equity contracts reclassified from accumulated other comprehensive loss	—			—			129.0
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	15.0			13.7			9.0
Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	78.8			(28.2		)	(20.4		)

During the years ended December 31, 2016, 2015, and 2014, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.

The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)

The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:



	2016			2015			2014
Cash flow hedges:
Equity contracts	$	—		$	—		$	149.6
Forward-starting interest rate swaps	(3.4		)	(56.7		)	(164.7		)
Net investment hedges:
Foreign currency-denominated notes	137.5			—			—
Cross-currency interest rate swaps	32.5			—			—
Foreign currency exchange contracts	31.9			—			—

Fair Value Hedges

There were no material terminations of interest rate swaps in 2016. During the years ended December 31, 2015 and 2014, we terminated certain interest rate swaps designated as fair value hedges with an aggregate notional amount of $876.0 million and $1.30 billion, respectively. The termination of certain interest rate swaps in 2015 was in connection with the note purchase and redemption discussed in Note 10. As a result of the terminations, we received cash of $20.2 million and $340.7 million in 2015 and 2014, respectively, which represented the fair value of the interest rate swaps at the time of termination. In 2015, the related fair value adjustment was recorded as an increase to the carrying value of the underlying notes and was included as a component of the debt extinguishment loss. In 2014, the related fair value was recorded as an increase to the carrying value of the underlying notes and is being amortized into earnings as a reduction of interest expense over the remaining life of the underlying debt.

Cash Flow Hedges

Upon issuance of the underlying fixed-rate notes in March 2015, which are discussed in Note 10, we terminated forward-starting interest rate contracts in designated cash flow hedging instruments with an aggregate notional amount of $1.35 billion and paid $206.3 million in cash to the counterparties for settlement. The settlement amount represented the fair value of the forward-starting interest rate contracts at the time of termination and was recorded in other comprehensive income (loss).

During the year ended December 31, 2014, we sold all of the underlying equity securities that had been in designated cash flow hedging relationships. At the time of the sales, we reclassified to earnings the accumulated other comprehensive loss related to the cash flow hedges and the previously unrealized gains on the underlying equity securities.

During the next 12 months, we expect to reclassify from accumulated other comprehensive loss to earnings $15.1 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on our floating rate debt.

Fair Value of Financial Instruments

The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:



					Fair Value Measurements Using
Description	Carrying Amount		Cost⁽¹⁾		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Fair Value
December 31, 2016
Cash equivalents	$	2,986.8	$	2,986.8	$	2,699.4	$	287.4	$	—	$	2,986.8
Short-term investments:
U.S. government and agency securities	$	232.5	$	232.6	$	232.5	$	—	$	—	$	232.5
Corporate debt securities	1,219.2		1,219.1		—		1,219.2		—		1,219.2
Asset-backed securities	4.3		4.3		—		4.3		—		4.3
Other securities	0.5		0.5		—		0.5		—		0.5
Short-term investments	$	1,456.5
Noncurrent investments:
U.S. government and agency securities	$	318.9	$	323.8	$	318.9	$	—	$	—	$	318.9
Corporate debt securities	3,062.2		3,074.3		—		3,062.2		—		3,062.2
Mortgage-backed securities	183.1		185.4		—		183.1		—		183.1
Asset-backed securities	502.7		503.5		—		502.7		—		502.7
Other securities	153.7		77.6		—		—		153.7		153.7
Marketable equity securities	418.2		91.9		418.2		—		—		418.2
Cost and equity method investments⁽²⁾	568.7
Noncurrent investments	$	5,207.5

December 31, 2015
Cash equivalents	$	1,644.4	$	1,644.4	$	1,637.0	$	7.4	$	—	$	1,644.4
Short-term investments:
U.S. government and agency securities	$	153.2	$	153.4	$	153.2	$	—	$	—	$	153.2
Corporate debt securities	625.8		626.9		—		625.8		—		625.8
Asset-backed securities	3.3		3.3		—		3.3		—		3.3
Other securities	3.1		3.1		—		3.1		—		3.1
Short-term investments	$	785.4
Noncurrent investments:
U.S. government and agency securities	$	284.5	$	286.0	$	283.5	$	1.0	$	—	$	284.5
Corporate debt securities	1,962.6		1,995.8		—		1,962.6		—		1,962.6
Mortgage-backed securities	153.3		154.7		—		153.3		—		153.3
Asset-backed securities	441.9		443.1		—		441.9		—		441.9
Other securities	137.1		97.3		—		4.1		133.0		137.1
Marketable equity securities	128.9		74.8		128.9		—		—		128.9
Cost and equity method investments⁽²⁾	538.3
Noncurrent investments	$	3,646.6

⁽¹⁾ For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.

⁽²⁾ Fair value disclosures are not applicable for cost method and equity method investments.



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Fair Value
Short-term commercial paper borrowings
December 31, 2016	$	(1,299.3	)	$	—	$	(1,299.3	)	$	—	$	(1,299.3	)
December 31, 2015	—			—		—			—		—

Long-term debt, including current portion
December 31, 2016	$	(9,005.9	)	$	—	$	(9,419.1	)	$	—	$	(9,419.1	)
December 31, 2015	(7,978.5		)	—		(8,172.0		)	—		(8,172.0		)



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Fair Value
December 31, 2016
Risk-management instruments
Interest rate contracts designated as fair value hedges:
Other receivables	$	2.4		$	—	$	2.4		$	—		$	2.4
Sundry	37.0			—		37.0			—			37.0
Other noncurrent liabilities	(0.5		)	—		(0.5		)	—			(0.5		)
Cross-currency interest rate contracts designated as net investment hedges:
Sundry	31.4			—		31.4			—			31.4
Foreign exchange contracts not designated as hedging instruments:
Other receivables	31.8			—		31.8			—			31.8
Other current liabilities	(21.7		)	—		(21.7		)	—			(21.7		)
Contingent consideration liabilities⁽¹⁾:
Other current liabilities	(215.9		)	—		—			(215.9		)	(215.9		)
Other noncurrent liabilities	(242.6		)	—		—			(242.6		)	(242.6		)

December 31, 2015
Risk-management instruments
Interest rate contracts designated as fair value hedges:
Sundry	$	70.1		$	—	$	70.1		$	—		$	70.1
Other noncurrent liabilities	(0.4		)	—		(0.4		)	—			(0.4		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	13.1			—		13.1			—			13.1
Other current liabilities	(17.3		)	—		(17.3		)	—			(17.3		)
Contingent consideration liabilities⁽¹⁾:
Other current liabilities	(243.7		)	—		—			(243.7		)	(243.7		)
Other noncurrent liabilities	(427.2		)	—		—			(427.2		)	(427.2		)

⁽¹⁾ Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.

Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.

We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. The fair value of cost and equity method investments is not readily available.

Contingent consideration liabilities primarily include contingent consideration related to Erbitux for which the fair value was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant view for net sales in North America through September 2018 and an estimated discount rate. The amount to be paid is calculated as a tiered percentage of net sales (see Note 4) and will, therefore, vary directly with increases and decreases in net sales of Erbitux in North America. There is no cap on the amount that may be paid pursuant to this arrangement. The decreases in the fair value of the contingent consideration liability during December 31, 2016 was due to cash payments of $231.0 million related to Erbitux. The change in the fair value of the contingent consideration liabilities recognized in earnings during the years ended December 31, 2016 and 2015 due to changes in time value of money were not material.

The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2016:



	Maturities by Period
	Total		Within 1 Year		After 1 Year Through 5 Years		After 5 Years Through 10 Years		After 10 Years
Fair value of debt securities	$	5,522.9	$	1,456.0	$	3,762.2	$	89.0	$	215.7

A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:



	2016		2015
Unrealized gross gains	$	352.6	$	68.0
Unrealized gross losses	34.1		52.5
Fair value of securities in an unrealized gain position	1,869.7		764.5
Fair value of securities in an unrealized loss position	3,262.3		2,933.4

We periodically assess our investment securities for other-than-temporary impairment losses. Other-than-temporary impairment losses recognized during the year ended December 31, 2016, December 31, 2015, and December 31, 2014 totaled $53.0 million, $42.6 million and $12.5 million, respectively. Other-than-temporary impairment losses recognized during these years related primarily to our cost and equity method investments.

For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.

For equity securities, factors considered in assessing other-than-temporary impairment losses include the length of time and the extent to which the fair value has been less than cost, the financial condition and near term prospects of the issuer, our intent and ability to retain the securities for a period of time sufficient to allow for recovery in fair value, and general market conditions and industry specific factors.

As of December 31, 2016, the securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities. The value of fixed-income securities is sensitive to changes in the yield curve and other market conditions. Approximately 95 percent of the securities in a loss position are investment-grade debt securities. As of December 31, 2016, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.

Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows:



	2016		2015		2014
Proceeds from sales	$	3,240.5	$	4,733.3	$	14,609.5
Realized gross gains on sales	30.7		255.1		353.5
Realized gross losses on sales	14.6		10.3		29.4

Realized gains and losses on sales of investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.

Accounts Receivable Factoring Arrangements

We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $661.6 million and $670.6 million of accounts receivable as of December 31, 2016 and 2015, respectively, under these factoring arrangements. The cost of factoring such accounts receivable on our consolidated results of operations for the years ended December 31, 2016, 2015, and 2014 was not material.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangibles

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Text Block]

Note 8: Goodwill and Other Intangibles

Goodwill

Goodwill by segment at December 31 was as follows:



	2016		2015
Human pharmaceutical products	$	1,366.4	$	1,366.5
Animal health	2,606.3		2,673.4
Total goodwill	$	3,972.7	$	4,039.9

Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of implied fair value to the carrying amount of goodwill is performed to determine the amount of any impairment. The decrease in goodwill for the animal health segment is primarily the result of foreign exchange translation adjustments.

No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2016, 2015, and 2014.

Other Intangibles

The components of intangible assets other than goodwill at December 31 were as follows:



	2016							2015
Description	Carrying Amount, Gross		Accumulated Amortization			Carrying Amount, Net		Carrying Amount, Gross		Accumulated Amortization			Carrying Amount, Net
Finite-lived intangible assets:
Marketed products	$	7,400.2	$	(3,301.4	)	$	4,098.8	$	7,528.0	$	(2,756.6	)	$	4,771.4
Other	150.7		(71.8		)	78.9		151.1		(65.3		)	85.8
Total finite-lived intangible assets	7,550.9		(3,373.2		)	4,177.7		7,679.1		(2,821.9		)	4,857.2
Indefinite-lived intangible assets:
Acquired in-process research and development	180.2		—			180.2		177.6		—			177.6
Other intangibles	$	7,731.1	$	(3,373.2	)	$	4,357.9	$	7,856.7	$	(2,821.9	)	$	5,034.8

Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.

Other finite-lived intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations.

Acquired IPR&D consists of the related costs capitalized, adjusted for subsequent impairments, if any. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations are capitalized as other intangible assets.

Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.

See Note 3 for further discussion of intangible assets acquired in recent business combinations and Note 4 for additional discussion of recent capitalized milestone payments.

Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D assets for impairment testing purposes, we utilize the "income method" discussed above. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present. No material impairments occurred with respect to the carrying value of other intangible assets for the years ended December 31, 2016, 2015 and 2014.

Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from 3 to 20 years. As of December 31, 2016, the remaining weighted-average amortization period for finite-lived intangible assets is approximately 12 years.

Amortization expense related to finite-lived intangible assets was as follows:



	2016		2015		2014
Amortization expense	$	687.9	$	631.8	$	535.9

The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2016 is as follows:



	2017		2018		2019		2020		2021
Estimated amortization expense	$	649.6	$	491.7	$	314.1	$	312.8	$	311.0

Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

Property, Plant and Equipment [Abstract]

Property and Equipment (Notes)

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment Disclosure [Text Block]

Note 9: Property and Equipment

Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

At December 31, property and equipment consisted of the following:



	2016			2015
Land	$	197.6		$	220.6
Buildings	6,917.8			6,786.5
Equipment	7,864.7			7,988.5
Construction in progress	1,797.5			1,665.3
	16,777.6			16,660.9
Less accumulated depreciation	(8,525.0		)	(8,607.4		)
Property and equipment, net	$	8,252.6		$	8,053.5

Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows:



	2016		2015		2014
Depreciation expense	$	716.2	$	717.6	$	759.1
Rental expense	221.0		225.7		227.3

The future minimum rental commitments under non-cancelable operating leases are as follows:



	2017		2018		2019		2020		2021		After 2021
Lease commitments	$	134.8	$	120.9	$	109.9	$	93.3	$	75.3	$	339.4

Capitalized interest costs were not material for the years ended December 31, 2016, 2015, and 2014.

Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

Borrowings

12 Months Ended

Dec. 31, 2016

Long-term Debt, Current and Noncurrent [Abstract]

Debt Disclosure [Text Block]

Note 10: Borrowings

Debt at December 31 consisted of the following:



	2016			2015
Short-term commercial paper borrowings	$	1,299.3		$	—
0.00 to 7.13 percent long-term notes (due 2017-2045)	8,776.5			7,700.1
Other long-term debt, including capitalized leases	14.4			23.1
Unamortized debt issuance costs	(37.5		)	(37.1		)
Fair value adjustment on hedged long-term notes	252.5			292.4
Total debt	10,305.2			7,978.5
Less current portion	(1,937.4		)	(6.1		)
Long-term debt	$	8,367.8		$	7,972.4

The weighted-average effective borrowing rate on outstanding commercial paper at December 31, 2016 was 0.59 percent.

At December 31, 2016, we had a total of $2.87 billion of unused committed bank credit facilities, which consisted primarily of a $1.20 billion credit facility that expires in August 2021 and a $1.50 billion 364-day facility that expires in December 2017, both of which are available to support our commercial paper program. There were no amounts outstanding under the revolving credit facilities during the years ended December 31, 2016 and 2015. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn.

In May 2016, we issued Swiss franc-denominated notes consisting of Fr.200.0 million of 0.00 percent fixed-rate notes due in May 2018, Fr.600.0 million of 0.15 percent fixed-rate notes due in May 2024, and Fr.400.0 million of 0.45 percent fixed-rate notes due in May 2028, with interest to be paid annually. We are using the net cash proceeds of the offering of $1.21 billion for general corporate purposes, which may include the repayment or redemption prior to maturity of certain of our U.S. dollar denominated fixed-rate notes due March 2017.

In June 2015, we issued euro-denominated notes consisting of €600.0 million of 1.00 percent fixed-rate notes due in June 2022, €750.0 million of 1.63 percent fixed-rate notes due in June 2026, and €750.0 million of 2.13 percent fixed-rate notes due in June 2030 with interest to be paid annually. The net cash proceeds of the offering of $2.27 billion were used primarily to purchase and redeem certain higher interest rate U.S. dollar-denominated notes and to repay outstanding commercial paper. We paid $1.95 billion to purchase and redeem notes with an aggregate principal amount of $1.65 billion and a net carrying value of $1.78 billion in June 2015, resulting in a pretax debt extinguishment loss of $166.7 million, which was included in other–net, (income) expense in our consolidated statement of operations during the year ended December 31, 2015.

In March 2015, we issued $600.0 million of 1.25 percent fixed-rate notes due in March 2018, $800.0 million of 2.75 percent fixed-rate notes due in June 2025, and $800.0 million of 3.70 percent fixed-rate notes due in March 2045 with interest to be paid semi-annually. The proceeds from the issuance of the notes were used primarily to repay outstanding commercial paper issued in connection with our January 2015 acquisition of Novartis AH.

In February 2014, we issued $600.0 million of 1.95 percent and $400.0 million of 4.65 percent fixed-rate notes with interest to be paid semi-annually and maturity dates in March 2019, and June 2044, respectively. Current maturities of long-term notes of $1.00 billion were repaid in March 2014.

The aggregate amounts of maturities on long-term debt for the next five years are as follows:



	2017		2018		2019		2020		2021
Maturities on long-term debt	$	635.3	$	999.2	$	603.0	$	1.6	$	0.5

We have converted approximately 35 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December 31, 2016 and 2015, including the effects of interest rate swaps for hedged debt obligations, were 2.51 percent and 2.67 percent, respectively.

The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:



	2016		2015		2014
Cash payments for interest on borrowings	$	146.4	$	129.6	$	140.4

In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge, is reflected in the consolidated balance sheets as an amount equal to the sum of the debt’s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2016

Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]

Stock-Based Compensation [Text Block]

Note 11: Stock-Based Compensation

Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares.

Stock-based compensation expense and the related tax benefits were as follows:



	2016		2015		2014
Stock-based compensation expense	$	255.3	$	217.8	$	156.0
Tax benefit	89.4		76.2		54.6

At December 31, 2016, additional stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 99.6 million shares.

Performance Award Program

PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period. The fair values of PAs granted for the years ended December 31, 2016, 2015, and 2014 were $72.00, $70.34, and $48.81, respectively. The number of shares ultimately issued for the PA program is dependent upon the earnings achieved during the vesting period. Pursuant to this program, approximately 0.5 million shares, 0.5 million shares, and 0.7 million shares were issued during the years ended December 31, 2016, 2015, and 2014, respectively. Approximately 1.3 million shares are expected to be issued in 2017. As of December 31, 2016, the total remaining unrecognized compensation cost related to nonvested PAs was $43.7 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.

Shareholder Value Award Program

SVAs are granted to officers and management and are payable in shares of our common stock. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December 31, 2016, 2015, and 2014 were $48.68, $54.81, and $41.97, respectively, determined using the following assumptions:



(Percents)	2016		2015		2014
Expected dividend yield	2.00	%	2.50	%	3.50	%
Risk-free interest rate	0.92		0.79		.08-.71
Volatility	21.68		20.37		18.87-21.56

Pursuant to this program, approximately 1.0 million shares, 1.4 million shares, and 1.4 million shares were issued during the years ended December 31, 2016, 2015, and 2014, respectively. Approximately 1.2 million shares are expected to be issued in 2017. As of December 31, 2016, the total remaining unrecognized compensation cost related to nonvested SVAs was $65.1 million, which will be amortized over the weighted-average remaining requisite service period of 20 months.

Restricted Stock Units

RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically three years. The fair values of RSU awards granted during the years ended December 31, 2016, 2015, and 2014 were $71.46, $71.69, and $52.72, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this program, 1.3 million, 0.9 million, and 1.2 million shares were granted and approximately 0.6 million, 0.9 million, and 0.9 million shares were issued during the years ended December 31, 2016, 2015, and 2014, respectively. Approximately 0.7 million shares are expected to be issued in 2017. As of December 31, 2016, the total remaining unrecognized compensation cost related to nonvested RSUs was $103.3 million, which will be amortized over the weighted-average remaining requisite service period of 22 months.

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

Shareholders' Equity	12 Months Ended
Shareholders' Equity	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Shareholders' Equity [Text Block]	Note 12: Shareholders' Equity During 2016, 2015, and 2014, we repurchased $540.1 million, $749.5 million and $800.0 million, respectively, of shares associated with our $5.00 billion share repurchase program announced in 2013. As of December 31, 2016, there were $2.41 billion of shares remaining in that program. Our share repurchases are facilitated through payments to a financial institution that purchases the shares on our behalf. As of December 31, 2016, we had paid $60.0 million to a financial institution for shares that were subsequently repurchased in the first quarter of 2017. We have 5.0 million authorized shares of preferred stock. As of December 31, 2016 and 2015, no preferred stock was issued. We have an employee benefit trust that held 50.0 million shares of our common stock at both December 31, 2016 and 2015, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01 billion at both December 31, 2016 and 2015, and is shown as a reduction of shareholders’ equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of EPS. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2016, 2015, and 2014.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Income Taxes [Text Block]

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Note 13: Income Taxes

Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable. When foreign earnings are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. income taxes is provided.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

Following is the composition of income tax expense:



	2016			2015			2014
Current:
Federal	$	(57.0	)	$	660.5		$	168.9
Foreign	378.9			422.0			406.2
State	(125.0		)	47.5			(2.1		)
Total current tax expense	196.9			1,130.0			573.0
Deferred:
Federal	517.0			(689.6		)	(83.3		)
Foreign	(83.3		)	(66.0		)	120.2
State	5.8			7.2			(0.1		)
Total deferred tax (benefit) expense	439.5			(748.4		)	36.8
Income taxes	$	636.4		$	381.6		$	609.8

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:



	2016			2015
Deferred tax assets:
Compensation and benefits	$	1,126.0		$	1,034.6
Purchases of intangible assets	620.3			613.8
Tax credit carryforwards and carrybacks	458.9			294.2
Tax loss carryforwards and carrybacks	327.3			247.8
Contingent consideration	142.7			214.6
Product return reserves	128.1			212.1
Other comprehensive loss on hedging transactions	123.3			129.7
Debt	95.3			111.3
Other	587.3			679.4
Total gross deferred tax assets	3,609.2			3,537.5
Valuation allowances	(648.3		)	(590.3		)
Total deferred tax assets	2,960.9			2,947.2
Deferred tax liabilities:
Inventories	(955.5		)	(771.3		)
Unremitted earnings	(673.6		)	(218.8		)
Intangibles	(604.2		)	(792.3		)
Property and equipment	(398.6		)	(411.6		)
Financial instruments	(279.3		)	(144.0		)
Prepaid employee benefits	(265.3		)	(317.8		)
Total deferred tax liabilities	(3,176.5		)	(2,655.8		)
Deferred tax assets (liabilities) - net	$	(215.6	)	$	291.4

The deferred tax asset and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.

At December 31, 2016, based on filed tax returns we have tax credit carryforwards and carrybacks of $738.4 million available to reduce future income taxes; $178.7 million, if unused, will expire by 2026; $53.6 million, if unused, will expire by 2036. The remaining portion of the tax credit carryforwards is related to federal tax credits of $96.1 million, international tax credits of $106.2 million, and state tax credits of $303.8 million, all of which are substantially reserved.

At December 31, 2016, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. federal income tax purposes of $856.0 million: $142.6 million will expire by 2021; $462.5 million will expire between 2022 and 2036; and $250.9 million of the carryforwards will never expire. Net operating losses and other carryforwards for international and U.S. federal income tax purposes are partially reserved. Deferred tax assets related to state net operating losses of $102.0 million and other state carryforwards of $5.0 million are fully reserved.

Domestic and Puerto Rican companies contributed approximately 70 percent, 35 percent, and 20 percent for the years ended December 31, 2016, 2015, and 2014, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant effective through the end of 2016. A similar, new tax incentive grant began in 2017 and will be in effect for 15 years.

At December 31, 2016, U.S. income taxes have not been provided on approximately $28.0 billion of unremitted earnings of foreign subsidiaries as we consider these unremitted earnings to be indefinitely invested for continued use in our foreign operations. Additional tax provisions will be required if these earnings are repatriated in the future to the U.S. Due to complexities in the tax laws and assumptions that we would have to make, it is not practicable to determine the amount of the related unrecognized deferred income tax liability.

Cash payments of income taxes were as follows:



	2016		2015		2014
Cash payments of income taxes	$	700.6	$	969.0	$	729.7

Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:



	2016			2015			2014
Income tax at the U.S. federal statutory tax rate	$	1,180.9		$	976.5		$	1,050.1
Add (deduct):
International operations, including Puerto Rico	(313.7		)	(565.2		)	(344.8		)
General business credits	(58.3		)	(69.2		)	(44.3		)
Other	(172.5		)	39.5			(51.2		)
Income taxes	$	636.4		$	381.6		$	609.8

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:



	2016			2015			2014
Beginning balance at January 1	$	1,066.6		$	1,338.8		$	1,136.4
Additions based on tax positions related to the current year	73.4			131.3			126.4
Additions for tax positions of prior years	14.8			116.6			132.6
Reductions for tax positions of prior years	(15.2		)	(45.2		)	(32.1		)
Settlements	(171.9		)	(446.2		)	(4.2		)
Lapses of statutes of limitation	(110.0		)	(4.0		)	(3.5		)
Changes related to the impact of foreign currency translation	(4.3		)	(24.7		)	(16.8		)
Ending balance at December 31	$	853.4		$	1,066.6		$	1,338.8

The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $382.8 million and $404.1 million at December 31, 2016 and 2015, respectively.

We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in most major taxing jurisdictions for years before 2009.

The U.S. examination of tax years 2010-2012 commenced during the fourth quarter of 2013. In December 2015, we executed a closing agreement with the Internal Revenue Service which effectively settled certain matters for tax years 2010-2012. Accordingly, we reduced our gross uncertain tax positions by approximately $320 million in 2015. During 2016, we effectively settled the remaining matters related to tax years 2010-2012. As a result of this resolution, our gross uncertain tax positions were further reduced by approximately $140 million, and our consolidated results of operations benefited from an immaterial reduction in income tax expense. During 2016, we made cash payments of approximately $150 million related to tax years 2010-2012 after application of available tax credit carryforwards and carrybacks. The U.S. examination of tax years 2013-2015 began in 2016. Because the examination of tax years 2013-2015 is still in the early stages, the resolution of matters in this audit period will likely extend beyond the next 12 months.

We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:



	2016			2015		2014
Income tax (benefit) expense	$	(52.5	)	$	13.2	$	35.9

At December 31, 2016 and 2015, our accruals for the payment of interest and penalties totaled $134.9 million and $216.3 million, respectively.

Following is the composition of income tax expense:



	2016			2015			2014
Current:
Federal	$	(57.0	)	$	660.5		$	168.9
Foreign	378.9			422.0			406.2
State	(125.0		)	47.5			(2.1		)
Total current tax expense	196.9			1,130.0			573.0
Deferred:
Federal	517.0			(689.6		)	(83.3		)
Foreign	(83.3		)	(66.0		)	120.2
State	5.8			7.2			(0.1		)
Total deferred tax (benefit) expense	439.5			(748.4		)	36.8
Income taxes	$	636.4		$	381.6		$	609.8

Retirement Benefits

12 Months Ended

Dec. 31, 2016

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

Retirement Benefits [Text Block]

Note 14: Retirement Benefits

We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:



	Defined Benefit Pension Plans						Retiree Health Benefit Plans
	2016			2015			2016			2015
Change in benefit obligation:
Benefit obligation at beginning of year	$	11,719.2		$	12,012.4		$	1,467.4		$	1,553.5
Benefit obligation assumed in Novartis AH acquisition	—			334.7			—			9.9
Service cost	277.7			315.7			39.1			45.1
Interest cost	420.8			476.8			53.2			62.6
Actuarial (gain) loss	806.5			(812.4		)	50.9			(113.5		)
Benefits paid	(454.5		)	(437.8		)	(59.8		)	(77.5		)
Plan amendments	—			(0.4		)	(35.8		)	—
Foreign currency exchange rate changes and other adjustments	(313.8		)	(169.8		)	(20.4		)	(12.7		)
Benefit obligation at end of year	12,455.9			11,719.2			1,494.6			1,467.4



Change in plan assets:
Fair value of plan assets at beginning of year	9,995.6		9,835.7		1,943.7		1,918.7
Fair value of plan assets assumed in Novartis AH acquisition	—		235.9		—		—
Actual return on plan assets	853.4		90.4		68.9		85.1
Employer contribution	110.2		404.1		8.4		17.4
Benefits paid	(454.5	)	(437.8	)	(59.8	)	(77.5	)
Foreign currency exchange rate changes and other adjustments	(325.0	)	(132.7	)	—		—
Fair value of plan assets at end of year	10,179.7		9,995.6		1,961.2		1,943.7



Funded status	(2,276.2		)	(1,723.6		)	466.6			476.3
Unrecognized net actuarial loss	4,915.7			4,552.7			458.8			347.9
Unrecognized prior service (benefit) cost	21.7			32.5			(525.1		)	(574.8		)
Net amount recognized	$	2,661.2		$	2,861.6		$	400.3		$	249.4



Amounts recognized in the consolidated balance sheet consisted of:
Sundry	$	29.7		$	261.6		$	689.3		$	722.1
Other current liabilities	(68.0		)	(63.8		)	(6.7		)	(6.9		)
Accrued retirement benefits	(2,237.9		)	(1,921.4		)	(216.0		)	(238.9		)
Accumulated other comprehensive (income) loss before income taxes	4,937.4			4,585.2			(66.3		)	(226.9		)
Net amount recognized	$	2,661.2		$	2,861.6		$	400.3		$	249.4

The unrecognized net actuarial loss and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2016.

During 2017, we expect the following components of accumulated other comprehensive loss to be recognized as components of net periodic benefit cost:



	Defined Benefit Pension Plans		Retiree Health Benefit Plans
Unrecognized net actuarial loss	$	289.5	$	16.1
Unrecognized prior service (benefit) cost	5.4		(90.0		)
Total	$	294.9	$	(73.9	)

We do not expect any plan assets to be returned to us in 2017.

The following represents our weighted-average assumptions as of December 31:



	Defined Benefit Pension Plans						Retiree Health Benefit Plans
(Percents)	2016		2015		2014		2016		2015		2014
Discount rate for benefit obligation	3.9	%	4.3	%	4.0	%	4.3	%	4.5	%	4.1	%
Discount rate for net benefit costs	4.3		4.0		4.9		4.5		4.1		5.0
Rate of compensation increase for benefit obligation	3.4		3.4		3.4
Rate of compensation increase for net benefit costs	3.4		3.4		3.4
Expected return on plan assets for net benefit costs	7.4		7.4		8.1		8.0		8.0		8.5

We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable.

Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:



	2017		2018		2019		2020		2021		2022-2026
Defined benefit pension plans	$	464.5	$	471.3	$	486.1	$	505.3	$	526.9	$	3,016.3
Retiree health benefit plans	72.8		75.5		78.1		80.8		83.9		465.6

Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:



	2016		2015
Projected benefit obligation	$	10,597.0	$	10,054.1
Fair value of plan assets	8,291.2		8,069.7

Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:



	Defined Benefit Pension Plans				Retiree Health Benefit Plans
	2016		2015		2016		2015
Accumulated benefit obligation	$	9,805.4	$	2,028.1	$	222.7	$	245.8
Fair value of plan assets	8,285.2		844.9		—		—

The total accumulated benefit obligation for our defined benefit pension plans was $11.49 billion and $10.75 billion at December 31, 2016 and 2015, respectively.

Net pension and retiree health benefit expense included the following components:



	Defined Benefit Pension Plans									Retiree Health Benefit Plans
	2016			2015			2014			2016			2015			2014
Components of net periodic (benefit) cost:
Service cost	$	277.7		$	315.7		$	240.9		$	39.1		$	45.1		$	33.0
Interest cost	420.8			476.8			472.6			53.2			62.6			85.6
Expected return on plan assets	(752.1		)	(782.3		)	(756.6		)	(150.2		)	(150.0		)	(146.4		)
Amortization of prior service (benefit) cost	11.8			10.4			3.6			(85.8		)	(91.1		)	(37.6		)
Recognized actuarial loss	285.6			383.2			282.3			19.1			38.0			20.7
Net periodic (benefit) cost	$	243.8		$	403.8		$	242.8		$	(124.6	)	$	(95.4	)	$	(44.7	)

As of January 1, 2016, we changed the method used to estimate the service and interest cost components of the net periodic pension and retiree health benefit plan costs. This new method uses the spot yield curve approach to estimate the service and interest costs by applying the specific spot rates along the yield curve to the projected cash outflows of our obligations. Previously, those costs were determined using a single weighted-average discount rate. The new method provides a more precise measure of interest and service costs by improving the correlation between the projected benefit cash flows and the specific spot yield curve rates. The change did not affect the measurement of the total benefit obligations as the change in service and interest costs is recorded in the actuarial gains and losses recorded in accumulated other comprehensive loss. We have accounted for this change as a change in estimate prospectively.

The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31, 2016, 2015, and 2014:



	Defined Benefit Pension Plans								Retiree Health Benefit Plans
	2016			2015		2014			2016			2015			2014
Actuarial gain (loss) arising during period	$	(725.2	)	$	120.4	$	(1,939.3	)	$	(132.2	)	$	48.6		$	(282.9	)
Plan amendments during period	—			0.4		2.4			35.8			—			533.6
Amortization of prior service (benefit) cost included in net income	11.8			10.4		3.6			(85.8		)	(91.1		)	(37.6		)
Amortization of net actuarial loss included in net income	285.6			383.2		282.3			19.1			38.0			20.7
Foreign currency exchange rate changes and other	75.6			58.8		89.6			2.5			4.2			—
Total other comprehensive income (loss) during period	$	(352.2	)	$	573.2	$	(1,561.4	)	$	(160.6	)	$	(0.3	)	$	233.8

We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $175.0 million, $162.4 million, and $153.3 million for the years ended December 31, 2016, 2015, and 2014, respectively.

We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December 31, 2016, 2015, and 2014 were not material.

Benefit Plan Investments

Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent approximately 80 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.

We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.

Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.

The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 80 percent growth investments and 20 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.

Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.

Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.

Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests primarily in fund-of-funds structures to ensure diversification across many strategies and many individual managers. Plan holdings in hedge funds are valued based on NAVs calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.

Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, and special situation investing. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.

Real estate is composed of both public and private holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.

Other assets include cash and cash equivalents and mark-to-market value of derivatives.

The cash value of the trust-owned insurance contract is invested in investment-grade publicly traded equity and fixed-income securities.

Other than hedge funds, private equity-like investments, and real estate, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2016 by asset category are as follows:



				Fair Value Measurements Using
Asset Class	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans
Public equity securities:
U.S.	$	402.4		$	165.5	$	—		$	—	$	236.9
International	2,285.6			770.5		—			—		1,515.1
Fixed income:
Developed markets	2,631.3			27.2		1,983.0			—		621.1
Developed markets - repurchase agreements	(1,024.4		)	—		(1,024.4		)	—		—
Emerging markets	450.0			—		180.1			0.3		269.6
Private alternative investments:
Hedge funds	2,904.6			—		—			—		2,904.6
Equity-like funds	1,355.0			—		0.2			16.8		1,338.0
Real estate	504.1			344.5		—			—		159.6
Other	671.1			365.0		108.1			—		198.0
Total	$	10,179.7		$	1,672.7	$	1,247.0		$	17.1	$	7,242.9

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	38.7		$	16.7	$	—		$	—	$	22.0
International	146.3			52.0		—			—		94.3
Fixed income:
Developed markets	68.0			—		58.4			—		9.6
Emerging markets	42.6			—		18.2			—		24.4
Private alternative investments:
Hedge funds	261.0			—		—			—		261.0
Equity-like funds	116.0			—		—			1.7		114.3
Cash value of trust owned insurance contract	1,208.3			—		1,208.3			—		—
Real estate	34.8			34.8		—			—		—
Other	45.5			28.1		3.7			—		13.7
Total	$	1,961.2		$	131.6	$	1,288.6		$	1.7	$	539.3

⁽¹⁾Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2016. The activity in the Level 3 investments during the year ended December 31, 2016 was not material.

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2015 by asset category are as follows:



			Fair Value Measurements Using
Asset Class	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans
Public equity securities:
U.S.	$	414.3	$	180.1	$	—	$	—	$	234.2
International	2,261.7		751.5		—		—		1,510.2
Fixed income:
Developed markets	1,309.9		—		745.9		—		564.0
Emerging markets	472.3		—		151.5		0.3		320.5
Private alternative investments:
Hedge funds	3,073.2		2.4		—		—		3,070.8
Equity-like funds	1,221.6		—		0.3		16.8		1,204.5
Real estate	541.1		329.6		—		—		211.5
Other	701.5		255.6		94.4		—		351.5
Total	$	9,995.6	$	1,519.2	$	992.1	$	17.1	$	7,467.2

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	40.1	$	18.2	$	—	$	—	$	21.9
International	144.7		51.5		—		—		93.2
Fixed income:
Developed markets	61.2		—		52.9		—		8.3
Emerging markets	36.9		—		15.3		—		21.6
Private alternative investments:
Hedge funds	272.3		—		—		—		272.3
Equity-like funds	104.5		—		—		1.7		102.8
Cash value of trust owned insurance contract	1,208.2		—		1,208.2		—		—
Real estate	33.2		33.2		—		—		—
Other	42.6		25.0		0.5		—		17.1
Total	$	1,943.7	$	127.9	$	1,276.9	$	1.7	$	537.2

⁽¹⁾Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2015. The activity in the Level 3 investments during the year ended December 31, 2015 was not material.

In 2017, we expect to contribute approximately $35 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. Additional discretionary contributions are not expected to be significant.

Contingencies	12 Months Ended
Contingencies	Dec. 31, 2016
Loss Contingency, Information about Litigation Matters [Abstract]
Contingencies [Text Block]	Note 15: Contingencies We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta^® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period. Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable. Alimta Patent Litigation and Administrative Proceedings A number of generic manufacturers are seeking approvals in various countries to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues for the product in the relevant market. U.S. Patent Litigation and Administrative Proceedings We are engaged in various U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). More than ten Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP). These companies have also alleged the patent is invalid. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP and two other defendants seeking rulings that the U.S. vitamin regimen patent is valid and infringed (the Teva/APP litigation). A trial occurred in August 2013; the sole issue before the district court at that time was to determine patent validity. In March 2014, the court ruled that the asserted claims of the vitamin regimen patent are valid. The U.S. District Court for the Southern District of Indiana held a hearing on the issue of infringement in May 2015. In September 2015, the district court ruled that the vitamin regimen patent would be infringed by the generic challengers' proposed products. Teva and APP appealed all of the district court’s substantive decisions. In January 2017, the U.S. Court of Appeals for the Federal Circuit affirmed the district court’s decisions concerning validity and infringement. From 2012 through 2016, we filed similar lawsuits against other ANDA defendants seeking a ruling that our patents are valid and infringed. Some of these cases have been stayed pending the outcome of the Teva/APP litigation, and several parties have agreed to be bound by the outcome of the Teva/APP litigation; the remaining cases have been administratively closed. In 2016 we filed lawsuits alleging infringement against Dr. Reddy's Laboratories and Hospira in response to their alternative salt forms of pemetrexed product. In June 2016, the United States Patent and Trademark Office (USPTO) granted petitions by Neptune Generics, LLC and Sandoz Inc. seeking inter partes review (IPR) of our vitamin regimen patent. Several additional generic companies have filed petitions and joined these proceedings. The final written IPR decisions are expected in mid-2017. European Patent Litigation and Administrative Proceedings Generic manufacturers filed an opposition to the European Patent Office's (EPO) decision to grant us a vitamin regimen patent. The Opposition Division of the EPO upheld the patent and the generic manufacturers lodged an appeal. In October 2015 the generic manufacturers withdrew the appeal. As a result, the original EPO decision upholding the patent is now final. In addition, in the United Kingdom (U.K.), Actavis Group ehf and other Actavis companies (collectively, Actavis) filed litigation asking for a declaratory judgment that commercialization of certain salt forms of pemetrexed (the active ingredient in Alimta) diluted in saline solution would not infringe the vitamin regimen patents for Alimta in the U.K., Italy, France, and Spain. In May 2014, the trial court ruled that the vitamin regimen patents for Alimta would not be infringed by commercialization of alternative salt forms of pemetrexed, after expiration of the compound patents in December 2015. We appealed, and in June 2015, the U.K. Court of Appeal reversed the trial court's decision granting declarations of non-infringement over the Alimta vitamin regimen patents in those countries, ruling that the Alimta vitamin regimen patent would be infringed by commercialization of Actavis' products as proposed to be diluted in saline solution prior to the patent's expiration in June 2021. In February 2016, the U.K. Supreme Court granted our and Actavis' requests for permission to appeal different aspects of the judgment. A hearing is scheduled for April 2017. In parallel proceedings, Actavis returned to the lower court seeking a declaration of non-infringement for a different proposed product diluted in dextrose solution. In February 2016, the trial court ruled that Actavis’ commercialization of this product would not infringe the patent in the U.K., Italy, France, and Spain. We have sought to appeal this ruling. We commenced separate infringement proceedings against certain Actavis companies in Germany. Following a trial, in April 2014, the German trial court ruled in our favor. The defendants appealed, and after a hearing in March 2015, the German Court of Appeal overturned the trial court and ruled that our vitamin regimen patent in Germany would not be infringed by a dipotassium salt form of pemetrexed. In June 2016, the German Federal Supreme Court granted our appeal, vacating the prior decision denying infringement, and returned the case to the Court of Appeal to reconsider infringement based on its judgment. In separate proceedings, in May 2016 and June 2016, the German courts confirmed preliminary injunctions against Hexal AG (Hexal), which had stated its intention to launch a generic disodium salt product diluted in saline solution in Germany, and ratiopharm GmbH, a subsidiary of Teva, which had stated its intention to launch a proposed alternative salt form of pemetrexed product diluted in dextrose solution. Hexal has separately filed a challenge to the validity of our vitamin regimen patent before the German Federal Patent court. In late 2016, the German courts issued preliminary injunctions against two other companies that had stated their intentions to launch a proposed alternative salt form of pemetrexed product diluted in dextrose solution. We do not anticipate any generic entry into the German market at least until the Court of Appeal proceedings against Actavis considers the issues remanded by the German Federal Supreme Court or the injunctions are lifted. Additional legal proceedings are ongoing in various national courts of other European countries. We are aware that at least two generic pemetrexed products have launched in a major European market. Japanese Administrative Proceedings Three separate demands for invalidation of our two vitamin regimen patents, involving several companies, have been filed with the Japanese Patent Office (JPO). In November 2015, the JPO issued written decisions in the invalidation trial initiated by Sawai Pharmaceutical Co., Ltd. (Sawai), which had been joined by three other companies, upholding both vitamin regimen patents. In February 2017, the Japan Intellectual Property High Court confirmed the decisions of the JPO and ruled in our favor in the invalidation trials initiated by Sawai. If generic challengers do not petition or if their petitions are not accepted to the Japan Supreme Court, the Japan Intellectual Property High Court’s decisions are final. These patents provide intellectual property protection for Alimta until June 2021. The remaining invalidation trials initiated by the other parties are currently suspended and are likely to remain so until the High Court decision becomes final. Notwithstanding our patents, generic versions of Alimta were approved in Japan in 2016. To date, each manufacturer of the generic version of Alimta has agreed not to proceed to pricing approval. Effient Patent Litigation and Administrative Proceedings We, along with Daiichi Sankyo, Daiichi Sankyo, Inc., and Ube Industries (Ube) are engaged in U.S. patent litigation involving Effient brought pursuant to procedures set out in the Hatch-Waxman Act. More than 10 different companies have submitted ANDAs seeking approval to market generic versions of Effient prior to the expiration of Daiichi Sankyo’s and Ube’s patents (expiring in 2023) covering methods of using Effient with aspirin, and alleging the patents are invalid. One of these ANDAs also alleged that the compound patent for Effient (expiring in April 2017) was invalid. We have entered into a settlement relating to the compound patent litigation and anticipate that a generic version could launch as early as mid-August 2017. Beginning in March 2014, we filed lawsuits in the U.S. District Court for the Southern District of Indiana against these companies, seeking a ruling that the patents are valid and infringed. These cases have been consolidated. In 2015, several generic pharmaceutical companies filed petitions with the USPTO, requesting IPR of the method patents. In September 2016, the USPTO determined that the method-of-use patents are invalid. Daiichi Sankyo and Ube have appealed these decisions to the U.S. Court of Appeals for the Federal Circuit. We expect a final decision in late 2017. The consolidated lawsuit is currently stayed with respect to all parties pending the outcome of this appeal. We believe the Effient patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. We expect a loss of exclusivity for Effient would result in a rapid and severe decline in future revenues for the product in the relevant market. Actos^® Product Liability Litigation We have been named along with Takeda Chemical Industries, Ltd., and Takeda affiliates (collectively, Takeda) as a defendant in approximately 6,500 product liability cases in the U.S. related to the diabetes medication Actos, which we co-promoted with Takeda in the U.S. from 1999 until 2006. In general, plaintiffs in these actions allege that Actos caused or contributed to their bladder cancer. Almost all of the active cases have been consolidated in federal multidistrict litigation in the Western District of Louisiana or are pending in a coordinated state court proceeding in California or a coordinated state court proceeding in Illinois. In April 2015, Takeda announced they will pay approximately $2.4 billion to resolve the vast majority of the U.S. product liability lawsuits involving Actos. Although the vast majority of U.S. product liability lawsuits involving Actos are included in the resolution program, there may be additional cases pending against Takeda and us following completion of the resolution program. Our agreement with Takeda calls for Takeda to defend and indemnify us against our losses and expenses with respect to the U.S. litigation arising out of the manufacture, use, or sale of Actos and other related expenses in accordance with the terms of the agreement. We believe we are entitled to full indemnification of our losses and expenses in the U.S. cases; however, there can be no guarantee we will ultimately be successful in obtaining full indemnification. We are also named along with Takeda as a defendant in four purported product liability class actions in Canada related to Actos, including two in Ontario (Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. and Carrier et al. v. Eli Lilly et al.), one in Quebec (Whyte et al. v. Eli Lilly et al.), and one in Alberta (Epp v. Takeda Canada et al.). We promoted Actos in Canada until 2009. We believe these lawsuits are without merit, and we and Takeda are prepared to defend against them vigorously. Cymbalta^® Product Liability Litigation In October 2012, we were named as a defendant in a purported class-action lawsuit in the U.S. District Court for the Central District of California ( Saavedra et al v. Eli Lilly and Company ) involving Cymbalta. The plaintiffs, purporting to represent a class of all persons within the U.S. who purchased and/or paid for Cymbalta, asserted claims under the consumer protection statutes of four states, California, Massachusetts, Missouri, and New York, and sought declaratory, injunctive, and monetary relief for various alleged economic injuries arising from discontinuing treatment with Cymbalta. In December 2014, the district court denied the plaintiffs' motion for class certification. Plaintiffs filed a petition with the U.S. Court of Appeals for the Ninth Circuit requesting permission to file an interlocutory appeal of the denial of class certification, which was denied. Plaintiffs filed a second motion for certification under the consumer protection acts of New York and Massachusetts. The district court denied that motion for class certification in July 2015. The district court dismissed the suit and plaintiffs are appealing to the U.S. Court of Appeals for the Ninth Circuit. Oral argument is expected in late 2017. We are named in approximately 140 lawsuits involving approximately 1,470 plaintiffs filed in various federal and state courts alleging injuries arising from discontinuation of treatment with Cymbalta. These include approximately 40 individual and multi-plaintiff cases filed in California state court, centralized in a California Judicial Counsel Coordination Proceeding pending in Los Angeles. The first individual product liability cases were tried in August 2015 and resulted in defense verdicts against four plaintiffs. We have reached a settlement framework which provides for a comprehensive resolution of nearly all of these personal injury claims, filed or unfiled, alleging injuries from discontinuing treatment with Cymbalta. There can be no assurances, however, that a final settlement will be reached. We believe all these Cymbalta lawsuits and claims are without merit and are prepared to defend against them vigorously. Brazil–Employee Litigation Our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. The plaintiffs allege that some employees at the facility were exposed to benzene and heavy metals; however, Lilly Brasil maintains that these alleged contaminants were never used in the facility. In May 2014, the labor court judge ruled against Lilly Brasil. The judge's ruling orders Lilly Brasil to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. While we cannot currently estimate the range of reasonably possible financial losses that could arise in the event we do not ultimately prevail in the litigation, the judge has estimated the total financial impact of the ruling to be approximately 1.0 billion Brazilian real (approximately $305 million as of December 31, 2016) plus interest. We strongly disagree with the decision and filed an appeal in May 2014. We are also named in approximately 30 lawsuits filed in the same court by individual former employees making similar claims. We believe these lawsuits are without merit and are prepared to defend against them vigorously. Product Liability Insurance Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2016

Other Comprehensive Income (Loss), Tax [Abstract]

Comprehensive Income (Loss) [Text Block]

Note 16: Other Comprehensive Income (Loss)

The following table summarizes the activity related to each component of other comprehensive income (loss):



(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
Beginning balance at January 1, 2014	$	463.0		$	205.2		$	(2,489.1	)	$	(181.8	)	$	(2,002.7	)

Other comprehensive income (loss) before reclassifications	(961.4		)	105.2			(1,098.5		)	(15.2		)	(1,969.9		)
Net amount reclassified from accumulated other comprehensive loss	—			(210.7		)	185.6			5.9			(19.2		)
Net other comprehensive income (loss)	(961.4		)	(105.5		)	(912.9		)	(9.3		)	(1,989.1		)

Balance at December 31, 2014	(498.4		)	99.7			(3,402.0		)	(191.1		)	(3,991.8		)

Other comprehensive income (loss) before reclassifications	(861.8		)	38.6			155.0			(36.9		)	(705.1		)
Net amount reclassified from accumulated other comprehensive loss	—			(128.2		)	234.9			9.5			116.2
Net other comprehensive income (loss)	(861.8		)	(89.6		)	389.9			(27.4		)	(588.9		)

Balance at December 31, 2015	(1,360.2		)	10.1			(3,012.1		)	(218.5		)	(4,580.7		)

Other comprehensive income (loss) before reclassifications	(581.6		)	206.7			(518.7		)	(2.2		)	(895.8		)
Net amount reclassified from accumulated other comprehensive loss	74.5			7.2			159.2			9.8			250.7
Net other comprehensive income (loss)	(507.1		)	213.9			(359.5		)	7.6			(645.1		)

Ending balance at December 31, 2016⁽¹⁾	$	(1,867.3	)	$	224.0		$	(3,371.6	)	$	(210.9	)	$	(5,225.8	)

⁽¹⁾ Accumulated other comprehensive loss as of December 31, 2016 consists of $5,274.0 million of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to non-controlling interest.

The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:



Tax (expense) benefit	2016			2015			2014
Foreign currency translation gains (losses)	$	(70.6	)	$	(2.0	)	$	—
Unrealized net gains (losses) on securities	(89.2		)	48.5			56.7
Defined benefit pension and retiree health benefit plans	153.3			(183.0		)	414.7
Effective portion of cash flow hedges	(4.1		)	14.6			5.2
Provision for income taxes related to other comprehensive income (loss) items	$	(10.6	)	$	(121.9	)	$	476.6

Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.

Reclassifications out of accumulated other comprehensive loss were as follows:



Details about Accumulated Other Comprehensive Loss Components	Year Ended December 31,									Affected Line Item in the Consolidated Statements of Operations
	2016			2015			2014
Amortization of retirement benefit items:
Prior service benefits, net	$	(74.0	)	$	(80.7	)	$	(34.0	)	⁽¹⁾
Actuarial losses	304.7			421.2			303.0			⁽¹⁾
Total before tax	230.7			340.5			269.0
Tax benefit	(71.5		)	(105.6		)	(83.4		)	Income taxes
Net of tax	159.2			234.9			185.6

Unrealized gains/losses on available-for-sale securities:
Realized gains, net	(16.1		)	(209.3		)	(324.1		)	Other—net, (income) expense
Impairment losses	27.3			12.0			—			Other—net, (income) expense
Total before tax	11.2			(197.3		)	(324.1		)
Tax expense	(4.0		)	69.1			113.4			Income taxes
Net of tax	7.2			(128.2		)	(210.7		)

Other, net of tax ⁽²⁾	84.3			9.5			5.9			Other—net, (income) expense
Total reclassifications for the period, net of tax	$	250.7		$	116.2		$	(19.2	)

⁽¹⁾These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

⁽²⁾Amount for year ended December 31, 2016 included primarily $74.5 million of foreign currency translation losses.

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Nonoperating Income (Expense) [Abstract]

Other-Net, Expense (Income)

12 Months Ended

Dec. 31, 2016

Other - Net, Expense (Income) [Text Block]

Note 17: Other–Net, (Income) Expense

Other–net, (income) expense consisted of the following:



	2016			2015			2014
Interest expense	$	185.2		$	161.2		$	148.8
Interest income	(108.7		)	(87.0		)	(121.0		)
Venezuela charge	203.9			—			—
Debt extinguishment loss (Note 10)	—			166.7			—
Other income	(195.6		)	(341.5		)	(368.3		)
Other–net, (income) expense	$	84.8		$	(100.6	)	$	(340.5	)

In 2016, due to the financial crisis in Venezuela and the significant deterioration of the bolívar, we changed the exchange rate used to translate the assets and liabilities of our subsidiaries in Venezuela which resulted in a charge of $203.9 million. Prior to this change, we used the Supplementary Foreign Currency Administration System (SICAD) rate; however, this official rate was discontinued in 2016. After considering several factors, including the future uncertainty of the Venezuelan economy, published exchange rates, and the limited amount of foreign currency exchanged, we changed to the Divisa Complementaria (DICOM) rate.

For the years ended December 31, 2016, 2015, and 2014, other income is primarily related to net gains on investments (Note 7). Other income in 2014 also related to the transfer to Boehringer Ingelheim of our license rights to co-promote linagliptin and empagliflozin in certain countries (Note 4).

Segment Information

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Note 18: Segment Information

We have two operating segments—human pharmaceutical products and animal health products. Our operating segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. The accounting policies of the individual segments are the same as those described throughout the notes to the consolidated financial statements.

Our human pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: endocrinology, neuroscience, oncology, cardiovascular, and other. We lost our data package protection for Cymbalta in major European countries in 2014 and lost patent exclusivity in the U.S. for Evista^® in March 2014, both of which resulted in the immediate entry of generic competitors and a rapid and severe decline in revenue. We also lost patent exclusivity for the schizophrenia and bipolar mania indications in December 2015 and April 2016, respectively, for Zyprexa^® in Japan. Generic versions of Zyprexa were launched in Japan in June 2016. The loss of exclusivity for Zyprexa in Japan has caused a rapid and severe decline in revenue for the product. We will lose our patent protection for Strattera^® in the U.S. in May 2017 and Cialis^® in the U.S. and major European markets in November 2017. We will also lose exclusivity for Effient in the U.S. in October 2017, and we have authorized one generic manufacturer to enter the market as early as mid-August 2017.

Our animal health segment, operating through our Elanco animal health division, includes the development, manufacturing, marketing, and sales of animal health products worldwide for both food and companion animals. Animal health products include Rumensin^®, Posilac^®, Maxiban^®,Tylan^®, Denagard^®, Optaflexx^®, and other products for livestock and poultry, as well as Trifexis^®, Comfortis^®, and other products for companion animals. The animal health segment amounts for the years ended December 31, 2016 and 2015 include the results of operations from Novartis AH, which was acquired on January 1, 2015 (Note 3).

Most of our pharmaceutical products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December 31, 2016, 2015, and 2014, our three largest wholesalers each accounted for between 8 percent and 17 percent of consolidated total revenue. Further, they each accounted for between 12 percent and 21 percent of accounts receivable as of December 31, 2016 and 2015. Animal health products are sold primarily to wholesale distributors.

We manage our assets on a total company basis, not by operating segment, as the assets of the animal health business are intermixed with those of the pharmaceutical products business. Therefore, our chief operating decision maker does not review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign operations, and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

The following table summarizes our revenue activity:



	2016		2015		2014
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:

Endocrinology:
Humalog^®	$	2,768.8	$	2,841.9	$	2,785.2
Forteo^®	1,500.0		1,348.3		1,322.0
Humulin^®	1,365.9		1,307.4		1,400.1
Trulicity^®	925.5		248.7		10.2
Trajenta	436.6		356.8		328.8
Evista	172.4		237.3		419.8
Other Endocrinology	913.6		696.4		672.9
Total Endocrinology	8,082.8		7,036.8		6,939.0

Oncology:
Alimta	2,283.3		2,493.1		2,792.0
Erbitux	687.0		485.0		373.3
Cyramza^®	614.1		383.8		75.6
Other Oncology	137.4		147.9		152.1
Total Oncology	3,721.8		3,509.8		3,393.0

Cardiovascular:
Cialis	2,471.6		2,310.7		2,291.0
Effient	535.2		523.0		522.2
Other Cardiovascular	218.6		234.3		240.3
Total Cardiovascular	3,225.4		3,068.0		3,053.5

Neuroscience:
Cymbalta⁽¹⁾	930.5		1,027.6		1,614.7
Strattera	854.7		784.0		738.5
Zyprexa	725.3		940.3		1,037.3
Other Neuroscience	209.8		183.5		206.0
Total Neuroscience	2,720.3		2,935.4		3,596.5

Other human pharmaceutical products	313.6		227.7		287.0
Total human pharmaceutical products	18,063.9		16,777.7		17,269.0
Animal health products	3,158.2		3,181.0		2,346.6
Revenue	$	21,222.1	$	19,958.7	$	19,615.6



	2016			2015			2014
Segment profits:
Human pharmaceutical products	$	4,010.0		$	4,026.7		$	3,604.6
Animal health products	663.7			597.9			621.8
Total segment profits	$	4,673.7		$	4,624.6		$	4,226.4

Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	4,673.7		$	4,624.6		$	4,226.4
Other profits (losses):
Amortization of intangible assets (Note 8)	(683.3		)	(626.2		)	(530.2		)
Asset impairment, restructuring, and other special charges (Note 5)	(382.5		)	(367.7		)	(468.7		)
Venezuela charge (Note 17)	(203.9		)	—			—
Acquired in-process research and development (Notes 3 and 4)	(30.0		)	(535.0		)	(200.2		)
Inventory fair value adjustment related to Novartis AH (Note 3)	—			(153.0		)	—
Debt repurchase charges, net⁽²⁾ (Note 10)	—			(152.7		)	—
U.S. Branded Prescription Drug Fee	—			—			(119.0		)
Income related to transfer of linagliptin and empagliflozin rights in certain countries to Boehringer Ingelheim (Note 4)	—			—			92.0
Consolidated income before taxes	$	3,374.0		$	2,790.0		$	3,000.3

Numbers may not add due to rounding.

⁽¹⁾ Cymbalta revenues benefited from reductions to the reserve for expected product returns of approximately $175 million during the year ended December 31, 2016.

⁽²⁾ We recognized pretax net charges of $152.7 million for the year ended December 31, 2015, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes.

Depreciation and software amortization expense included in our segment profits was as follows:



	2016		2015		2014
Human pharmaceutical products	$	723.4	$	720.7	$	790.0
Animal health products	89.9		80.8		58.8
Total depreciation expense and software amortization included in segment profits	$	813.3	$	801.5	$	848.8

For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global administrative services, certain acquisition-related transaction costs, and certain manufacturing costs.



	2016		2015		2014
Geographic Information
Revenue—to unaffiliated customers⁽¹⁾:
United States	$	11,506.2	$	10,097.4	$	9,134.1
Europe	3,768.1		3,943.6		4,506.7
Japan	2,330.9		2,033.1		2,027.1
Other foreign countries	3,616.9		3,884.6		3,947.7
Revenue	$	21,222.1	$	19,958.7	$	19,615.6

Long-lived assets⁽²⁾:
United States	$	4,984.6	$	4,576.8	$	4,566.2
Europe	2,140.7		2,306.4		2,401.5
Japan	92.4		89.2		80.4
Other foreign countries	1,776.8		1,724.2		1,499.1
Long-lived assets	$	8,994.5	$	8,696.6	$	8,547.2

⁽¹⁾ Revenue is attributed to the countries based on the location of the customer.

⁽²⁾ Long-lived assets consist of property and equipment, net, and certain sundry assets.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Data (Notes)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information [Text Block]

Note 19: Selected Quarterly Data (unaudited)



2016	Fourth			Third			Second			First
Revenue	$	5,760.5		$	5,191.7		$	5,404.8		$	4,865.1
Cost of sales	1,466.0			1,400.9			1,465.0			1,323.0
Operating expenses⁽¹⁾	3,240.7			2,801.8			2,958.5			2,694.9
Acquired in-process research and development	30.0			—			—			—
Asset impairment, restructuring, and other special charges	147.6			45.5			58.0			131.4
Other—net, (income) expense	(15.8		)	(27.2		)	(21.2		)	149.0
Income before income taxes	892.0			970.7			944.5			566.8
Net income	771.8			778.0			747.7			440.1
Earnings per share—basic	0.73			0.74			0.71			0.42
Earnings per share—diluted	0.73			0.73			0.71			0.41
Dividends paid per share	0.51			0.51			0.51			0.51
Common stock closing prices:
High	83.06			83.40			78.75			84.11
Low	65.97			76.85			72.57			69.06

2015	Fourth			Third			Second			First
Revenue	$	5,375.6		$	4,959.7		$	4,978.7		$	4,644.7
Cost of sales	1,389.2			1,236.9			1,218.4			1,192.7
Operating expenses⁽¹⁾	3,242.6			2,719.1			2,804.9			2,562.8
Acquired in-process research and development	199.0			—			80.0			256.0
Asset impairment, restructuring, and other special charges	144.9			42.4			72.4			108.0
Other—net, (income) expense	(44.7		)	(86.5		)	123.3			(92.7		)
Income before income taxes	444.6			1,047.8			679.7			617.9
Net income	478.4			799.7			600.8			529.5
Earnings per share—basic	0.45			0.75			0.57			0.50
Earnings per share—diluted	0.45			0.75			0.56			0.50
Dividends paid per share	0.50			0.50			0.50			0.50
Common stock closing prices:
High	87.52			89.98			86.59			76.36
Low	76.98			78.26			70.89			68.41

⁽¹⁾ Includes research and development and marketing, selling, and administrative expenses.

Our common stock is listed on the New York Stock Exchange (NYSE), NYSE Euronext, and SIX Swiss Exchange.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Cash and Cash Equivalents, Policy [Policy Text Block]

We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.

Inventory, Policy [Policy Text Block]

Investment, Policy [Policy Text Block]

Derivatives, Policy [Policy Text Block]

Goodwill and Intangible Assets, Policy [Policy Text Block]

For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.

The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations are capitalized as other intangible assets.

Property, Plant and Equipment, Policy [Policy Text Block]

Commitments and Contingencies, Policy [Policy Text Block]

Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.

Revenue Recognition, Policy [Policy Text Block]

Revenue recognition

Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.

Research and Development Expense, Policy [Policy Text Block]

Research and development expenses and acquired in-process research and development

Research and development expenses include the following:


•	Research and development costs, which are expensed as incurred.


•	Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.

Income Tax, Policy [Policy Text Block]

Earnings Per Share, Policy [Policy Text Block]

Earnings per share

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation

Acquisitions Acquisitions (Policies)	12 Months Ended
Acquisitions Acquisitions (Policies)	Dec. 31, 2016
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	These transactions were accounted for as business combinations under the acquisition method of accounting. See Note 4 for additional information related to the Erbitux arrangement. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated financial statements from the dates of acquisition.

Inventories Inventories (Policies) (Policies)	12 Months Ended
Inventories Inventories (Policies) (Policies)	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory, Policy [Policy Text Block]	We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.

Financial Instruments (Policies)	12 Months Ended
Financial Instruments (Policies)	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-science products account for a substantial portion of our trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.
Derivatives, Policy [Policy Text Block]	In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statement of cash flows. We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities. We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt. Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of gains and losses is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the effective portion of foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, Japanese yen, and the Swiss franc). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments.
Cash and Cash Equivalents, Policy [Policy Text Block]	We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
Investment, Policy [Policy Text Block]	Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded, net of tax, in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis. Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other–net, (income) expense. We own no investments that are considered to be trading securities.

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

Goodwill and Other Intangibles Goodwill and Other Intangibles (Policies)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Policy [Policy Text Block]	For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing. Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized but is reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of implied fair value to the carrying amount of goodwill is performed to determine the amount of any impairment. The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed immediately. The fair values of acquired IPR&D projects acquired in business combinations are capitalized as other intangible assets. Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination. We utilize the “income method,” which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each asset independently. The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. Other indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived acquired IPR&D assets for impairment testing purposes, we utilize the "income method" discussed above. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present.

Property and Equipment Property and Equipment (Policies)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 25 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

Stock-Based Compensation Stock-Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of PA, SVA, and RSU shares.

Income Taxes Income Taxes (Policies)	12 Months Ended
Income Taxes Income Taxes (Policies)	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax, Policy [Policy Text Block]	Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable. When foreign earnings are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. income taxes is provided. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

Inventory Disclosure [Text Block]

Contingencies Contingencies (Policies)	12 Months Ended
Contingencies Contingencies (Policies)	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies, Policy [Policy Text Block]	Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Note 6: Inventories

Inventories at December 31 consisted of the following:



	2016		2015
Finished products	$	987.3	$	1,053.4
Work in process	2,117.2		2,058.1
Raw materials and supplies	435.3		403.0
Total (approximates replacement cost)	3,539.8		3,514.5
Increase (reduction) to LIFO cost	22.1		(68.7		)
Inventories	$	3,561.9	$	3,445.8

Inventories valued under the LIFO method comprised $1.43 billion and $1.30 billion of total inventories at December 31, 2016 and 2015, respectively.

Property, Plant and Equipment Disclosure [Text Block]

Note 9: Property and Equipment

At December 31, property and equipment consisted of the following:



	2016			2015
Land	$	197.6		$	220.6
Buildings	6,917.8			6,786.5
Equipment	7,864.7			7,988.5
Construction in progress	1,797.5			1,665.3
	16,777.6			16,660.9
Less accumulated depreciation	(8,525.0		)	(8,607.4		)
Property and equipment, net	$	8,252.6		$	8,053.5

Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows:



	2016		2015		2014
Depreciation expense	$	716.2	$	717.6	$	759.1
Rental expense	221.0		225.7		227.3

The future minimum rental commitments under non-cancelable operating leases are as follows:



	2017		2018		2019		2020		2021		After 2021
Lease commitments	$	134.8	$	120.9	$	109.9	$	93.3	$	75.3	$	339.4

Capitalized interest costs were not material for the years ended December 31, 2016, 2015, and 2014.

Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

Implementation of New Financial Accounting Pronouncements Implementation of New Financial Accounting Pronouncements (Tables)

12 Months Ended

Dec. 31, 2016

New Accounting Pronouncement, Early Adoption [Line Items]

New Accounting Pronouncement, Early Adoption [Table Text Block]



Description of changes	Method of adoption	Effect on the financial statements or other significant matters
All excess tax benefits and tax deficiencies are recognized in the statement of operations as a discrete item in the reporting period in which they occur.	Prospective	We recognized $39.5 million of excess tax benefits in income taxes in 2016. We cannot predict the impact on our consolidated financial statements in future reporting periods following adoption as this will be dependent upon various factors including the number of shares issued and changes in the price of our stock between the grant date and settlement date.
Excess tax benefits and deficiencies on the statement of cash flows are classified as an operating activity.	Retrospective	We reclassified $72.5 million of excess tax benefits in 2015 and $2.1 million of excess tax deficiencies in 2014 from cash flows from financing activities to cash flows from operating activities on the consolidated statements of cash flows.
Employee taxes paid when an employer withholds shares for tax-withholding purposes on the statement of cash flows are classified as a financing activity.	Retrospective	We reclassified $119.3 million and $93.4 million in 2015 and 2014, respectively, of employee taxes paid from cash flows from operating activities to cash flows from financing activities on the consolidated statements of cash flows.

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

The following table provides a brief description of accounting standards that have not yet been adopted and could have a material effect on our financial statements:



Standard	Description	Effective Date	Effect on the financial statements or other significant matters
Accounting Standards Update 2014-09, Revenue from Contracts with Customers	This standard will replace existing revenue recognition standards and will require entities to recognize revenues to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. We currently plan to use the latter approach.	This standard is effective January 1, 2018, but we are permitted to adopt this standard one year earlier if we choose. We intend to adopt this standard on January 1, 2018.	We are in the process of evaluating the impact of the adoption of the standard. We have identified two revenue streams from our contracts with customers: 1) product sales and 2) licensing arrangements. While our evaluation of our contracts for product sales is not yet complete, based upon the results of our work to date we currently do not expect the application of the new standard to these contracts to have a material impact to our consolidated financial statements either at initial implementation or on an ongoing basis. We are in the process of reviewing arrangements in which we have licensed or sold intellectual property and are not yet able to estimate the anticipated impact to our consolidated financial statements from the application of the new standard to our arrangements as we continue to interpret and apply the principles in the new standard to our arrangements.
Accounting Standards Update 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities	This standard will require entities to recognize changes in the fair value of equity investments with readily determinable fair values in net income (except for investments accounted for under the equity method of accounting or those that result in consolidation of the investee). An entity should apply the new standard through a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption.	This standard is effective January 1, 2018. Early adoption of the majority of the amendments in this standard is not permitted, however, early application of certain amendments is permitted. We intend to fully adopt this standard on January 1, 2018.	We are unable to estimate the impact of adopting this standard as the significance of the impact will depend upon our equity investments as of the date of adoption.



Standard	Description	Effective Date	Effect on the financial statements or other significant matters
Accounting Standards Update 2016-02, Leases	This standard was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under current GAAP, on the balance sheet and requiring additional disclosures about leasing arrangements. This standard requires a modified retrospective approach to adoption.	This standard is effective January 1, 2019, with early adoption permitted. We intend to adopt this standard on January 1, 2019.	We are in the process of determining the potential impact on our consolidated financial statements.
Accounting Standards Update 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory	This standard will require entities to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time of transfer. This standard requires a modified retrospective approach to adoption.	This standard is effective January 1, 2018, with early adoption permitted. We intend to adopt this standard on January 1, 2018.	We are continuing to assess the potential impact of this standard on our consolidated financial statements and currently estimate that the cumulative effect of initially applying the standard would result in an increase to the opening balance of retained earnings of approximately $2 billion on January 1, 2018. This estimate is subject to change based upon 2017 intra-entity transfers of assets other than inventory and ongoing assessments of the future deductibility and realizability of the deferred tax assets that would result from implementation.

Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]

Acquisitions Acquisitions (Tables)

12 Months Ended

Dec. 31, 2016

Business Acquisition [Line Items]

The following table summarizes our asset acquisitions during 2016, 2015, and 2014, which are discussed in detail below.



Counterparty	Compound(s) or Therapy	Acquisition Month	Phase of Development⁽¹⁾	Acquired IPR&D Expense
AstraZeneca	Antibody selective for amyloid-beta 42 (Aβ42) - MEDI1814	December 2016	Phase I	$	30.0

Innovent Biologics, Inc. (Innovent)	Monoclonal antibody targeting protein CD-20 Immuno-oncology molecule cMet monoclonal antibody	March 2015	Pre-clinical⁽²⁾	56.0
Hanmi Pharmaceutical Co., Ltd. (Hanmi)	BTK Inhibitor - HM71224	April 2015	Phase I	50.0
BioNTech AG (BioNTech)	Cancer immunotherapies	May 2015	Pre-clinical	30.0
Locemia Solutions	Intranasal glucagon	October 2015	Phase III	149.0
Undisclosed	Technology collaboration	December 2015	N/A	25.0
Halozyme Therapeutics, Inc. (Halozyme)	Recombinant human hyaluronidase enzyme - rHuPH20	December 2015	N/A	25.0

Immunocore Limited (Immunocore)	T cell-based cancer therapies	July 2014	Pre-clinical	45.0
AstraZeneca⁽³⁾	Oral beta-secretase cleaving enzyme inhibitor - AZD3293	September 2014	Phase I	50.0
Adocia	BioChaperone Lispro	December 2014	Phase I	50.0

⁽¹⁾ The phase of development presented is as of the date of the arrangement.

⁽²⁾ Prior to acquisition, Innovent's monoclonal antibody targeting protein CD-20 had received investigational new drug approval in China to begin Phase I development.

⁽³⁾ See Note 4 for additional information on our collaboration with AstraZeneca related to this oral beta-secretase cleaving enzyme (BACE) inhibitor.

Novartis Animal Health [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at January 1, 2015
Inventories	$	380.2
Acquired in-process research and development	298.0
Marketed products⁽¹⁾	1,953.0
Property and equipment	199.9
Assets held for sale (primarily the U.S. Sentinel rights)	422.7
Accrued retirement benefits	(108.7		)
Deferred income taxes	(60.1		)
Other assets and liabilities - net	(73.0		)
Total identifiable net assets	3,012.0
Goodwill⁽²⁾	2,271.1
Total consideration transferred - net of cash acquired	$	5,283.1

Business Acquisition, Pro Forma Information [Table Text Block]



	Unaudited Pro Forma Consolidated Results
	2015		2014
Revenue	$	19,958.7	$	20,696.7
Net income	2,518.1		2,127.9
Diluted earnings per share	2.36		1.98

Lohmann Animal Health [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at April 30, 2014
Marketed products	$	275.4
Other intangible assets	23.9
Property and equipment	81.9
Deferred income taxes	(92.7		)
Other assets and liabilities - net	51.1
Total identifiable net assets	339.6
Goodwill⁽¹⁾	251.6
Total consideration transferred - net of cash acquired	$	591.2

⁽¹⁾Goodwill associated with this acquisition is not deductible for tax purposes.

Collaborations (Tables)

12 Months Ended

Dec. 31, 2016

Erbitux Acquisition [Member]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:



Estimated Fair Value at October 1, 2015
Marketed products⁽¹⁾	$	602.1
Deferred tax asset	232.2
Deferred tax liability	(228.2		)
Other assets and liabilities - net	57.2
Total identifiable net assets	$	663.3
Total consideration - contingent consideration liability⁽²⁾	$	(663.3	)

⁽²⁾See Note 7 for discussion on the estimation of the contingent consideration liability.

Diabetes Collaboration [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our collaboration and other revenue recognized with respect to the Trajenta and Jardiance families of products and revenue recognized with respect to Basaglar:



	2016		2015		2014
Trajenta	$	436.6	$	356.8	$	328.8
Jardiance	201.9		60.2		—
Basaglar	86.1		11.1		—

The table below summarizes significant regulatory and commercialization events and milestones (received) paid for the compounds included in this collaboration:



Product Family	Product Status			Milestones (Deferred) Capitalized⁽¹⁾
Product Family	U.S.	Europe	Japan	Year	Amount
Trajenta⁽²⁾	Launched 2011	Launched 2011	Launched 2011	2016	$	—
				2015	—
				2014	—
				Cumulative⁽⁴⁾	446.4
Jardiance⁽³⁾	Launched 2014	Launched 2014	Launched 2015	2016	—
				2015	—
				2014	299.5
				Cumulative⁽⁴⁾	299.5
Basaglar	Launched 2016	Launched 2015	Launched 2015	2016	(187.5		)
				2015	—
				2014	(62.5		)
				Cumulative⁽⁴⁾	(250.0		)

⁽²⁾ Jentadueto is included in the Trajenta family of product results.

⁽³⁾ Glyxambi and Synjardyare included in the Jardiance family of product results.

⁽⁴⁾ The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.

Erbitux [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our revenue recognized with respect to Erbitux:



	2016		2015		2014
Net product revenues - BMS	$	—	$	23.3	$	46.1
Net product revenues - third party	587.0		152.3		—
Collaboration and other revenue	100.0		309.4		327.2
Revenue	$	687.0	$	485.0	$	373.3

Effient [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our revenue recognized with respect to Effient:



	2016		2015		2014
Revenue	$	535.2	$	523.0	$	522.2



Territory	Marketing Rights	Selling Party
U.S.	Co-promotion	Lilly
Major European markets	Co-promotion	Pre-January 1, 2016, Lilly Post-January 1, 2016, Daiichi Sankyo
Japan	Exclusive	Daiichi Sankyo

Selling, General and Administrative Expenses [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]



	2016		2015		2014
Marketing, selling, and administrative	$	194.9	$	213.2	$	211.2

Collaborative Arrangement [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes our collaboration and other revenue, which is included in revenue in the consolidated statements of operations:



	2016		2015		2014
Collaboration and other revenue	$	833.7	$	808.1	$	788.4

Asset Impairments, Restructuring, and Other Special Charges (Tables)

12 Months Ended

Dec. 31, 2016

Unusual or Infrequent Items, or Both [Abstract]

Schedule of Other Operating Cost and Expense, by Component [Table Text Block]

The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below.



	2016			2015		2014
Severance:
Human pharmaceutical products	$	85.9		$	81.5	$	225.5
Animal health	40.8			59.5		—
Total severance	126.7			141.0		225.5
Asset impairment (gains from facility sales) and other special charges:
Human pharmaceutical products	(13.0		)	24.6		204.4
Animal health	268.8			202.1		38.8
Total asset impairment and other special charges	255.8			226.7		243.2
Asset impairment, restructuring, and other special charges	$	382.5		$	367.7	$	468.7

Inventories (Tables)

12 Months Ended

Dec. 31, 2016

Inventory [Line Items]

Schedule of Inventory, Current [Table Text Block]

Inventories at December 31 consisted of the following:



	2016		2015
Finished products	$	987.3	$	1,053.4
Work in process	2,117.2		2,058.1
Raw materials and supplies	435.3		403.0
Total (approximates replacement cost)	3,539.8		3,514.5
Increase (reduction) to LIFO cost	22.1		(68.7		)
Inventories	$	3,561.9	$	3,445.8

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]

The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:



	2016			2015			2014
Cash flow hedges:
Equity contracts	$	—		$	—		$	149.6
Forward-starting interest rate swaps	(3.4		)	(56.7		)	(164.7		)
Net investment hedges:
Foreign currency-denominated notes	137.5			—			—
Cross-currency interest rate swaps	32.5			—			—
Foreign currency exchange contracts	31.9			—			—

Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]

The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2016:



	Maturities by Period
	Total		Within 1 Year		After 1 Year Through 5 Years		After 5 Years Through 10 Years		After 10 Years
Fair value of debt securities	$	5,522.9	$	1,456.0	$	3,762.2	$	89.0	$	215.7

Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following effects of risk-management instruments were recognized in other–net, (income) expense:



	2016			2015			2014
Fair value hedges:
Effect from hedged fixed-rate debt	$	(30.8	)	$	(11.9	)	$	156.9
Effect from interest rate contracts	30.8			11.9			(156.9		)
Cash flow hedges:
Effective portion of losses on equity contracts reclassified from accumulated other comprehensive loss	—			—			129.0
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	15.0			13.7			9.0
Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	78.8			(28.2		)	(20.4		)

Fair Value, Assets Measured on Recurring Basis [Table Text Block]



					Fair Value Measurements Using
Description	Carrying Amount		Cost⁽¹⁾		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Fair Value
December 31, 2016
Cash equivalents	$	2,986.8	$	2,986.8	$	2,699.4	$	287.4	$	—	$	2,986.8
Short-term investments:
U.S. government and agency securities	$	232.5	$	232.6	$	232.5	$	—	$	—	$	232.5
Corporate debt securities	1,219.2		1,219.1		—		1,219.2		—		1,219.2
Asset-backed securities	4.3		4.3		—		4.3		—		4.3
Other securities	0.5		0.5		—		0.5		—		0.5
Short-term investments	$	1,456.5
Noncurrent investments:
U.S. government and agency securities	$	318.9	$	323.8	$	318.9	$	—	$	—	$	318.9
Corporate debt securities	3,062.2		3,074.3		—		3,062.2		—		3,062.2
Mortgage-backed securities	183.1		185.4		—		183.1		—		183.1
Asset-backed securities	502.7		503.5		—		502.7		—		502.7
Other securities	153.7		77.6		—		—		153.7		153.7
Marketable equity securities	418.2		91.9		418.2		—		—		418.2
Cost and equity method investments⁽²⁾	568.7
Noncurrent investments	$	5,207.5

December 31, 2015
Cash equivalents	$	1,644.4	$	1,644.4	$	1,637.0	$	7.4	$	—	$	1,644.4
Short-term investments:
U.S. government and agency securities	$	153.2	$	153.4	$	153.2	$	—	$	—	$	153.2
Corporate debt securities	625.8		626.9		—		625.8		—		625.8
Asset-backed securities	3.3		3.3		—		3.3		—		3.3
Other securities	3.1		3.1		—		3.1		—		3.1
Short-term investments	$	785.4
Noncurrent investments:
U.S. government and agency securities	$	284.5	$	286.0	$	283.5	$	1.0	$	—	$	284.5
Corporate debt securities	1,962.6		1,995.8		—		1,962.6		—		1,962.6
Mortgage-backed securities	153.3		154.7		—		153.3		—		153.3
Asset-backed securities	441.9		443.1		—		441.9		—		441.9
Other securities	137.1		97.3		—		4.1		133.0		137.1
Marketable equity securities	128.9		74.8		128.9		—		—		128.9
Cost and equity method investments⁽²⁾	538.3
Noncurrent investments	$	3,646.6

⁽¹⁾ For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.

⁽²⁾ Fair value disclosures are not applicable for cost method and equity method investments.

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Fair Value
Short-term commercial paper borrowings
December 31, 2016	$	(1,299.3	)	$	—	$	(1,299.3	)	$	—	$	(1,299.3	)
December 31, 2015	—			—		—			—		—

Long-term debt, including current portion
December 31, 2016	$	(9,005.9	)	$	—	$	(9,419.1	)	$	—	$	(9,419.1	)
December 31, 2015	(7,978.5		)	—		(8,172.0		)	—		(8,172.0		)

Fair Value, by Balance Sheet Grouping [Table Text Block]



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Fair Value
December 31, 2016
Risk-management instruments
Interest rate contracts designated as fair value hedges:
Other receivables	$	2.4		$	—	$	2.4		$	—		$	2.4
Sundry	37.0			—		37.0			—			37.0
Other noncurrent liabilities	(0.5		)	—		(0.5		)	—			(0.5		)
Cross-currency interest rate contracts designated as net investment hedges:
Sundry	31.4			—		31.4			—			31.4
Foreign exchange contracts not designated as hedging instruments:
Other receivables	31.8			—		31.8			—			31.8
Other current liabilities	(21.7		)	—		(21.7		)	—			(21.7		)
Contingent consideration liabilities⁽¹⁾:
Other current liabilities	(215.9		)	—		—			(215.9		)	(215.9		)
Other noncurrent liabilities	(242.6		)	—		—			(242.6		)	(242.6		)

December 31, 2015
Risk-management instruments
Interest rate contracts designated as fair value hedges:
Sundry	$	70.1		$	—	$	70.1		$	—		$	70.1
Other noncurrent liabilities	(0.4		)	—		(0.4		)	—			(0.4		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	13.1			—		13.1			—			13.1
Other current liabilities	(17.3		)	—		(17.3		)	—			(17.3		)
Contingent consideration liabilities⁽¹⁾:
Other current liabilities	(243.7		)	—		—			(243.7		)	(243.7		)
Other noncurrent liabilities	(427.2		)	—		—			(427.2		)	(427.2		)

⁽¹⁾ Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.

Available-for-sale Securities [Table Text Block]



	2016		2015
Unrealized gross gains	$	352.6	$	68.0
Unrealized gross losses	34.1		52.5
Fair value of securities in an unrealized gain position	1,869.7		764.5
Fair value of securities in an unrealized loss position	3,262.3		2,933.4

Gain (Loss) on Investments [Table Text Block]

Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows:



	2016		2015		2014
Proceeds from sales	$	3,240.5	$	4,733.3	$	14,609.5
Realized gross gains on sales	30.7		255.1		353.5
Realized gross losses on sales	14.6		10.3		29.4

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

Tabular disclosure of the realized and unrealized gains and losses reported in the statement of income which have resulted from the sale and holding of marketable securities, respectively, as well as the sale or disposal of cost method investments. Such amounts would include realized gains and losses on the sale or disposal of trading, available-for-sale, and held-to-maturity securities, unrealized gains and losses on trading securities, unrealized gains and losses on available-for-sale and held-to-maturity securities transferred to the trading securities category, realized gains and losses on the sale or disposal of cost method investments, and losses recognized for other than temporary impairments (OTTI) of such investments.

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangibles (Tables)

12 Months Ended

Dec. 31, 2016

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

Amortization expense related to finite-lived intangible assets was as follows:



	2016		2015		2014
Amortization expense	$	687.9	$	631.8	$	535.9

Schedule of Indefinite-Lived Intangible Assets [Table Text Block]

Goodwill by segment at December 31 was as follows:



	2016		2015
Human pharmaceutical products	$	1,366.4	$	1,366.5
Animal health	2,606.3		2,673.4
Total goodwill	$	3,972.7	$	4,039.9

Schedule of Intangible Assets and Goodwill [Table Text Block]

The components of intangible assets other than goodwill at December 31 were as follows:



	2016							2015
Description	Carrying Amount, Gross		Accumulated Amortization			Carrying Amount, Net		Carrying Amount, Gross		Accumulated Amortization			Carrying Amount, Net
Finite-lived intangible assets:
Marketed products	$	7,400.2	$	(3,301.4	)	$	4,098.8	$	7,528.0	$	(2,756.6	)	$	4,771.4
Other	150.7		(71.8		)	78.9		151.1		(65.3		)	85.8
Total finite-lived intangible assets	7,550.9		(3,373.2		)	4,177.7		7,679.1		(2,821.9		)	4,857.2
Indefinite-lived intangible assets:
Acquired in-process research and development	180.2		—			180.2		177.6		—			177.6
Other intangibles	$	7,731.1	$	(3,373.2	)	$	4,357.9	$	7,856.7	$	(2,821.9	)	$	5,034.8

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2016 is as follows:



	2017		2018		2019		2020		2021
Estimated amortization expense	$	649.6	$	491.7	$	314.1	$	312.8	$	311.0

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment [Table Text Block]

At December 31, property and equipment consisted of the following:



	2016			2015
Land	$	197.6		$	220.6
Buildings	6,917.8			6,786.5
Equipment	7,864.7			7,988.5
Construction in progress	1,797.5			1,665.3
	16,777.6			16,660.9
Less accumulated depreciation	(8,525.0		)	(8,607.4		)
Property and equipment, net	$	8,252.6		$	8,053.5

Schedule of Rent Expense [Table Text Block]

Depreciation expense related to property and equipment and rental expense for all leases, including contingent rentals (not material), was as follows:



	2016		2015		2014
Depreciation expense	$	716.2	$	717.6	$	759.1
Rental expense	221.0		225.7		227.3

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

The future minimum rental commitments under non-cancelable operating leases are as follows:



	2017		2018		2019		2020		2021		After 2021
Lease commitments	$	134.8	$	120.9	$	109.9	$	93.3	$	75.3	$	339.4

Borrowings (Tables)

12 Months Ended

Dec. 31, 2016

Long-term Debt, Current and Noncurrent [Abstract]

Schedule of Additional Borrowings Disclosures [Table Text Block]

The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:



	2016		2015		2014
Cash payments for interest on borrowings	$	146.4	$	129.6	$	140.4

Schedule of Maturities of Long-term Debt [Table Text Block]

The aggregate amounts of maturities on long-term debt for the next five years are as follows:



	2017		2018		2019		2020		2021
Maturities on long-term debt	$	635.3	$	999.2	$	603.0	$	1.6	$	0.5

Schedule of Debt [Table Text Block]

Debt at December 31 consisted of the following:



	2016			2015
Short-term commercial paper borrowings	$	1,299.3		$	—
0.00 to 7.13 percent long-term notes (due 2017-2045)	8,776.5			7,700.1
Other long-term debt, including capitalized leases	14.4			23.1
Unamortized debt issuance costs	(37.5		)	(37.1		)
Fair value adjustment on hedged long-term notes	252.5			292.4
Total debt	10,305.2			7,978.5
Less current portion	(1,937.4		)	(6.1		)
Long-term debt	$	8,367.8		$	7,972.4

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block]

Stock-based compensation expense and the related tax benefits were as follows:



	2016		2015		2014
Stock-based compensation expense	$	255.3	$	217.8	$	156.0
Tax benefit	89.4		76.2		54.6

Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]

The weighted-average fair values of the SVA units granted during the years ended December 31, 2016, 2015, and 2014 were $48.68, $54.81, and $41.97, respectively, determined using the following assumptions:



(Percents)	2016		2015		2014
Expected dividend yield	2.00	%	2.50	%	3.50	%
Risk-free interest rate	0.92		0.79		.08-.71
Volatility	21.68		20.37		18.87-21.56

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Additional Income Tax Disclosures [Table Text Block]

Cash payments of income taxes were as follows:



	2016		2015		2014
Cash payments of income taxes	$	700.6	$	969.0	$	729.7

Income Taxes [Text Block]

Note 13: Income Taxes

Following is the composition of income tax expense:



	2016			2015			2014
Current:
Federal	$	(57.0	)	$	660.5		$	168.9
Foreign	378.9			422.0			406.2
State	(125.0		)	47.5			(2.1		)
Total current tax expense	196.9			1,130.0			573.0
Deferred:
Federal	517.0			(689.6		)	(83.3		)
Foreign	(83.3		)	(66.0		)	120.2
State	5.8			7.2			(0.1		)
Total deferred tax (benefit) expense	439.5			(748.4		)	36.8
Income taxes	$	636.4		$	381.6		$	609.8

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:



	2016			2015
Deferred tax assets:
Compensation and benefits	$	1,126.0		$	1,034.6
Purchases of intangible assets	620.3			613.8
Tax credit carryforwards and carrybacks	458.9			294.2
Tax loss carryforwards and carrybacks	327.3			247.8
Contingent consideration	142.7			214.6
Product return reserves	128.1			212.1
Other comprehensive loss on hedging transactions	123.3			129.7
Debt	95.3			111.3
Other	587.3			679.4
Total gross deferred tax assets	3,609.2			3,537.5
Valuation allowances	(648.3		)	(590.3		)
Total deferred tax assets	2,960.9			2,947.2
Deferred tax liabilities:
Inventories	(955.5		)	(771.3		)
Unremitted earnings	(673.6		)	(218.8		)
Intangibles	(604.2		)	(792.3		)
Property and equipment	(398.6		)	(411.6		)
Financial instruments	(279.3		)	(144.0		)
Prepaid employee benefits	(265.3		)	(317.8		)
Total deferred tax liabilities	(3,176.5		)	(2,655.8		)
Deferred tax assets (liabilities) - net	$	(215.6	)	$	291.4

Cash payments of income taxes were as follows:



	2016		2015		2014
Cash payments of income taxes	$	700.6	$	969.0	$	729.7

Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:



	2016			2015			2014
Income tax at the U.S. federal statutory tax rate	$	1,180.9		$	976.5		$	1,050.1
Add (deduct):
International operations, including Puerto Rico	(313.7		)	(565.2		)	(344.8		)
General business credits	(58.3		)	(69.2		)	(44.3		)
Other	(172.5		)	39.5			(51.2		)
Income taxes	$	636.4		$	381.6		$	609.8

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:



	2016			2015			2014
Beginning balance at January 1	$	1,066.6		$	1,338.8		$	1,136.4
Additions based on tax positions related to the current year	73.4			131.3			126.4
Additions for tax positions of prior years	14.8			116.6			132.6
Reductions for tax positions of prior years	(15.2		)	(45.2		)	(32.1		)
Settlements	(171.9		)	(446.2		)	(4.2		)
Lapses of statutes of limitation	(110.0		)	(4.0		)	(3.5		)
Changes related to the impact of foreign currency translation	(4.3		)	(24.7		)	(16.8		)
Ending balance at December 31	$	853.4		$	1,066.6		$	1,338.8

The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $382.8 million and $404.1 million at December 31, 2016 and 2015, respectively.

We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:



	2016			2015		2014
Income tax (benefit) expense	$	(52.5	)	$	13.2	$	35.9

At December 31, 2016 and 2015, our accruals for the payment of interest and penalties totaled $134.9 million and $216.3 million, respectively.

Following is the composition of income tax expense:



	2016			2015			2014
Current:
Federal	$	(57.0	)	$	660.5		$	168.9
Foreign	378.9			422.0			406.2
State	(125.0		)	47.5			(2.1		)
Total current tax expense	196.9			1,130.0			573.0
Deferred:
Federal	517.0			(689.6		)	(83.3		)
Foreign	(83.3		)	(66.0		)	120.2
State	5.8			7.2			(0.1		)
Total deferred tax (benefit) expense	439.5			(748.4		)	36.8
Income taxes	$	636.4		$	381.6		$	609.8

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:



	2016			2015
Deferred tax assets:
Compensation and benefits	$	1,126.0		$	1,034.6
Purchases of intangible assets	620.3			613.8
Tax credit carryforwards and carrybacks	458.9			294.2
Tax loss carryforwards and carrybacks	327.3			247.8
Contingent consideration	142.7			214.6
Product return reserves	128.1			212.1
Other comprehensive loss on hedging transactions	123.3			129.7
Debt	95.3			111.3
Other	587.3			679.4
Total gross deferred tax assets	3,609.2			3,537.5
Valuation allowances	(648.3		)	(590.3		)
Total deferred tax assets	2,960.9			2,947.2
Deferred tax liabilities:
Inventories	(955.5		)	(771.3		)
Unremitted earnings	(673.6		)	(218.8		)
Intangibles	(604.2		)	(792.3		)
Property and equipment	(398.6		)	(411.6		)
Financial instruments	(279.3		)	(144.0		)
Prepaid employee benefits	(265.3		)	(317.8		)
Total deferred tax liabilities	(3,176.5		)	(2,655.8		)
Deferred tax assets (liabilities) - net	$	(215.6	)	$	291.4

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:



	2016			2015			2014
Income tax at the U.S. federal statutory tax rate	$	1,180.9		$	976.5		$	1,050.1
Add (deduct):
International operations, including Puerto Rico	(313.7		)	(565.2		)	(344.8		)
General business credits	(58.3		)	(69.2		)	(44.3		)
Other	(172.5		)	39.5			(51.2		)
Income taxes	$	636.4		$	381.6		$	609.8

Summary of Income Tax Contingencies [Table Text Block]

We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. We recognized income tax (benefit) expense related to interest and penalties as follows:



	2016			2015		2014
Income tax (benefit) expense	$	(52.5	)	$	13.2	$	35.9

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:



	2016			2015			2014
Beginning balance at January 1	$	1,066.6		$	1,338.8		$	1,136.4
Additions based on tax positions related to the current year	73.4			131.3			126.4
Additions for tax positions of prior years	14.8			116.6			132.6
Reductions for tax positions of prior years	(15.2		)	(45.2		)	(32.1		)
Settlements	(171.9		)	(446.2		)	(4.2		)
Lapses of statutes of limitation	(110.0		)	(4.0		)	(3.5		)
Changes related to the impact of foreign currency translation	(4.3		)	(24.7		)	(16.8		)
Ending balance at December 31	$	853.4		$	1,066.6		$	1,338.8

Retirement Benefits (Tables)

12 Months Ended

Dec. 31, 2016

Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]



	Defined Benefit Pension Plans						Retiree Health Benefit Plans
	2016			2015			2016			2015
Change in benefit obligation:
Benefit obligation at beginning of year	$	11,719.2		$	12,012.4		$	1,467.4		$	1,553.5
Benefit obligation assumed in Novartis AH acquisition	—			334.7			—			9.9
Service cost	277.7			315.7			39.1			45.1
Interest cost	420.8			476.8			53.2			62.6
Actuarial (gain) loss	806.5			(812.4		)	50.9			(113.5		)
Benefits paid	(454.5		)	(437.8		)	(59.8		)	(77.5		)
Plan amendments	—			(0.4		)	(35.8		)	—
Foreign currency exchange rate changes and other adjustments	(313.8		)	(169.8		)	(20.4		)	(12.7		)
Benefit obligation at end of year	12,455.9			11,719.2			1,494.6			1,467.4

Schedule of Changes in Fair Value of Plan Assets [Table Text Block]



Change in plan assets:
Fair value of plan assets at beginning of year	9,995.6		9,835.7		1,943.7		1,918.7
Fair value of plan assets assumed in Novartis AH acquisition	—		235.9		—		—
Actual return on plan assets	853.4		90.4		68.9		85.1
Employer contribution	110.2		404.1		8.4		17.4
Benefits paid	(454.5	)	(437.8	)	(59.8	)	(77.5	)
Foreign currency exchange rate changes and other adjustments	(325.0	)	(132.7	)	—		—
Fair value of plan assets at end of year	10,179.7		9,995.6		1,961.2		1,943.7

Schedule of Net Funded Status [Table Text Block]



Funded status	(2,276.2		)	(1,723.6		)	466.6			476.3
Unrecognized net actuarial loss	4,915.7			4,552.7			458.8			347.9
Unrecognized prior service (benefit) cost	21.7			32.5			(525.1		)	(574.8		)
Net amount recognized	$	2,661.2		$	2,861.6		$	400.3		$	249.4

Schedule of Amounts Recognized in Balance Sheet [Table Text Block]



Amounts recognized in the consolidated balance sheet consisted of:
Sundry	$	29.7		$	261.6		$	689.3		$	722.1
Other current liabilities	(68.0		)	(63.8		)	(6.7		)	(6.9		)
Accrued retirement benefits	(2,237.9		)	(1,921.4		)	(216.0		)	(238.9		)
Accumulated other comprehensive (income) loss before income taxes	4,937.4			4,585.2			(66.3		)	(226.9		)
Net amount recognized	$	2,661.2		$	2,861.6		$	400.3		$	249.4

Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year [Table Text Block]

During 2017, we expect the following components of accumulated other comprehensive loss to be recognized as components of net periodic benefit cost:



	Defined Benefit Pension Plans		Retiree Health Benefit Plans
Unrecognized net actuarial loss	$	289.5	$	16.1
Unrecognized prior service (benefit) cost	5.4		(90.0		)
Total	$	294.9	$	(73.9	)

Schedule of Assumptions Used [Table Text Block]

The following represents our weighted-average assumptions as of December 31:



	Defined Benefit Pension Plans						Retiree Health Benefit Plans
(Percents)	2016		2015		2014		2016		2015		2014
Discount rate for benefit obligation	3.9	%	4.3	%	4.0	%	4.3	%	4.5	%	4.1	%
Discount rate for net benefit costs	4.3		4.0		4.9		4.5		4.1		5.0
Rate of compensation increase for benefit obligation	3.4		3.4		3.4
Rate of compensation increase for net benefit costs	3.4		3.4		3.4
Expected return on plan assets for net benefit costs	7.4		7.4		8.1		8.0		8.0		8.5

Schedule of Expected Benefit Payments [Table Text Block]

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:



	2017		2018		2019		2020		2021		2022-2026
Defined benefit pension plans	$	464.5	$	471.3	$	486.1	$	505.3	$	526.9	$	3,016.3
Retiree health benefit plans	72.8		75.5		78.1		80.8		83.9		465.6

Schedule of Net Benefit Costs [Table Text Block]

Net pension and retiree health benefit expense included the following components:



	Defined Benefit Pension Plans									Retiree Health Benefit Plans
	2016			2015			2014			2016			2015			2014
Components of net periodic (benefit) cost:
Service cost	$	277.7		$	315.7		$	240.9		$	39.1		$	45.1		$	33.0
Interest cost	420.8			476.8			472.6			53.2			62.6			85.6
Expected return on plan assets	(752.1		)	(782.3		)	(756.6		)	(150.2		)	(150.0		)	(146.4		)
Amortization of prior service (benefit) cost	11.8			10.4			3.6			(85.8		)	(91.1		)	(37.6		)
Recognized actuarial loss	285.6			383.2			282.3			19.1			38.0			20.7
Net periodic (benefit) cost	$	243.8		$	403.8		$	242.8		$	(124.6	)	$	(95.4	)	$	(44.7	)

Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]

The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31, 2016, 2015, and 2014:



	Defined Benefit Pension Plans								Retiree Health Benefit Plans
	2016			2015		2014			2016			2015			2014
Actuarial gain (loss) arising during period	$	(725.2	)	$	120.4	$	(1,939.3	)	$	(132.2	)	$	48.6		$	(282.9	)
Plan amendments during period	—			0.4		2.4			35.8			—			533.6
Amortization of prior service (benefit) cost included in net income	11.8			10.4		3.6			(85.8		)	(91.1		)	(37.6		)
Amortization of net actuarial loss included in net income	285.6			383.2		282.3			19.1			38.0			20.7
Foreign currency exchange rate changes and other	75.6			58.8		89.6			2.5			4.2			—
Total other comprehensive income (loss) during period	$	(352.2	)	$	573.2	$	(1,561.4	)	$	(160.6	)	$	(0.3	)	$	233.8



Details about Accumulated Other Comprehensive Loss Components	Year Ended December 31,									Affected Line Item in the Consolidated Statements of Operations
	2016			2015			2014
Amortization of retirement benefit items:
Prior service benefits, net	$	(74.0	)	$	(80.7	)	$	(34.0	)	⁽¹⁾
Actuarial losses	304.7			421.2			303.0			⁽¹⁾
Total before tax	230.7			340.5			269.0
Tax benefit	(71.5		)	(105.6		)	(83.4		)	Income taxes
Net of tax	159.2			234.9			185.6

Unrealized gains/losses on available-for-sale securities:
Realized gains, net	(16.1		)	(209.3		)	(324.1		)	Other—net, (income) expense
Impairment losses	27.3			12.0			—			Other—net, (income) expense
Total before tax	11.2			(197.3		)	(324.1		)
Tax expense	(4.0		)	69.1			113.4			Income taxes
Net of tax	7.2			(128.2		)	(210.7		)

Other, net of tax ⁽²⁾	84.3			9.5			5.9			Other—net, (income) expense
Total reclassifications for the period, net of tax	$	250.7		$	116.2		$	(19.2	)

⁽¹⁾These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

Schedule of Allocation of Plan Assets [Table Text Block]

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2016 by asset category are as follows:



				Fair Value Measurements Using
Asset Class	Total			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans
Public equity securities:
U.S.	$	402.4		$	165.5	$	—		$	—	$	236.9
International	2,285.6			770.5		—			—		1,515.1
Fixed income:
Developed markets	2,631.3			27.2		1,983.0			—		621.1
Developed markets - repurchase agreements	(1,024.4		)	—		(1,024.4		)	—		—
Emerging markets	450.0			—		180.1			0.3		269.6
Private alternative investments:
Hedge funds	2,904.6			—		—			—		2,904.6
Equity-like funds	1,355.0			—		0.2			16.8		1,338.0
Real estate	504.1			344.5		—			—		159.6
Other	671.1			365.0		108.1			—		198.0
Total	$	10,179.7		$	1,672.7	$	1,247.0		$	17.1	$	7,242.9

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	38.7		$	16.7	$	—		$	—	$	22.0
International	146.3			52.0		—			—		94.3
Fixed income:
Developed markets	68.0			—		58.4			—		9.6
Emerging markets	42.6			—		18.2			—		24.4
Private alternative investments:
Hedge funds	261.0			—		—			—		261.0
Equity-like funds	116.0			—		—			1.7		114.3
Cash value of trust owned insurance contract	1,208.3			—		1,208.3			—		—
Real estate	34.8			34.8		—			—		—
Other	45.5			28.1		3.7			—		13.7
Total	$	1,961.2		$	131.6	$	1,288.6		$	1.7	$	539.3

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2015 by asset category are as follows:



			Fair Value Measurements Using
Asset Class	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Investments Valued at Net Asset Value⁽¹⁾
Defined Benefit Pension Plans
Public equity securities:
U.S.	$	414.3	$	180.1	$	—	$	—	$	234.2
International	2,261.7		751.5		—		—		1,510.2
Fixed income:
Developed markets	1,309.9		—		745.9		—		564.0
Emerging markets	472.3		—		151.5		0.3		320.5
Private alternative investments:
Hedge funds	3,073.2		2.4		—		—		3,070.8
Equity-like funds	1,221.6		—		0.3		16.8		1,204.5
Real estate	541.1		329.6		—		—		211.5
Other	701.5		255.6		94.4		—		351.5
Total	$	9,995.6	$	1,519.2	$	992.1	$	17.1	$	7,467.2

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	40.1	$	18.2	$	—	$	—	$	21.9
International	144.7		51.5		—		—		93.2
Fixed income:
Developed markets	61.2		—		52.9		—		8.3
Emerging markets	36.9		—		15.3		—		21.6
Private alternative investments:
Hedge funds	272.3		—		—		—		272.3
Equity-like funds	104.5		—		—		1.7		102.8
Cash value of trust owned insurance contract	1,208.2		—		1,208.2		—		—
Real estate	33.2		33.2		—		—		—
Other	42.6		25.0		0.5		—		17.1
Total	$	1,943.7	$	127.9	$	1,276.9	$	1.7	$	537.2

Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]

Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:



	2016		2015
Projected benefit obligation	$	10,597.0	$	10,054.1
Fair value of plan assets	8,291.2		8,069.7

Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]

Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:



	Defined Benefit Pension Plans				Retiree Health Benefit Plans
	2016		2015		2016		2015
Accumulated benefit obligation	$	9,805.4	$	2,028.1	$	222.7	$	245.8
Fair value of plan assets	8,285.2		844.9		—		—

Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2016

Other Comprehensive Income (Loss), Tax [Abstract]

Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]

The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31, 2016, 2015, and 2014:



	Defined Benefit Pension Plans								Retiree Health Benefit Plans
	2016			2015		2014			2016			2015			2014
Actuarial gain (loss) arising during period	$	(725.2	)	$	120.4	$	(1,939.3	)	$	(132.2	)	$	48.6		$	(282.9	)
Plan amendments during period	—			0.4		2.4			35.8			—			533.6
Amortization of prior service (benefit) cost included in net income	11.8			10.4		3.6			(85.8		)	(91.1		)	(37.6		)
Amortization of net actuarial loss included in net income	285.6			383.2		282.3			19.1			38.0			20.7
Foreign currency exchange rate changes and other	75.6			58.8		89.6			2.5			4.2			—
Total other comprehensive income (loss) during period	$	(352.2	)	$	573.2	$	(1,561.4	)	$	(160.6	)	$	(0.3	)	$	233.8



Details about Accumulated Other Comprehensive Loss Components	Year Ended December 31,									Affected Line Item in the Consolidated Statements of Operations
	2016			2015			2014
Amortization of retirement benefit items:
Prior service benefits, net	$	(74.0	)	$	(80.7	)	$	(34.0	)	⁽¹⁾
Actuarial losses	304.7			421.2			303.0			⁽¹⁾
Total before tax	230.7			340.5			269.0
Tax benefit	(71.5		)	(105.6		)	(83.4		)	Income taxes
Net of tax	159.2			234.9			185.6

Unrealized gains/losses on available-for-sale securities:
Realized gains, net	(16.1		)	(209.3		)	(324.1		)	Other—net, (income) expense
Impairment losses	27.3			12.0			—			Other—net, (income) expense
Total before tax	11.2			(197.3		)	(324.1		)
Tax expense	(4.0		)	69.1			113.4			Income taxes
Net of tax	7.2			(128.2		)	(210.7		)

Other, net of tax ⁽²⁾	84.3			9.5			5.9			Other—net, (income) expense
Total reclassifications for the period, net of tax	$	250.7		$	116.2		$	(19.2	)

⁽¹⁾These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The following table summarizes the activity related to each component of other comprehensive income (loss):



(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
Beginning balance at January 1, 2014	$	463.0		$	205.2		$	(2,489.1	)	$	(181.8	)	$	(2,002.7	)

Other comprehensive income (loss) before reclassifications	(961.4		)	105.2			(1,098.5		)	(15.2		)	(1,969.9		)
Net amount reclassified from accumulated other comprehensive loss	—			(210.7		)	185.6			5.9			(19.2		)
Net other comprehensive income (loss)	(961.4		)	(105.5		)	(912.9		)	(9.3		)	(1,989.1		)

Balance at December 31, 2014	(498.4		)	99.7			(3,402.0		)	(191.1		)	(3,991.8		)

Other comprehensive income (loss) before reclassifications	(861.8		)	38.6			155.0			(36.9		)	(705.1		)
Net amount reclassified from accumulated other comprehensive loss	—			(128.2		)	234.9			9.5			116.2
Net other comprehensive income (loss)	(861.8		)	(89.6		)	389.9			(27.4		)	(588.9		)

Balance at December 31, 2015	(1,360.2		)	10.1			(3,012.1		)	(218.5		)	(4,580.7		)

Other comprehensive income (loss) before reclassifications	(581.6		)	206.7			(518.7		)	(2.2		)	(895.8		)
Net amount reclassified from accumulated other comprehensive loss	74.5			7.2			159.2			9.8			250.7
Net other comprehensive income (loss)	(507.1		)	213.9			(359.5		)	7.6			(645.1		)

Ending balance at December 31, 2016⁽¹⁾	$	(1,867.3	)	$	224.0		$	(3,371.6	)	$	(210.9	)	$	(5,225.8	)

The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:



Tax (expense) benefit	2016			2015			2014
Foreign currency translation gains (losses)	$	(70.6	)	$	(2.0	)	$	—
Unrealized net gains (losses) on securities	(89.2		)	48.5			56.7
Defined benefit pension and retiree health benefit plans	153.3			(183.0		)	414.7
Effective portion of cash flow hedges	(4.1		)	14.6			5.2
Provision for income taxes related to other comprehensive income (loss) items	$	(10.6	)	$	(121.9	)	$	476.6

Other - Net, Expense (Income) (Tables)

12 Months Ended

Dec. 31, 2016

Nonoperating Income (Expense) [Abstract]

Schedule of Other Nonoperating Income (Expense) [Table Text Block]

Other–net, (income) expense consisted of the following:



	2016			2015			2014
Interest expense	$	185.2		$	161.2		$	148.8
Interest income	(108.7		)	(87.0		)	(121.0		)
Venezuela charge	203.9			—			—
Debt extinguishment loss (Note 10)	—			166.7			—
Other income	(195.6		)	(341.5		)	(368.3		)
Other–net, (income) expense	$	84.8		$	(100.6	)	$	(340.5	)

Segment Information Segment Information (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Schedule of Additional Segment Information Disclosures [Table Text Block]

Depreciation and software amortization expense included in our segment profits was as follows:



	2016		2015		2014
Human pharmaceutical products	$	723.4	$	720.7	$	790.0
Animal health products	89.9		80.8		58.8
Total depreciation expense and software amortization included in segment profits	$	813.3	$	801.5	$	848.8

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]



	2016		2015		2014
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:

Endocrinology:
Humalog^®	$	2,768.8	$	2,841.9	$	2,785.2
Forteo^®	1,500.0		1,348.3		1,322.0
Humulin^®	1,365.9		1,307.4		1,400.1
Trulicity^®	925.5		248.7		10.2
Trajenta	436.6		356.8		328.8
Evista	172.4		237.3		419.8
Other Endocrinology	913.6		696.4		672.9
Total Endocrinology	8,082.8		7,036.8		6,939.0

Oncology:
Alimta	2,283.3		2,493.1		2,792.0
Erbitux	687.0		485.0		373.3
Cyramza^®	614.1		383.8		75.6
Other Oncology	137.4		147.9		152.1
Total Oncology	3,721.8		3,509.8		3,393.0

Cardiovascular:
Cialis	2,471.6		2,310.7		2,291.0
Effient	535.2		523.0		522.2
Other Cardiovascular	218.6		234.3		240.3
Total Cardiovascular	3,225.4		3,068.0		3,053.5

Neuroscience:
Cymbalta⁽¹⁾	930.5		1,027.6		1,614.7
Strattera	854.7		784.0		738.5
Zyprexa	725.3		940.3		1,037.3
Other Neuroscience	209.8		183.5		206.0
Total Neuroscience	2,720.3		2,935.4		3,596.5

Other human pharmaceutical products	313.6		227.7		287.0
Total human pharmaceutical products	18,063.9		16,777.7		17,269.0
Animal health products	3,158.2		3,181.0		2,346.6
Revenue	$	21,222.1	$	19,958.7	$	19,615.6



	2016			2015			2014
Segment profits:
Human pharmaceutical products	$	4,010.0		$	4,026.7		$	3,604.6
Animal health products	663.7			597.9			621.8
Total segment profits	$	4,673.7		$	4,624.6		$	4,226.4

Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	4,673.7		$	4,624.6		$	4,226.4
Other profits (losses):
Amortization of intangible assets (Note 8)	(683.3		)	(626.2		)	(530.2		)
Asset impairment, restructuring, and other special charges (Note 5)	(382.5		)	(367.7		)	(468.7		)
Venezuela charge (Note 17)	(203.9		)	—			—
Acquired in-process research and development (Notes 3 and 4)	(30.0		)	(535.0		)	(200.2		)
Inventory fair value adjustment related to Novartis AH (Note 3)	—			(153.0		)	—
Debt repurchase charges, net⁽²⁾ (Note 10)	—			(152.7		)	—
U.S. Branded Prescription Drug Fee	—			—			(119.0		)
Income related to transfer of linagliptin and empagliflozin rights in certain countries to Boehringer Ingelheim (Note 4)	—			—			92.0
Consolidated income before taxes	$	3,374.0		$	2,790.0		$	3,000.3

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]



	2016		2015		2014
Geographic Information
Revenue—to unaffiliated customers⁽¹⁾:
United States	$	11,506.2	$	10,097.4	$	9,134.1
Europe	3,768.1		3,943.6		4,506.7
Japan	2,330.9		2,033.1		2,027.1
Other foreign countries	3,616.9		3,884.6		3,947.7
Revenue	$	21,222.1	$	19,958.7	$	19,615.6

Long-lived assets⁽²⁾:
United States	$	4,984.6	$	4,576.8	$	4,566.2
Europe	2,140.7		2,306.4		2,401.5
Japan	92.4		89.2		80.4
Other foreign countries	1,776.8		1,724.2		1,499.1
Long-lived assets	$	8,994.5	$	8,696.6	$	8,547.2

⁽¹⁾ Revenue is attributed to the countries based on the location of the customer.

⁽²⁾ Long-lived assets consist of property and equipment, net, and certain sundry assets.

Selected Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]



2016	Fourth			Third			Second			First
Revenue	$	5,760.5		$	5,191.7		$	5,404.8		$	4,865.1
Cost of sales	1,466.0			1,400.9			1,465.0			1,323.0
Operating expenses⁽¹⁾	3,240.7			2,801.8			2,958.5			2,694.9
Acquired in-process research and development	30.0			—			—			—
Asset impairment, restructuring, and other special charges	147.6			45.5			58.0			131.4
Other—net, (income) expense	(15.8		)	(27.2		)	(21.2		)	149.0
Income before income taxes	892.0			970.7			944.5			566.8
Net income	771.8			778.0			747.7			440.1
Earnings per share—basic	0.73			0.74			0.71			0.42
Earnings per share—diluted	0.73			0.73			0.71			0.41
Dividends paid per share	0.51			0.51			0.51			0.51
Common stock closing prices:
High	83.06			83.40			78.75			84.11
Low	65.97			76.85			72.57			69.06

2015	Fourth			Third			Second			First
Revenue	$	5,375.6		$	4,959.7		$	4,978.7		$	4,644.7
Cost of sales	1,389.2			1,236.9			1,218.4			1,192.7
Operating expenses⁽¹⁾	3,242.6			2,719.1			2,804.9			2,562.8
Acquired in-process research and development	199.0			—			80.0			256.0
Asset impairment, restructuring, and other special charges	144.9			42.4			72.4			108.0
Other—net, (income) expense	(44.7		)	(86.5		)	123.3			(92.7		)
Income before income taxes	444.6			1,047.8			679.7			617.9
Net income	478.4			799.7			600.8			529.5
Earnings per share—basic	0.45			0.75			0.57			0.50
Earnings per share—diluted	0.45			0.75			0.56			0.50
Dividends paid per share	0.50			0.50			0.50			0.50
Common stock closing prices:
High	87.52			89.98			86.59			76.36
Low	76.98			78.26			70.89			68.41

⁽¹⁾ Includes

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Average Remaining Maturity of Foreign Currency Derivatives									12 months
Depreciation									$ 716.2	$ 717.6	$ 759.1
Operating Leases, Rent Expense									221.0	225.7	227.3
Collaboration and other revenue									833.7	808.1	788.4
Revenue	$ 5,760.5	$ 5,191.7	$ 5,404.8	$ 4,865.1	$ 5,375.6	$ 4,959.7	$ 4,978.7	$ 4,644.7	$ 21,222.1	$ 19,958.7	$ 19,615.6
Minimum [Member]
Finite-Lived Intangible Assets, Useful Life									3 years
Minimum [Member] \| Building [Member]
Property, Plant and Equipment, Useful Life									12 years
Minimum [Member] \| Equipment [Member]
Property, Plant and Equipment, Useful Life									3 years
Maximum [Member]
Finite-Lived Intangible Assets, Useful Life									20 years
Maximum [Member] \| Building [Member]
Property, Plant and Equipment, Useful Life									50 years
Maximum [Member] \| Equipment [Member]
Property, Plant and Equipment, Useful Life									25 years

Implementation of New Financial Accounting Pronouncements (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
New Accounting Pronouncement, Early Adoption [Line Items]
Income taxes	$ 636.4	$ 381.6	$ 609.8
Net Cash Provided by (Used in) Operating Activities	4,851.0	2,964.6	4,458.4
Net Cash Provided by (Used in) Financing Activities	(559.8)	(3,111.0)	(166.4)
New Accounting Pronouncement or Change in Accounting Principle Not Yet Adopted, Estimated Cumulative Effect of Change on Equity Upon Adoption	2,000.0
New Accounting Pronouncement, Early Adoption, Effect [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Income taxes	39.5
Net Cash Provided by (Used in) Operating Activities	0.0	72.5	2.1
Net Cash Provided by (Used in) Financing Activities	$ 0.0	$ 119.3	$ 93.4

Acquisitions (Details) - USD ($)
$ / shares in Units, $ in Millions

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 30, 2014

Jan. 31, 2017

Jan. 31, 2015

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Jan. 01, 2015

$ 687.9

$ 631.8

$ 535.9

$ 1,466.0

$ 1,400.9

$ 1,465.0

$ 1,323.0

$ 1,389.2

$ 1,236.9

$ 1,218.4

$ 1,192.7

5,654.9

5,037.2

4,932.5

Interest Expense

185.2

161.2

148.8

Restricted cash

$ 5,410.0

5,410.0

Payments to Acquire Businesses, Net of Cash Acquired

30.0

$ 0.0

199.0

$ 0.0

80.0

256.0

30.0

535.0

200.2

45.0

5,283.1

551.4

Goodwill

3,972.7

4,039.9

3,972.7

4,039.9

Vetmedica Inc.'s U.S. Feline, Canine, and Rabies Vaccine Portfolio [Member] | Subsequent Event [Member]

CoLucid Pharmaceuticals [Member] | Subsequent Event [Member]

$ 885.0

960.0

Business Combination, Consideration Transferred, Per Share

$ 850.0

$ 46.50

Innovent Biologics, Inc. [Member]

Hanmi Pharmaceutical Co., Ltd. [Member]

56.0

50.0

BioNTech AG [Member]

Lohmann Animal Health [Member]

$ 30.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 591.2

275.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Other Intangible Assets

23.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

339.6

Payments to Acquire Businesses, Net of Cash Acquired

551.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

39.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

81.9

Goodwill

^[1]

251.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

(92.7)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

$ 51.1

Novartis Animal Health [Member]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

19 years

Business Acquisition, Goodwill, Expected Tax Deductible Amount

$ 1,000.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

380.2

Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual

$ 1,020.0

Business Acquisition, Pro Forma Revenue

$ 5,280.0

19,958.7

20,696.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

^[2]

1,953.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets

298.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

3,012.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

199.9

Goodwill

^[3]

2,271.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

(60.1)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other

422.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other

(108.7)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

(73.0)

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

$ 5,283.1

Business Acquisition, Pro Forma Net Income (Loss)

$ 2,518.1

$ 2,127.9

Business Acquisition, Pro Forma Earnings Per Share, Diluted

$ 2.36

$ 1.98

Immunocore Limited [Member]

Locemia Solutions [Member]

$ 45.0

Other Product Acquisition Counterparty [Member]

149.0

Halozyme Therapeutics, Inc [Member]

25.0

$ 25.0

AstraZeneca [Member]

$ 30.0

$ 50.0

^[4]

Adocia [Member]

$ 50.0

Tanezumab [Member]

United States [Member] | U.S. Sentinel Product Line [Member]

$ 200.0

Proceeds from Divestiture of Businesses

$ 410.0

Interest Expense

$ 112.0

Fair Value Adjustment to Inventory [Member] | Novartis Animal Health [Member]

Amortization of Fair Value Adjusted Intangible Assets [Member] | Novartis Animal Health [Member]

$ (153.1)

153.1

$ 104.0

[1]	(1) Goodwill associated with this acquisition is not deductible for tax purposes.
[2]	(1) These intangible assets, which are being amortized to cost of sales on a straight-line basis over their estimated useful lives, were expected to have a weighted average useful life of 19 years.
[3]	(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Novartis AH with our legacy animal health business, future unidentified projects and products, and the assembled workforce of Novartis AH. Approximately $1.0 billion of the goodwill associated with this acquisition is deductible for tax purposes.
[4]	(3) See Note 4 for additional information on our collaboration with AstraZeneca related to this oral beta-secretase cleaving enzyme (BACE) inhibitor.

Collaborations (Details) - USD ($)
$ in Millions

1 Months Ended

3 Months Ended

12 Months Ended

Sep. 30, 2014

Oct. 31, 2013

Dec. 31, 2009

Jun. 30, 2001

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

^[8]

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Oct. 01, 2015

$ 833.7

$ 808.1

$ 788.4

Other Nonoperating Income (Expense)

$ 5,760.5

$ 5,191.7

$ 5,404.8

$ 4,865.1

$ 5,375.6

$ 4,959.7

$ 4,978.7

$ 4,644.7

21,222.1

19,958.7

19,615.6

195.6

341.5

368.3

Research and Development Expense

5,243.9

4,796.4

4,733.6

Marketing, selling, and administrative

15.8

27.2

21.2

(149.0)

44.7

86.5

(123.3)

92.7

(84.8)

100.6

340.5

6,452.0

6,533.0

6,620.8

30.0

$ 0.0

0.0

$ 199.0

$ 0.0

$ 80.0

256.0

30.0

535.0

200.2

687.9

631.8

535.9

Erbitux API [Member]

0.0

23.3

46.1

Erbitux [Member]

587.0

152.3

0.0

100.0

309.4

327.2

687.0

485.0

373.3

Trajenta (BI) [Member]

436.6

356.8

328.8

Effient [Member]

535.2

523.0

522.2

BI compounds [Member]

92.0

LLY compounds [Member]

$ 55.2

Tanezumab [Member]

$ 200.0

Jardiance (BI) [Member]

201.9

60.2

0.0

Basaglar [Member]

86.1

11.1

0.0

United States [Member]

Milestone Payments, Sales-based [Member] | Baricitinib [Member]

^[1]

11,506.2

10,097.4

9,134.1

Collaborative Arrangement, Rights and Obligations, Terms

$ (150.0)

Milestone Payments, Sales-based [Member] | Tanezumab [Member]

Collaborative Arrangement, Rights and Obligations, Terms

$ (1,230.0)

Milestone Payments, Development and Regulatory, Capitalized [Member] | Trajenta (BI) [Member]

Collaborative Arrangement, Rights and Obligations, Terms

^[2],[3]

0.0

Milestone Payments, Development and Regulatory, Capitalized [Member] | Jardiance [Member]

Collaborative Arrangement, Rights and Obligations, Terms

^[4]

0.0

(299.5)

Milestone Payments, Development and Regulatory, Capitalized [Member] | LLY compounds [Member]

Collaborative Arrangement, Rights and Obligations, Terms

^[2]

187.5

0.0

62.5

Milestone Payments, Development and Regulatory, Capitalized [Member] | Baricitinib [Member] | Subsequent Event [Member]

Collaborative Arrangement, Rights and Obligations, Terms

$ (65.0)

Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Trajenta (BI) [Member]

Collaborative Arrangement, Rights and Obligations, Terms

^[2],[3],[5]

(446.4)

Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Jardiance [Member]

Collaborative Arrangement, Rights and Obligations, Terms

^[2],[4],[5]

(299.5)

Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | LLY compounds [Member]

Collaborative Arrangement, Rights and Obligations, Terms

^[2],[5]

$ 250.0

Profit And Development And Marketing Share [Member] | Effient [Member]

Collaborative Arrangement, Rights and Obligations Percent

50.00%

Sales Reported [Member] | Erbitux [Member]

Collaborative Arrangement, Rights and Obligations Percent

38.00%

Research And Development Exp [Member] | Baricitinib [Member]

Collaborative Arrangement, Rights and Obligations Percent

30.00%

Milestone Payments, Development and Regulatory, Expensed [Member] | Baricitinib [Member]

Research and Development Expense

$ 55.0

Milestone Payments, Development and Regulatory [Member] | Baricitinib [Member]

Collaborative Arrangement, Rights and Obligations, Terms

$ (295.0)

Milestone Payments, Development and Regulatory [Member] | Tanezumab [Member]

Collaborative Arrangement, Rights and Obligations, Terms

$ (350.0)

Milestone Payments, Development and Regulatory [Member] | BACE (AZ) Inhibitor [Member]

Research and Development Expense

$ 100.0

Collaborative Arrangement, Rights and Obligations, Terms

$ (350.0)

Milestone Payments, Development and Regulatory, First Indication [Member] | Baricitinib [Member]

Collaborative Arrangement, Rights and Obligations, Terms

$ (115.0)

Royalty Payments Received [Member] | Baricitinib [Member]

Collaborative Arrangement, Rights and Obligations Percent

20.00%

Collaborative Arrangement [Member]

Marketing, selling, and administrative

$ 194.9

213.2

$ 211.2

Erbitux Acquisition [Member]

Business Acquisition, Pro Forma Revenue

20,200.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

^[6]

$ 602.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent

232.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

(228.2)

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

57.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

663.3

Business Combination, Contingent Consideration, Liability

^[7]

$ (663.3)

Erbitux Acquisition [Member] | Erbitux [Member]

Business Acquisition, Pro Forma Revenue

$ 735.0

AstraZeneca [Member]

Transfer of Financial Assets Accounted for as Sales, Amount Derecognized

$ 30.0

$ 50.0

[1]	(1) Revenue is attributed to the countries based on the location of the customer.
[2]	(1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales.
[3]	(2) Jentadueto is included in the Trajenta family of product results.
[4]	(3) Glyxambi and Synjardy are included in the Jardiance family of product results.
[5]	(4) The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.
[6]	(1) These intangible assets are being amortized to cost of sales using the straight-line method through the co-development period in North America as set forth in the original agreement, which was scheduled to expire in September 2018.
[7]	(2) See Note 7 for discussion on the estimation of the contingent consideration liability.
[8]	(3) See Note 4 for additional information on our collaboration with AstraZeneca related to this oral beta-secretase cleaving enzyme (BACE) inhibitor.

Asset Impairments, Restructuring, and Other Special Charges (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges									$ 255.8	$ 226.7	$ 243.2
Severance Costs									126.7	141.0	225.5
Asset impairment, restructuring, and other special charges	$ 147.6	$ 45.5	$ 58.0	$ 131.4	$ 144.9	$ 42.4	$ 72.4	$ 108.0	382.5	367.7	468.7
PUERTO RICO
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges											180.8
Human Pharmaceutical Products [Member]
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges									(13.0)	24.6	204.4
Severance Costs									85.9	81.5	225.5
Animal Health Products [Member]
Unusual or Infrequent Item [Line Items]
Asset Impairment Charges									268.8	202.1	38.8
Severance Costs									$ 40.8	$ 59.5	$ 0.0

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
LIFO Inventory Amount	$ 1,430.0	$ 1,300.0
Finished products	987.3	1,053.4
Work in process	2,117.2	2,058.1
Raw materials and supplies	435.3	403.0
Inventory, Gross, Total	3,539.8	3,514.5
Reduction to LIFO cost	22.1	(68.7)
Inventories	$ 3,561.9	$ 3,445.8

Financial Instruments (Details)
€ in Millions, ¥ in Millions, £ in Millions, SFr in Millions, $ in Millions

1 Months Ended

12 Months Ended

Feb. 28, 2015

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Dec. 31, 2014

USD ($)

Dec. 31, 2016

EUR (€)

Dec. 31, 2016

CHF (SFr)

Dec. 31, 2016

GBP (£)

Dec. 31, 2016

USD ($)

Dec. 31, 2016

JPY (¥)

Feb. 27, 2015

USD ($)

$ 670.6

$ 661.6

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

$ 231.0

Average Remaining Maturity of Foreign Currency Derivatives

12 months

Net proceeds from (payments for) terminations of interest rate swaps

0.0

1,299.3

$ (3.4)

(186.1)

$ 340.7

Proceeds from Sale of Available-for-sale Securities

$ 3,240.5

4,733.3

14,609.5

^[1]

1,644.4

2,986.8

Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets

(7,978.5)

$ (9,005.9)

95.00%

Maximum Remaining Maturity of Foreign Currency Derivatives

30 days

Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate

35.00%

Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net

$ 15.1

Available-for-sale Securities, Continuous Unrealized Gain Position, Fair Value

764.5

1,869.7

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value

2,933.4

3,262.3

Other than Temporary Impairment Losses, Investments

$ 53.0

42.6

12.5

Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax

52.5

34.1

Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax

68.0

352.6

Available-for-sale Securities, Gross Realized Gains

30.7

255.1

353.5

Available-for-sale Securities, Gross Realized Losses

14.6

10.3

29.4

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value

1,456.0

Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value

3,762.2

Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value

89.0

Available-for-sale Securities, Debt Maturities, after Ten Years, Fair Value

215.7

Available-for-sale Securities, Debt Securities

5,522.9

Reported Value Measurement [Member]

Derivative Asset, Notional Amount

876.0

1,300.0

Business Combination, Contingent Consideration, Liability, Current

1,644.4

2,986.8

^[2]

(243.7)

(215.9)

Business Combination, Contingent Consideration, Liability, Noncurrent

^[2]

(427.2)

(242.6)

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Current, Total

785.4

1,456.5

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Noncurrent, Total

3,646.6

5,207.5

Estimate of Fair Value Measurement [Member]

0.0

1,299.3

1,644.4

2,986.8

Business Combination, Contingent Consideration, Liability, Current

(8,172.0)

(9,419.1)

^[2]

(243.7)

(215.9)

Business Combination, Contingent Consideration, Liability, Noncurrent

^[2]

(427.2)

(242.6)

Fair Value, Inputs, Level 1 [Member]

0.0

1,637.0

2,699.4

Business Combination, Contingent Consideration, Liability, Current

0.0

^[2]

0.0

Business Combination, Contingent Consideration, Liability, Noncurrent

^[2]

0.0

Fair Value, Inputs, Level 2 [Member]

0.0

1,299.3

7.4

287.4

Business Combination, Contingent Consideration, Liability, Current

(8,172.0)

(9,419.1)

^[2]

0.0

Business Combination, Contingent Consideration, Liability, Noncurrent

^[2]

0.0

Fair Value, Inputs, Level 3 [Member]

0.0

0.0

Business Combination, Contingent Consideration, Liability, Current

0.0

^[2]

(243.7)

(215.9)

Business Combination, Contingent Consideration, Liability, Noncurrent

^[2]

(427.2)

(242.6)

Corporate Debt Securities [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

^[1]

626.9

1,219.1

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

^[1]

1,995.8

3,074.3

Corporate Debt Securities [Member] | Reported Value Measurement [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

625.8

1,219.2

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

1,962.6

3,062.2

Corporate Debt Securities [Member] | Estimate of Fair Value Measurement [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

625.8

1,219.2

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

1,962.6

3,062.2

Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

0.0

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

0.0

Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

625.8

1,219.2

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

1,962.6

3,062.2

Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

0.0

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

0.0

US Government Agencies Debt Securities [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

^[1]

153.4

232.6

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

^[1]

286.0

323.8

US Government Agencies Debt Securities [Member] | Reported Value Measurement [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

153.2

232.5

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

284.5

318.9

US Government Agencies Debt Securities [Member] | Estimate of Fair Value Measurement [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

153.2

232.5

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

284.5

318.9

US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

153.2

232.5

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

283.5

318.9

US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

0.0

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

1.0

0.0

US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

0.0

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

0.0

Other Debt Obligations [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

^[1]

3.1

0.5

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

^[1]

97.3

77.6

Other Debt Obligations [Member] | Reported Value Measurement [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

3.1

0.5

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

137.1

153.7

Other Debt Obligations [Member] | Estimate of Fair Value Measurement [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

3.1

0.5

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

137.1

153.7

Other Debt Obligations [Member] | Fair Value, Inputs, Level 1 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

0.0

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

0.0

Other Debt Obligations [Member] | Fair Value, Inputs, Level 2 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

3.1

0.5

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

4.1

0.0

Other Debt Obligations [Member] | Fair Value, Inputs, Level 3 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

0.0

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

133.0

153.7

Collateralized Mortgage Backed Securities [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

^[1]

154.7

185.4

Collateralized Mortgage Backed Securities [Member] | Reported Value Measurement [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

153.3

183.1

Collateralized Mortgage Backed Securities [Member] | Estimate of Fair Value Measurement [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

153.3

183.1

Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

0.0

Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

153.3

183.1

Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

0.0

Asset-backed Securities [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

^[1]

3.3

4.3

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

^[1]

443.1

503.5

Asset-backed Securities [Member] | Reported Value Measurement [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

3.3

4.3

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

441.9

502.7

Asset-backed Securities [Member] | Estimate of Fair Value Measurement [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

3.3

4.3

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

441.9

502.7

Asset-backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

0.0

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

0.0

Asset-backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

3.3

4.3

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

441.9

502.7

Asset-backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

0.0

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

0.0

Equity Securities [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Equity Securities, Noncurrent

^[1]

74.8

91.9

Equity Securities [Member] | Reported Value Measurement [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Equity Securities, Noncurrent

128.9

418.2

Equity Securities [Member] | Estimate of Fair Value Measurement [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Equity Securities, Noncurrent

128.9

418.2

Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Equity Securities, Noncurrent

128.9

418.2

Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Equity Securities, Noncurrent

0.0

Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Equity Securities, Noncurrent

0.0

Equity Method and Other Investments [Member] | Reported Value Measurement [Member]

Available-for-sale Securities, Noncurrent [Abstract]

Other Long-term Investments

^[3]

538.3

568.7

Buy euro Sell US dollar [Member]

Derivative Liability, Notional Amount | €

€ 2,130.0

Derivative Asset, Notional Amount

2,240.0

Buy USD Sell Euro [Member]

Derivative Asset, Notional Amount | €

1,240.0

1,170.0

Buy GBP Sell Euro [Member]

Derivative Liability, Notional Amount | £

£ 246.0

Derivative Asset, Notional Amount | €

€ 292.8

Buy US dollar Sell British pound [Member]

Derivative Asset, Notional Amount | £

219.2

£ 172.8

Buy USD Sell Japanese Yen [Member]

Derivative Asset, Notional Amount | ¥

609.8

¥ 70,440

Buy Swiss francs Sell US dollar [Member]

Derivative Liability, Notional Amount | SFr

SFr 185.9

Derivative Asset, Notional Amount

183.3

Hedged Fixed Rate Debt [Member]

Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge

(30.8)

(11.9)

156.9

Equity Contract [Member]

Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion

0.0

129.0

Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net

0.0

149.6

Available-for-sale Securities, Gross Realized Gains

0.0

260.8

Interest Rate Swap [Member]

Net proceeds from (payments for) terminations of interest rate swaps

(20.2)

(340.7)

Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net

(3.4)

(56.7)

(164.7)

Interest Rate Contract [Member]

Net proceeds from (payments for) terminations of interest rate swaps

$ 1,350.0

$ (206.3)

Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments

30.8

11.9

(156.9)

Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion

15.0

13.7

9.0

Foreign Exchange Contract [Member]

Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments

78.8

(28.2)

(20.4)

Designated as Hedging Instrument [Member] | Cross Currency Interest Rate Contract [Member] | Reported Value Measurement [Member]

Designated as Hedging Instrument [Member] | Cross Currency Interest Rate Contract [Member] | Estimate of Fair Value Measurement [Member]

31.4

Designated as Hedging Instrument [Member] | Cross Currency Interest Rate Contract [Member] | Fair Value, Inputs, Level 1 [Member]

31.4

Designated as Hedging Instrument [Member] | Cross Currency Interest Rate Contract [Member] | Fair Value, Inputs, Level 2 [Member]

0.0

Designated as Hedging Instrument [Member] | Cross Currency Interest Rate Contract [Member] | Fair Value, Inputs, Level 3 [Member]

31.4

Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Reported Value Measurement [Member]

0.0

2.4

70.1

37.0

Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Estimate of Fair Value Measurement [Member]

(0.4)

(0.5)

2.4

70.1

37.0

Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Fair Value, Inputs, Level 1 [Member]

(0.4)

(0.5)

0.0

0.0

Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Fair Value, Inputs, Level 2 [Member]

0.0

2.4

70.1

37.0

Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Fair Value, Inputs, Level 3 [Member]

(0.4)

(0.5)

0.0

0.0

Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Reported Value Measurement [Member]

0.0

13.1

31.8

Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Estimate of Fair Value Measurement [Member]

17.3

21.7

13.1

31.8

Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Fair Value, Inputs, Level 1 [Member]

17.3

21.7

0.0

Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Fair Value, Inputs, Level 2 [Member]

0.0

13.1

31.8

Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Fair Value, Inputs, Level 3 [Member]

17.3

21.7

0.0

Net Investment Hedging [Member]

0.0

Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net

137.5

0.0

Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member]

Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net

32.5

0.0

Net Investment Hedging [Member] | Foreign Exchange Contract [Member]

Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net

$ 31.9

0.0

$ 0.0

Foreign Currency Denominated Debt [Member]

$ (2,270.0)

$ (3,340.0)

[1]	(1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.
[2]	(1) Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.
[3]	(2) Fair value disclosures are not applicable for cost method and equity method investments.

Goodwill and Other Intangibles (Details) - USD ($)	12 Months Ended
Goodwill and Other Intangibles (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets, Gross	$ 7,550,900,000	$ 7,679,100,000
Goodwill, Impairment Loss	0	0	$ 0
Goodwill	3,972,700,000	4,039,900,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)	180,200,000	177,600,000
Intangible Assets, Gross (Excluding Goodwill)	7,731,100,000	7,856,700,000
Finite-Lived Intangible Assets, Accumulated Amortization	(3,373,200,000)	(2,821,900,000)
Other intangibles, net	4,357,900,000	5,034,800,000
Finite-Lived Intangible Assets, Net	$ 4,177,700,000	4,857,200,000
Finite-Lived Intangible Assets, Weighted-Average Useful Life	12 years
Amortization of Intangible Assets	$ 687,900,000	631,800,000	$ 535,900,000
Future Amortization Expense, Year One	649,600,000
Future Amortization Expense, Year Two	491,700,000
Future Amortization Expense, Year Three	314,100,000
Future Amortization Expense, Year Four	312,800,000
Future Amortization Expense, Year Five	311,000,000
Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Gross	7,400,200,000	7,528,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(3,301,400,000)	(2,756,600,000)
Finite-Lived Intangible Assets, Net	4,098,800,000	4,771,400,000
Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Gross	150,700,000	151,100,000
Finite-Lived Intangible Assets, Accumulated Amortization	(71,800,000)	(65,300,000)
Finite-Lived Intangible Assets, Net	$ 78,900,000	85,800,000
Maximum [Member]
Finite-Lived Intangible Assets, Useful Life	20 years
Minimum [Member]
Finite-Lived Intangible Assets, Useful Life	3 years
In Process Research and Development [Member]
Finite-Lived Intangible Assets, Accumulated Amortization	$ 0	0
Human Pharmaceutical Products [Member]
Goodwill	1,366,400,000	1,366,500,000
Animal Health Products [Member]
Goodwill	$ 2,606,300,000	$ 2,673,400,000

Property and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 134.8
Operating Leases, Future Minimum Payments, Due in Two Years	120.9
Operating Leases, Future Minimum Payments, Due in Three Years	109.9
Operating Leases, Future Minimum Payments, Due in Four Years	93.3
Operating Leases, Future Minimum Payments, Due in Five Years	75.3
Operating Leases, Future Minimum Payments, Due in Rolling after Year Five	339.4
Depreciation	716.2	$ 717.6	$ 759.1
Land	197.6	220.6
Buildings	6,917.8	6,786.5
Equipment	7,864.7	7,988.5
Construction in progress	1,797.5	1,665.3
Property and equipment, gross	16,777.6	16,660.9
Less accumulated depreciation	(8,525.0)	(8,607.4)
Property and equipment, net	8,252.6	8,053.5
Operating Leases, Rent Expense	$ 221.0	$ 225.7	$ 227.3
Building [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	12 years
Building [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	50 years
Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	25 years

Borrowings (Details) € in Millions, SFr in Millions, $ in Millions	3 Months Ended		12 Months Ended
	Jun. 30, 2015 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jun. 30, 2016 CHF (SFr)	Jun. 30, 2015 EUR (€)	Mar. 31, 2015 USD ($)	Feb. 28, 2014 USD ($)
Commercial Paper			$ 1,299.3	$ 0.0
Short-term borrowings and current maturities of long-term debt			$ (1,937.4)	(6.1)
Short-term Debt, Weighted Average Interest Rate			0.59%
Repayments of Long-term Debt	$ 1,950.0	$ 1,000.0	$ 0.2	1,955.7	$ 1,034.8
Extinguishment of Debt, Amount	1,650.0
Gains (Losses) on Extinguishment of Debt			0.0	166.7	0.0
Notes Payable			8,776.5	7,700.1
Other Notes Payable			14.4	23.1
Unamortized Debt Issuance Expense			(37.5)	(37.1)
Long-term Debt, Fair Value Adjustment			252.5	292.4
Debt, Long-term and Short-term, Combined Amount			10,305.2	7,978.5
Long-term debt			$ 8,367.8	7,972.4
Description of Derivative Activity Volume Percent			35.00%
Proceeds from issuance of long-term debt			$ 1,206.6	4,454.7	992.9
Long-term Debt			9,005.9	7,978.5
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months			635.3
Long-term Debt, Maturities, Repayments of Principal in Year Two			999.2
Long-term Debt, Maturities, Repayments of Principal in Year Three			603.0
Long-term Debt, Maturities, Repayments of Principal in Year Four			1.6
Long-term Debt, Maturities, Repayments of Principal in Year Five			0.5
Line of Credit Facility, Remaining Borrowing Capacity			2,870.0
Line of Credit Facility, Amount Outstanding			0.0	0.0
Interest Paid, Net			$ 146.4	$ 129.6	$ 140.4
Debt Instrument, Interest Rate, Effective Percentage			2.51%	2.67%
Maturity Date, 2020 [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 1,200.0
Maturity Date, 2017 [Member]
Line of Credit Facility, Maximum Borrowing Capacity			1,500.0
Maturity Date, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage									1.95%
Long-term Debt									$ 600.0
Maturity Date, 2018 [Member]
Debt Instrument, Interest Rate, Stated Percentage						0.00%		1.25%
Long-term Debt						SFr 200.0		$ 600.0
Maturity Date, 2024 [Member]
Debt Instrument, Interest Rate, Stated Percentage						0.15%
Long-term Debt \| SFr						SFr 600.0
Maturity Date, 2028 [Member]
Debt Instrument, Interest Rate, Stated Percentage						0.45%
Long-term Debt \| SFr						SFr 400.0
Swiss Franc-Denominated Debt Issuance [Member]
Proceeds from issuance of long-term debt			$ 1,210.0
Maturity Date, 2025 [Member]
Debt Instrument, Interest Rate, Stated Percentage								2.75%
Long-term Debt								$ 800.0
Maturity Date, 2045 [Member]
Debt Instrument, Interest Rate, Stated Percentage								3.70%
Long-term Debt								$ 800.0
Maturity Date, 2022 [Member] [Member]
Debt Instrument, Interest Rate, Stated Percentage							1.00%
Long-term Debt \| €							€ 600.0
Maturity Date, 2026 [Member]
Debt Instrument, Interest Rate, Stated Percentage							1.63%
Long-term Debt \| €							€ 750.0
Maturity Date, 2030 [Member]
Debt Instrument, Interest Rate, Stated Percentage							2.13%
Long-term Debt \| €							€ 750.0
Euro-Denominated Debt Issuance [Member]
Proceeds from issuance of long-term debt	2,270.0
Maturity Date, 2044 [Member]
Debt Instrument, Interest Rate, Stated Percentage									4.65%
Long-term Debt									$ 400.0
Reported Value Measurement [Member]
Extinguishment of Debt, Amount	$ 1,780.0
Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage			0.00%
Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage			7.13%

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 255.3	$ 217.8	$ 156.0
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ 89.4	$ 76.2	$ 54.6
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	99.6
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 43.7
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	12 months
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	0.5	0.5	0.7
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	1.3
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 72.00	$ 70.34	$ 48.81
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	2 years
Shareholder Value Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 65.1
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	20 months
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	1.0	1.4	1.4
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	1.2
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 48.68	$ 54.81	$ 41.97
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	2.00%	2.50%	3.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.92%	0.79%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum			0.71%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	21.68%	20.37%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum		0.79%	0.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum		20.37%	18.87%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum			21.56%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 103.3
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	22 months
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	0.6	0.9	0.9
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	0.7
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 71.46	$ 71.69	$ 52.72
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1.3	0.9	1.2
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years

Shareholders' Equity (Details) - USD ($)
shares in Thousands, $ in Millions

3 Months Ended

12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Oct. 31, 2013

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

$ 600.1

$ 749.5

$ 800.0

$ 14,080.5

$ 14,590.3

14,080.5

14,590.3

Treasury Stock, Retired, Cost Method, Amount

$ 771.8

$ 778.0

$ 747.7

$ 440.1

$ 478.4

$ 799.7

$ 600.8

$ 529.5

2,737.6

2,408.4

2,390.5

$ 0.0

0.0

Preferred Stock, Shares Authorized

5,000

Preferred Stock, Shares Issued

Common Stock, Shares Held in Employee Trust, Shares

50,000

Employee benefit trust

$ 3,013.2

Allocated Share-based Compensation Expense

(645.1)

^[1]

(588.9)

(1,989.1)

$ 255.3

$ 217.8

156.0

Issued shares, shares in thousands

1,101,586

1,106,063

1,101,586

1,106,063

Additional Paid-in Capital [Member]

Retained Earnings [Member]

$ 60.0

Treasury Stock, Retired, Cost Method, Amount

2,737.6

$ 2,408.4

2,390.5

(535.5)

(743.3)

(792.1)

Treasury Stock [Member]

Treasury Stock, Retired, Cost Method, Amount

540.1

749.5

800.0

$ (540.1)

$ (749.5)

$ (800.0)

Retirement of treasury shares

(7,306)

(9,877)

(12,579)

2013 Share Repurchase Program [Member]

Stock Repurchase Program, Authorized Amount

$ 540.1

$ 749.5

$ 800.0

$ 5,000.0

Stock Repurchase Program, Remaining Authorized Repurchase Amount

$ 2,410.0

[1]	Other comprehensive loss in 2016 consists of $693.3 million of other comprehensive loss attributable to controlling interest and $48.2 million of other comprehensive income attributable to non-controlling interest.

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net income	$ 771.8	$ 778.0	$ 747.7	$ 440.1	$ 478.4	$ 799.7	$ 600.8	$ 529.5	$ 2,737.6	$ 2,408.4	$ 2,390.5
Basic									1,058,324	1,061,913	1,069,932
Basic	$ 0.73	$ 0.74	$ 0.71	$ 0.42	$ 0.45	$ 0.75	$ 0.57	$ 0.50	$ 2.59	$ 2.27	$ 2.23
Diluted									1,061,825	1,065,720	1,074,286
Diluted	$ 0.73	$ 0.73	$ 0.71	$ 0.41	$ 0.45	$ 0.75	$ 0.56	$ 0.50	$ 2.58	$ 2.26	$ 2.23

Income Taxes (Composition and Deferreds) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	$ 150.0
Unremitted Earnings of Foreign Subsidiaries	28,000.0
Current Federal Tax Expense (Benefit)	(57.0)	$ 660.5	$ 168.9
Current Foreign Tax Expense (Benefit)	378.9	422.0	406.2
Current State and Local Tax Expense (Benefit)	(125.0)	47.5	(2.1)
Current Income Tax Expense (Benefit), Total	196.9	1,130.0	573.0
Deferred Federal Income Tax Expense (Benefit)	517.0	(689.6)	(83.3)
Deferred Foreign Income Tax Expense (Benefit)	(83.3)	(66.0)	120.2
Deferred State and Local Income Tax Expense (Benefit)	5.8	7.2	(0.1)
Deferred Income Tax Expense (Benefit), Total	439.5	(748.4)	36.8
Income taxes	636.4	381.6	$ 609.8
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	1,126.0	1,034.6
Tax Credit Carryforward, Deferred Tax Asset	458.9	294.2
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves	128.1	212.1
Deferred Tax Assets, Other Comprehensive Loss	123.3	129.7
Deferred Tax Assets, Operating Loss Carryforwards	327.3	247.8
Deferred Tax Assets, Goodwill and Intangible Assets	620.3	613.8
Deferred Tax Asset, Fair Value Adjustments	95.3	111.3
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies	142.7	214.6
Deferred Tax Assets, Other	587.3	679.4
Deferred Tax Assets, Gross, Total	3,609.2	3,537.5
Deferred Tax Assets, Valuation Allowance	(648.3)	(590.3)
Deferred Tax Assets, Net, Total	2,960.9	2,947.2
Deferred Tax Liabilities, Undistributed Foreign Earnings	(673.6)	(218.8)
Deferred Tax Liabilities, Goodwill and Intangible Assets	(604.2)	(792.3)
Deferred Tax Liabilities, Prepaid Expenses	(265.3)	(317.8)
Deferred Tax Liabilities, Deferred Expense, Capitalized Inventory Costs	(955.5)	(771.3)
Deferred Tax Liabilities, Property, Plant and Equipment	(398.6)	(411.6)
Deferred Tax Liabilities, Derivatives	279.3	144.0
Deferred Tax Liabilities, Total	3,176.5	2,655.8
Deferred Tax Liabilities, Net	(215.6)
Deferred Tax Assets, Net		$ 291.4
Carryforward [Member]
Operating Loss Carryforwards	856.0
Tax Credit Carryforward, Amount	738.4
Expiration in 5 years [Member]
Operating Loss Carryforwards	$ 142.6
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2021
Expiration 5-20 years [Member]
Operating Loss Carryforwards	$ 462.5
Expiration 5-20 years, Minimum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2022
Expiration 5-20 years, Maximum [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2036
Expiration in 10 Years [Member]
Tax Credit Carryforward, Amount	$ 178.7
Tax Credit Carryforward, Expiration Date	Dec. 31, 2026
Expiration in 20 Years [Member]
Tax Credit Carryforward, Amount	$ 53.6
Tax Credit Carryforward, Expiration Date	Dec. 31, 2036
No Expiration [Member]
Operating Loss Carryforwards	$ 250.9
Internal Revenue Service (IRS) [Member] \| Designated Unusable [Member]
Tax Credit Carryforward, Amount	96.1
State and Local Jurisdiction [Member] \| Designated Unusable [Member]
Tax Credit Carryforward, Amount	303.8
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	102.0
Deferred Tax Assets, Tax Credit Carryforwards, Other	5.0
Foreign Tax Authority [Member] \| Designated Unusable [Member]
Tax Credit Carryforward, Amount	$ 106.2

Income Taxes (Income Tax Expense and Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Income Taxes Paid	$ 700.6	$ 969.0	$ 729.7
Income Tax Examination, Year under Examination		2015	2014	2013	2012	2011	2010
Domestic and Puerto Rican Contribution to Income before Income Taxes	70.00%	35.00%	20.00%
Income Tax Holiday, Termination Date	Dec. 31, 2016
Income Tax Holiday, Commencement Date	Dec. 31, 2017
Income Tax Holiday, Description	P15Y
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	$ 1,180.9	$ 976.5	$ 1,050.1
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount	313.7	565.2	344.8
Income Tax Reconciliation, Tax Credits	(58.3)	(69.2)	(44.3)
Income Tax Reconciliation, Other Adjustments	(172.5)	39.5	(51.2)
Income taxes	636.4	381.6	609.8
Unrecognized Tax Benefits, Beginning Balance	1,066.6	1,338.8	1,136.4
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	73.4	131.3	126.4
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions	14.8	116.6	132.6
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions	(15.2)	(45.2)	(32.1)
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations	(110.0)	(4.0)	(3.5)
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities	(171.9)	(446.2)	(4.2)
Unrecognized Tax Benefits, Increases Resulting from Foreign Currency Translation	(4.3)	(24.7)	(16.8)
Unrecognized Tax Benefits, Ending Balance	853.4	1,066.6	1,338.8	$ 1,136.4
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	382.8	404.1
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	150.0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	(52.5)	13.2	$ 35.9
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	134.9	216.3
Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Decrease in Unrecognized Tax Benefits is Reasonably Possible	$ 140.0
Expiration in 5 years [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2021
Operating Loss Carryforwards	$ 142.6
Expiration in 10 Years [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Tax Credit Carryforward, Expiration Date	Dec. 31, 2026
Tax Credit Carryforward, Amount	$ 178.7
Expiration 5-20 years, Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2022
Expiration 5-20 years [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Operating Loss Carryforwards	$ 462.5
Expiration 5-20 years, Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2036
Expiration in 20 Years [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Tax Credit Carryforward, Expiration Date	Dec. 31, 2036
Tax Credit Carryforward, Amount	$ 53.6
Tax Years 2010-2012 [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities		$ (320.0)
State and Local Jurisdiction [Member] \| Designated Unusable [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Tax Credit Carryforward, Amount	$ 303.8

Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Business Combinations and Acquisitions, Benefit Obligation	$ 0.0	$ 334.7
Defined Benefit Plan, Benefit Obligation, Beginning Balance	11,719.2	12,012.4
Defined Benefit Plan, Service Cost	277.7	315.7	$ 240.9
Defined Benefit Plan, Interest Cost	420.8	476.8	472.6
Defined Benefit Plan, Actuarial Net (Gains) Losses	806.5	(812.4)
Defined Benefit Plan, Benefits Paid	(454.5)	(437.8)
Defined Benefit Plan, Plan Amendments	0.0	(0.4)
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation	(313.8)	(169.8)
Defined Benefit Plan, Benefit Obligation, Ending Balance	12,455.9	11,719.2	12,012.4
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	9,995.6	9,835.7
Defined Benefit Plan, Actual Return on Plan Assets	853.4	90.4
Defined Benefit Plan, Contributions by Employer	110.2	404.1
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	(325.0)	(132.7)
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	10,179.7	9,995.6	9,835.7
Defined Benefit Plan, Funded Status of Plan	(2,276.2)	(1,723.6)
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	4,915.7	4,552.7
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax	21.7	32.5
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	2,661.2	2,861.6
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Business Combinations and Acquisitions, Benefit Obligation	0.0	9.9
Defined Benefit Plan, Benefit Obligation, Beginning Balance	1,467.4	1,553.5
Defined Benefit Plan, Service Cost	39.1	45.1	33.0
Defined Benefit Plan, Interest Cost	53.2	62.6	85.6
Defined Benefit Plan, Actuarial Net (Gains) Losses	50.9	(113.5)
Defined Benefit Plan, Benefits Paid	(59.8)	(77.5)
Defined Benefit Plan, Plan Amendments	(35.8)	0.0
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation	(20.4)	(12.7)
Defined Benefit Plan, Benefit Obligation, Ending Balance	1,494.6	1,467.4	1,553.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,943.7	1,918.7
Defined Benefit Plan, Actual Return on Plan Assets	68.9	85.1
Defined Benefit Plan, Contributions by Employer	8.4	17.4
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	0.0	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,961.2	1,943.7	$ 1,918.7
Defined Benefit Plan, Funded Status of Plan	466.6	476.3
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	458.8	347.9
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax	(525.1)	(574.8)
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	400.3	249.4
Fair Value, Inputs, Level 2 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	992.1
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,247.0	992.1
Fair Value, Inputs, Level 2 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,276.9
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,288.6	1,276.9
Fair Value, Inputs, Level 3 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	17.1
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	17.1	17.1
Fair Value, Inputs, Level 3 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1.7
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1.7	1.7
Fair Value, Inputs, Level 1 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,519.2
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,672.7	1,519.2
Fair Value, Inputs, Level 1 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	127.9
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	131.6	127.9
Equity Securities [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	414.3
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	402.4	414.3
Equity Securities [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	40.1
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	38.7	40.1
Equity Securities [Member] \| Fair Value, Inputs, Level 2 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.0	0.0
Equity Securities [Member] \| Fair Value, Inputs, Level 2 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.0	0.0
Equity Securities [Member] \| Fair Value, Inputs, Level 3 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.0	0.0
Equity Securities [Member] \| Fair Value, Inputs, Level 3 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.0	0.0
Equity Securities [Member] \| Fair Value, Inputs, Level 1 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	180.1
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	165.5	180.1
Equity Securities [Member] \| Fair Value, Inputs, Level 1 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	18.2
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	16.7	18.2
Equity Securities - International [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	2,261.7
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,285.6	2,261.7
Equity Securities - International [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	144.7
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	146.3	144.7
Equity Securities - International [Member] \| Fair Value, Inputs, Level 2 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.0	0.0
Equity Securities - International [Member] \| Fair Value, Inputs, Level 2 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.0	0.0
Equity Securities - International [Member] \| Fair Value, Inputs, Level 3 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.0	0.0
Equity Securities - International [Member] \| Fair Value, Inputs, Level 3 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.0	0.0
Equity Securities - International [Member] \| Fair Value, Inputs, Level 1 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	751.5
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	770.5	751.5
Equity Securities - International [Member] \| Fair Value, Inputs, Level 1 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	51.5
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	$ 52.0	$ 51.5

Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent

$ 2,453.9

$ 2,160.3

Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax

^[1]

(74.0)

(80.7)

$ (34.0)

Pension Plans, Defined Benefit [Member]

Defined Benefit Plan, Amortization of Net Gains (Losses)

(289.5)

Defined Benefit Plan, Assets for Plan Benefits, Noncurrent

29.7

261.6

Pension and Other Postretirement Defined Benefit Plans, Current Liabilities

(68.0)

(63.8)

Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent

2,237.9

1,921.4

Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax

4,937.4

4,585.2

Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total

2,661.2

2,861.6

Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax

285.6

383.2

282.3

Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax

11.8

10.4

3.6

Other Postretirement Benefit Plans, Defined Benefit [Member]

Defined Benefit Plan, Amortization of Net Gains (Losses)

(16.1)

Defined Benefit Plan, Assets for Plan Benefits, Noncurrent

689.3

722.1

Pension and Other Postretirement Defined Benefit Plans, Current Liabilities

(6.7)

(6.9)

Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent

216.0

238.9

Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax

(66.3)

(226.9)

Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total

400.3

249.4

Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax

19.1

38.0

20.7

Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax

$ (85.8)

$ (91.1)

$ (37.6)

[1]	(1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	3.90%	4.30%	4.00%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.30%	4.00%	4.90%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	3.40%	3.40%	3.40%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase	3.40%	3.40%	3.40%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	7.40%	7.40%	8.10%
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.30%	4.50%	4.10%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.50%	4.10%	5.00%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	8.00%	8.00%	8.50%

Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year, Description

$ 35.0

Defined Benefit Plan, Accumulated Benefit Obligation

11,490.0

$ 10,750.0

Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Benefit Obligation

10,597.0

10,054.1

Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets

8,291.2

8,069.7

Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax

^[1]

(74.0)

(80.7)

$ (34.0)

Change in defined benefit pension and retiree health benefit plans

(512.8)

572.9

(1,327.6)

Defined Contribution Plan, Cost Recognized

175.0

162.4

153.3

Pension Plans, Defined Benefit [Member]

Defined Benefit Plan, Expected Future Benefit Payments in Year One

(464.5)

Defined Benefit Plan, Expected Future Benefit Payments in Year Two

(471.3)

Defined Benefit Plan, Expected Future Benefit Payments in Year Three

(486.1)

Defined Benefit Plan, Expected Future Benefit Payments in Year Four

(505.3)

Defined Benefit Plan, Expected Future Benefit Payments in Year Five

(526.9)

Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter

(3,016.3)

Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Accumulated Benefit Obligation

9,805.4

2,028.1

Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets

8,285.2

844.9

Defined Benefit Plan, Service Cost

277.7

315.7

240.9

Defined Benefit Plan, Interest Cost

420.8

476.8

472.6

Defined Benefit Plan, Expected Return on Plan Assets

(752.1)

(782.3)

(756.6)

Defined Benefit Plan, Amortization of Prior Service Cost (Credit)

11.8

10.4

3.6

Defined Benefit Plan, Amortization of Gains (Losses)

285.6

383.2

282.3

Defined Benefit Plan, Amortization of Net Gains (Losses)

289.5

Defined Benefit Plan, Future Amortization of Prior Service Cost (Credit)

5.4

Defined Benefit Plan, Net Periodic Benefit Cost, Total

243.8

403.8

242.8

Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax

(725.2)

120.4

(1,939.3)

Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax

0.0

0.4

2.4

Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax

11.8

10.4

3.6

Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax

285.6

383.2

282.3

Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year

294.9

Foreign currency translation gains (losses)

75.6

58.8

89.6

Change in defined benefit pension and retiree health benefit plans

(352.2)

573.2

(1,561.4)

Other Postretirement Benefit Plans, Defined Benefit [Member]

Defined Benefit Plan, Expected Future Benefit Payments in Year One

(72.8)

Defined Benefit Plan, Expected Future Benefit Payments in Year Two

(75.5)

Defined Benefit Plan, Expected Future Benefit Payments in Year Three

(78.1)

Defined Benefit Plan, Expected Future Benefit Payments in Year Four

(80.8)

Defined Benefit Plan, Expected Future Benefit Payments in Year Five

(83.9)

Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter

(465.6)

Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Accumulated Benefit Obligation

222.7

245.8

Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets

0.0

Defined Benefit Plan, Service Cost

39.1

45.1

33.0

Defined Benefit Plan, Interest Cost

53.2

62.6

85.6

Defined Benefit Plan, Expected Return on Plan Assets

(150.2)

(150.0)

(146.4)

Defined Benefit Plan, Amortization of Prior Service Cost (Credit)

(85.8)

(91.1)

(37.6)

Defined Benefit Plan, Amortization of Gains (Losses)

19.1

38.0

20.7

Defined Benefit Plan, Amortization of Net Gains (Losses)

16.1

Defined Benefit Plan, Future Amortization of Prior Service Cost (Credit)

(90.0)

Defined Benefit Plan, Net Periodic Benefit Cost, Total

(124.6)

(95.4)

(44.7)

Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax

(132.2)

48.6

(282.9)

Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax

35.8

0.0

533.6

Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax

(85.8)

(91.1)

(37.6)

Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax

19.1

38.0

20.7

Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year

(73.9)

Foreign currency translation gains (losses)

2.5

4.2

0.0

Change in defined benefit pension and retiree health benefit plans

$ (160.6)

$ (0.3)

$ 233.8

[1]	(1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).

Contingencies (Details) $ in Millions, R$ in Billions	1 Months Ended	12 Months Ended
Contingencies (Details) $ in Millions, R$ in Billions	Apr. 30, 2015 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 BRL (R$)
Actos [Member] \| Product Liability Litigation [Member]
Loss Contingency, Number of Cases		6,500	6,500
Cymbalta [Member] \| Product Liability Litigation [Member]
Loss Contingency, Number of Lawsuits		140	140
Loss Contingency, Number of Plaintiffs		1,470	1,470
Compensatory Damages [Member] \| Actos [Member]
Litigation Settlement, Amount	$ 2,400
CANADA \| Actos [Member] \| Product Liability Litigation [Member]
Loss Contingency, Number of Cases		4	4
CALIFORNIA \| Cymbalta [Member] \| Product Liability Litigation [Member]
Loss Contingency, Number of Lawsuits		40	40
Brazil [Member] \| Employee Litigation [Member]
Loss Contingency, Damages Awarded, Value		$ 305	R$ 1.0
Loss Contingency, Number of Lawsuits		30	30
ONTARIO \| Actos [Member] \| Product Liability Litigation [Member]
Loss Contingency, Number of Cases		2	2
QUEBEC \| Actos [Member] \| Product Liability Litigation [Member]
Loss Contingency, Number of Cases		1	1
ALBERTA \| Actos [Member] \| Product Liability Litigation [Member]
Loss Contingency, Number of Cases		1	1

Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax

$ 74.5

Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax

^[1]

(74.0)

$ (80.7)

$ (34.0)

Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax

(70.6)

(2.0)

0.0

Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax

89.2

(48.5)

(56.7)

Accumulated Other Comprehensive Income (Loss), Net of Tax

(5,274.0)

(4,580.7)

Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, before Tax

(645.1)

^[2]

(588.9)

(1,989.1)

230.7

340.5

269.0

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax

^[1]

304.7

421.2

303.0

Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Tax

(71.5)

(105.6)

(83.4)

Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Net of Tax

159.2

234.9

185.6

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax

(16.1)

(209.3)

(324.1)

Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, before Tax

27.3

12.0

0.0

Other Comprehensive Income (Loss), Reclasification Adjustment from AOCI, Available-for-Sale Securities, before Tax, Total

11.2

(197.3)

(324.1)

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax

(4.0)

69.1

113.4

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Available-for-Sale Securities, Net of Tax, Total

7.2

(128.2)

(210.7)

Other Comprehensive Income, Other, Net of Tax

^[3]

84.3

9.5

5.9

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

250.7

116.2

(19.2)

Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax

(4.1)

14.6

5.2

Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, before Reclassification Adjustments, Tax

153.3

(183.0)

414.7

Other Comprehensive Income (Loss), Tax

(10.6)

(121.9)

476.6

Accumulated Other Comprehensive Income (Loss) [Member]

Accumulated Other Comprehensive Income (Loss), Net of Tax

^[4]

(5,274.0)

AOCI Attributable to Noncontrolling Interest [Member]

(693.3)

(588.9)

(1,989.1)

Accumulated Other Comprehensive Income (Loss), Net of Tax

^[4]

48.2

Accumulated Other Comprehensive Income (Loss) [Member]

Accumulated Other Comprehensive Income (Loss), Net of Tax

(5,225.8)

^[4]

(4,580.7)

(3,991.8)

$ (2,002.7)

Other Comprehensive Income (Loss), before Reclassifications, Net of Tax

895.8

705.1

1,969.9

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

(645.1)

(588.9)

(1,989.1)

(250.7)

(116.2)

19.2

Accumulated Translation Adjustment [Member]

Accumulated Other Comprehensive Income (Loss), Net of Tax

(1,867.3)

^[4]

(1,360.2)

(498.4)

463.0

Other Comprehensive Income (Loss), before Reclassifications, Net of Tax

581.6

861.8

961.4

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

(507.1)

(861.8)

(961.4)

(74.5)

0.0

Accumulated Net Unrealized Investment Gain (Loss) [Member]

Accumulated Other Comprehensive Income (Loss), Net of Tax

224.0

^[4]

10.1

99.7

205.2

Other Comprehensive Income (Loss), before Reclassifications, Net of Tax

(206.7)

(38.6)

(105.2)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

213.9

(89.6)

(105.5)

(7.2)

128.2

210.7

Accumulated Defined Benefit Plans Adjustment [Member]

Accumulated Other Comprehensive Income (Loss), Net of Tax

(3,371.6)

^[4]

(3,012.1)

(3,402.0)

(2,489.1)

Other Comprehensive Income (Loss), before Reclassifications, Net of Tax

518.7

(155.0)

1,098.5

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

(359.5)

389.9

(912.9)

(159.2)

(234.9)

(185.6)

Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]

Accumulated Other Comprehensive Income (Loss), Net of Tax

(210.9)

^[4]

(218.5)

(191.1)

$ (181.8)

Other Comprehensive Income (Loss), before Reclassifications, Net of Tax

2.2

36.9

15.2

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

7.6

(27.4)

(9.3)

$ (9.8)

$ (9.5)

$ (5.9)

[1]	(1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).
[2]	Other comprehensive loss in 2016 consists of $693.3 million of other comprehensive loss attributable to controlling interest and $48.2 million of other comprehensive income attributable to non-controlling interest.
[3]	(2) Amount for year ended December 31, 2016 included primarily $74.5 million of foreign currency translation losses.
[4]	(1) Accumulated other comprehensive loss as of December 31, 2016 consists of $5,274.0 million of accumulated other comprehensive loss attributable to controlling interest and $48.2 million of accumulated other comprehensive income attributable to non-controlling interest.

Other - Net, Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Revenue, Net									$ 833.7	$ 808.1	$ 788.4
Income related to termination of the exenatide collaboration with Amylin									203.9	0.0	0.0
Interest Expense									185.2	161.2	148.8
Investment Income, Interest									(108.7)	(87.0)	(121.0)
Gains (Losses) on Extinguishment of Debt									0.0	166.7	0.0
Other (income)expense									(195.6)	(341.5)	(368.3)
Nonoperating Income (Expense), Total	$ (15.8)	$ (27.2)	$ (21.2)	$ 149.0	$ (44.7)	$ (86.5)	$ 123.3	$ (92.7)	$ 84.8	$ (100.6)	$ (340.5)

Segment Information Segment Information (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Depreciation and amortization

$ 1,496.6

$ 1,427.7

$ 1,379.0

$ 5,760.5

$ 5,191.7

$ 5,404.8

$ 4,865.1

$ 5,375.6

$ 4,959.7

$ 4,978.7

$ 4,644.7

21,222.1

19,958.7

19,615.6

833.7

808.1

788.4

Asset impairment, restructuring, and other special charges

^[1]

8,994.5

8,696.6

8,994.5

8,696.6

8,547.2

(147.6)

(45.5)

(58.0)

(131.4)

(144.9)

(42.4)

(72.4)

(108.0)

(382.5)

(367.7)

(468.7)

Selling, General and Administrative Expense

(6,452.0)

(6,533.0)

(6,620.8)

3,374.0

2,790.0

3,000.3

1,466.0

1,400.9

1,465.0

1,323.0

1,389.2

1,236.9

1,218.4

1,192.7

5,654.9

5,037.2

4,932.5

(30.0)

0.0

(199.0)

0.0

(80.0)

(256.0)

(30.0)

(535.0)

(200.2)

Foreign Currency Transaction Gain (Loss), Realized

15.8

$ 27.2

$ 21.2

$ (149.0)

44.7

$ 86.5

$ (123.3)

$ 92.7

(84.8)

100.6

340.5

(203.9)

0.0

Gains (Losses) on Extinguishment of Debt

687.9

631.8

535.9

0.0

166.7

0.0

United States [Member]

^[2]

11,506.2

10,097.4

9,134.1

^[1]

4,984.6

4,576.8

4,984.6

4,576.8

4,566.2

Europe [Member]

^[2]

3,768.1

3,943.6

4,506.7

^[1]

2,140.7

2,306.4

2,140.7

2,306.4

2,401.5

JAPAN

^[2]

2,330.9

2,033.1

2,027.1

Other Foreign Countries [Member]

^[1]

92.4

89.2

92.4

89.2

80.4

^[2]

3,616.9

3,884.6

3,947.7

Human Pharmaceutical Products [Member]

^[1]

$ 1,776.8

$ 1,724.2

1,776.8

1,724.2

1,499.1

Other Depreciation and Amortization

723.4

720.7

790.0

18,063.9

16,777.7

17,269.0

4,010.0

4,026.7

3,604.6

Total segment [Member]

Other Depreciation and Amortization

813.3

801.5

848.8

Animal Health Products [Member]

4,673.7

4,624.6

4,226.4

Other Depreciation and Amortization

89.9

80.8

58.8

3,158.2

3,181.0

2,346.6

Corporate, Non-Segment [Member]

663.7

597.9

621.8

Asset impairment, restructuring, and other special charges

(382.5)

(367.7)

(468.7)

Selling, General and Administrative Expense

0.0

(119.0)

Foreign Currency Transaction Gain (Loss), Realized

(30.0)

(535.0)

(200.2)

(203.9)

0.0

Cymbalta [Member] | Human Pharmaceutical Products [Member]

(683.3)

(626.2)

(530.2)

Humalog [Member] | Human Pharmaceutical Products [Member]

^[3]

930.5

1,027.6

1,614.7

Humulin [Member] | Human Pharmaceutical Products [Member]

2,768.8

2,841.9

2,785.2

Forteo [Member] | Human Pharmaceutical Products [Member]

1,365.9

1,307.4

1,400.1

Evista [Member] | Human Pharmaceutical Products [Member]

1,500.0

1,348.3

1,322.0

Other Endocrinology [Member] | Human Pharmaceutical Products [Member]

172.4

237.3

419.8

Endocrinology [Member] | Human Pharmaceutical Products [Member]

913.6

696.4

672.9

8,082.8

7,036.8

6,939.0

Trajenta (BI) [Member]

Trajenta (BI) [Member] | Human Pharmaceutical Products [Member]

436.6

356.8

328.8

Trulicity [Member] [Member] | Human Pharmaceutical Products [Member]

436.6

356.8

328.8

Zyprexa [Member] | Human Pharmaceutical Products [Member]

925.5

248.7

10.2

Strattera [Member] | Human Pharmaceutical Products [Member]

725.3

940.3

1,037.3

Other Neuroscience [Member] | Human Pharmaceutical Products [Member]

854.7

784.0

738.5

Other Pharmaceuticals [Member] | Human Pharmaceutical Products [Member]

209.8

183.5

206.0

Alimta [Member] | Human Pharmaceutical Products [Member]

313.6

227.7

287.0

2,283.3

2,493.1

2,792.0

Erbitux [Member]

687.0

485.0

373.3

Erbitux [Member] | Human Pharmaceutical Products [Member]

100.0

309.4

327.2

Cyramza [Member] | Human Pharmaceutical Products [Member]

687.0

485.0

373.3

Other Oncology [Member] | Human Pharmaceutical Products [Member]

614.1

383.8

75.6

Oncology [Member] | Human Pharmaceutical Products [Member]

137.4

147.9

152.1

Cialis [Member] | Human Pharmaceutical Products [Member]

3,721.8

3,509.8

3,393.0

Effient [Member] | Human Pharmaceutical Products [Member]

2,471.6

2,310.7

2,291.0

Other Cardiovascular [Member] | Human Pharmaceutical Products [Member]

535.2

523.0

522.2

Cardiovascular [Member] | Human Pharmaceutical Products [Member]

218.6

234.3

240.3

3,225.4

3,068.0

3,053.5

BI compounds [Member]

BI compounds [Member] | Corporate, Non-Segment [Member]

92.0

Neuroscience [Member] | Human Pharmaceutical Products [Member]

0.0

92.0

Minimum [Member] | Sales Revenue, Goods, Net [Member]

$ 2,720.3

$ 2,935.4

$ 3,596.5

Minimum [Member] | Accounts Receivable [Member]

11.00%

9.00%

8.00%

Maximum [Member] | Sales Revenue, Goods, Net [Member]

14.00%

12.00%

Maximum [Member] | Accounts Receivable [Member]

17.00%

14.00%

Adjustment to Return Reserve [Member] | Cymbalta [Member] | Human Pharmaceutical Products [Member]

21.00%

16.00%

Fair Value Adjustment to Inventory [Member] | Corporate, Non-Segment [Member]

$ 175.0

Long-term Debt [Member] | Corporate, Non-Segment [Member]

0.0

$ (153.0)

$ 0.0

^[4]

$ 0.0

$ (152.7)

$ 0.0

[1]	(2) Long-lived assets consist of property and equipment, net, and certain sundry assets.
[2]	(1) Revenue is attributed to the countries based on the location of the customer.
[3]	(1) Cymbalta revenues benefited from reductions to the reserve for expected product returns of approximately $175 million during the year ended December 31, 2016.
[4]	(2) We recognized pretax net charges of $152.7 million for the year ended December 31, 2015, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes.

Selected Quarterly Data (Details) - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

$ 5,760.5

$ 5,191.7

$ 5,404.8

$ 4,865.1

$ 5,375.6

$ 4,959.7

$ 4,978.7

$ 4,644.7

$ 21,222.1

$ 19,958.7

$ 19,615.6

1,466.0

1,400.9

1,465.0

1,323.0

1,389.2

1,236.9

1,218.4

1,192.7

5,654.9

5,037.2

4,932.5

Operating Expenses

^[1]

3,240.7

2,801.8

2,958.5

2,694.9

3,242.6

2,719.1

2,804.9

2,562.8

Asset impairment, restructuring, and other special charges

30.0

0.0

199.0

0.0

80.0

256.0

30.0

535.0

200.2

147.6

45.5

58.0

131.4

144.9

42.4

72.4

108.0

382.5

367.7

468.7

(15.8)

(27.2)

(21.2)

149.0

(44.7)

(86.5)

123.3

(92.7)

84.8

(100.6)

(340.5)

892.0

970.7

944.5

566.8

444.6

1,047.8

679.7

617.9